<CPRS_TEMPLATE>
  <TEMPLATE NAME="AJCC STAGING 7TH. Edition Forms">
    <TYPE>C</TYPE>
    <STATUS>A</STATUS>
    <ITEMS>
      <TEMPLATE NAME="AJCC ADRENAL GLAND STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>ADRENAL GLAND</p>
          <p></p>
          <p>7th Edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p>Laterality:</p>
          <p> [ ] Left</p>
          <p> [ ] Right</p>
          <p> [ ] Bilateral</p>
          <p></p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     T1      Tumor 5 cm or less in greatest dimension, no </p>
          <p>                       extra-adrenal invasion</p>
          <p>[ ]    [ ]     T2      Tumor greater than 5 cm, no extra-adrenal </p>
          <p>                       invasion</p>
          <p>[ ]    [ ]     T3      Tumor of any size with local invasion, but not </p>
          <p>                       invading adjacent organs*</p>
          <p>[ ]    [ ]     T4      Tumor of any size with invasion of adjacent </p>
          <p>                       organs*</p>
          <p></p>
          <p>*Adjacent organs include kidney, diaphragm, great vessels, pancreas, </p>
          <p>spleen, and liver</p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Metastasis in regional lymph node(s)</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group)</p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>[ ]    [ ]     I       T1      N0      M0</p>
          <p>[ ]    [ ]     II      T2      N0      M0</p>
          <p>[ ]    [ ]     III     T1      N1      M0</p>
          <p>                       T2      N1      M0</p>
          <p>                       T3      N0      M0</p>
          <p>[ ]    [ ]     IV      T3      N1      M0</p>
          <p>                       T4      N0      M0</p>
          <p>                       T4      N1      M0</p>
          <p>[ ]    [ ]             Any T   Any N   M1</p>
          <p>[ ]    [ ]     UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>  Tumor weight in grams: ________</p>
          <p>  Vascular invasion:     ________</p>
          <p></p>
          <p>GRADING SYSTEM                                  </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be </p>
          <p>                                                       assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X: Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>   [ ]NCCN </p>
          <p>   [ ]Other (describe):</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
          <p></p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC AMPULLA OF VATER STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>AMPULLA OF VATER</p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size: _______________</p>
          <p></p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis     Carcinoma in situ</p>
          <p>[ ]    [ ]     T1      Limited to ampulla of Vater/sphincter of Oddi</p>
          <p>[ ]    [ ]     T2      Tumor invades duodenal wall</p>
          <p>[ ]    [ ]     T3      Tumor invades pancreas</p>
          <p>[ ]    [ ]     T4      Tumor invades peripancreatic soft tissues or </p>
          <p>                       other adjacent organs or structures other than pancreas</p>
          <p></p>
          <p> </p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Regional lymph node metastasis</p>
          <p> </p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>[ ]    [ ]     0       Tis     N0      M0</p>
          <p>[ ]    [ ]     IA      T1      N0      M0</p>
          <p>[ ]    [ ]     IB      T2      N0      M0</p>
          <p>[ ]    [ ]     IIA     T3      N0      M0</p>
          <p>[ ]    [ ]     IIB     T1      N1      M0</p>
          <p>                       T2      N1      M0</p>
          <p>                       T3      N1      M0</p>
          <p>[ ]    [ ]     III     T4      Any N   M0</p>
          <p>[ ]    [ ]     IV      Any T   Any N   M1</p>
          <p>[ ]    [ ]     UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>Preoperative or pre-treatment carcinoembryonic antigen (CEA):_________</p>
          <p>Preoperative or pre-treatment CA 19-9 lab value: _________</p>
          <p></p>
          <p>GRADING SYSTEM    					GRADE                              </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC ANUS STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>ANUS</p>
          <p>(Melanomas, carcinoid tumors and sarcomas are not included)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size: _________________</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis     Carcinoma in situ (Bowen's disease, High-</p>
          <p>                       grade Squamous Intraepithelial Lesion (HSIL),</p>
          <p>                       Anal Intraepithelial Neoplasia II-III (AIN </p>
          <p>                       II-III</p>
          <p>[ ]    [ ]     T1      Tumor 2 cm or less in greatest dimension</p>
          <p>[ ]    [ ]     T2      Tumor more than 2 cm but not more than 5 cm </p>
          <p>                       in greatest dimension</p>
          <p>[ ]    [ ]     T3      Tumor more than 5 cm in greatest dimension</p>
          <p>[ ]    [ ]     T4      Tumor of any size invades adjacent organ(s),</p>
          <p>                       vagina,urethra,bladder*</p>
          <p></p>
          <p>			   *Direct invasion of the rectal wall, perirectal skin,                         </p>
          <p>			   subcutaneous tissue, or the sphincter muscle(s) is not </p>
          <p>			   classified as T4)</p>
          <p> </p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Metastasis in perirectal lymph node(s)</p>
          <p>[ ]    [ ]     N2      Metastasis in unilateral internal iliac</p>
          <p>                       and/or inguinal lymph node(s)</p>
          <p>[ ]    [ ]     N3      Metastasis in perirectal &amp; inguinal lymph nodes</p>
          <p>                       and/or bilateral internal iliac and/or</p>
          <p>                       inguinal lymph nodes</p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p>        STAGE GROUPING</p>
          <p>[ ]    [ ]     0       Tis     N0      M0</p>
          <p>[ ]    [ ]     I       T1      N0      M0</p>
          <p>[ ]    [ ]     II      T2      N0      M0</p>
          <p>                       T3      N0      M0</p>
          <p>[ ]    [ ]     IIIA    T1      N1      M0</p>
          <p>                       T2      N1      M0</p>
          <p>                       T3      N1      M0</p>
          <p>                       T4      N0      M0</p>
          <p>[ ]    [ ]     IIIB    T4      N1      M0</p>
          <p>                       Any T   N2      M0</p>
          <p>                       Any T   N3      M0</p>
          <p>[ ]    [ ]     IV      Any T   Any N   M1</p>
          <p>[ ]    [ ]     STAGE UNKNOWN</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT: HPV Status _________</p>
          <p></p>
          <p>GRADING SYSTEM                                  GRADE</p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been</p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some</p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC APPENDIX STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>APPENDIX</p>
          <p>(Carcinomas and carcinoid tumors of the appendix are included, but separately </p>
          <p>categorized) </p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:  ___________</p>
          <p></p>
          <p>CARCINOMA</p>
          <p></p>
          <p>CLIN   PATH            PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis     Carcinoma in situ, intraepithelial or </p>
          <p>                       invasion of lamina propria*</p>
          <p>[ ]    [ ]     T1      Tumor invades submucosa</p>
          <p>[ ]    [ ]     T2      Tumor invades muscularis propria</p>
          <p>[ ]    [ ]     T3      Tumor invades through muscularis propria into</p>
          <p>                       subserosa, or into mesoappendix</p>
          <p>[ ]    [ ]     T4      Tumor penetrates visceral peritoneum, </p>
          <p>                       including mucinous peritoneal tumor within </p>
          <p>                       the right lower quadrant and/or directly </p>
          <p>                       invades other organs or structures**,***</p>
          <p>[ ]    [ ]     T4a     Tumor penetrates visceral peritoneum, </p>
          <p>                       including mucinous peritoneal tumor within</p>
          <p>                       the right lower quadrant</p>
          <p>[ ]    [ ]     T4b     Tumor directly invades other organs or </p>
          <p>                       structures</p>
          <p></p>
          <p></p>
          <p>* Tis includes cancer cells confined within the glandular basement</p>
          <p>membrane (intraepithelial) or lamina propria (intramucosal) with no</p>
          <p>extension through the muscularis mucosae into the submucosa.</p>
          <p>** Direct invasion in T4 includes invasion of the other segments of the </p>
          <p>colorectum by way of the serosa, e.g. invasion of ileum.</p>
          <p>*** Tumor that is adherent to other organs or structures, grossly, is </p>
          <p>classified cT4b. However, if no tumor is present in the adhesion, </p>
          <p>microscopically, the classification should be pT1-3 depending on the </p>
          <p>anatomical depth of wall invasion.</p>
          <p></p>
          <p>CARCINOID </p>
          <p>CLIN   PATH            PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     T1      Tumor 2 cm or less in greatest dimension</p>
          <p>[ ]    [ ]     T1a     Tumor 1 cm or less in greatest dimension</p>
          <p>[ ]    [ ]     T1b     Tumor more than 1 cm but not more than 2 cm</p>
          <p>[ ]    [ ]     T2      Tumor more than 2 cm but not more than 4 cm</p>
          <p>                       or with extension to the cecum</p>
          <p>[ ]    [ ]     T3      Tumor more than 4 cm or with extension to the</p>
          <p>                       ileum</p>
          <p>[ ]    [ ]     T4      Tumor directly invades other adjacent organs </p>
          <p>                       or structures, e.g., abdominal wall and </p>
          <p>                       skeletal muscle*</p>
          <p></p>
          <p>Note: Tumor that is adherent to other organs or structures, grossly, is </p>
          <p>classified cT4. However, if no tumor is present in the adhesion, microscopically,</p>
          <p>the classification should be classified pT1-3 depending on the anatomical depth</p>
          <p>of wall invasion.</p>
          <p></p>
          <p>*Penetration of the mesoappendix does not seem to be as important a prognostic</p>
          <p>factor as the size of the primary tumor and is not separately categorized.</p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>               CARCINOMA</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Metastasis in 1 to 3 regional nodes</p>
          <p>[ ]    [ ]     N2      Metastasis in 4 or more regional lymph nodes</p>
          <p> </p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>               CARCINOID</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Regional lymph node metastasis</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>               CARCINOMA</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p>[ ]    [ ]     M1a     Intraperitoneal metastasis beyond the right </p>
          <p>                       lower quadrant, including pseudomyxoma </p>
          <p>                       peritonei</p>
          <p>[ ]    [ ]     M1b     Non-peritoneal metastasis</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>               CARCINOID</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    STAGE GROUPING</p>
          <p>CARCINOMA</p>
          <p>[ ]    [ ]     0       Tis     N0      M0</p>
          <p>[ ]    [ ]     I       T1      N0      M0</p>
          <p>                       T2      N0      M0</p>
          <p>[ ]    [ ]     IIA     T3      N0      M0</p>
          <p>[ ]    [ ]     IIB     T4a     N0      M0</p>
          <p>[ ]    [ ]     IIC     T4b     N0      M0</p>
          <p>[ ]    [ ]     IIIA    T1      N1      M0</p>
          <p>                       T2      N1      M0</p>
          <p>[ ]    [ ]     IIIB    T3      N1      M0</p>
          <p>                       T4      N1      M0</p>
          <p>[ ]    [ ]     IIIC    Any T   N2      M0</p>
          <p>[ ]    [ ]     IVA     Any T   N0      M1a  G1</p>
          <p>[ ]    [ ]     IVB     Any T   N0      M1a  G2,3</p>
          <p>                       Any T   N1      M1a  Any G</p>
          <p>                       Any T   N2      M1a  Any G</p>
          <p>[ ]    [ ]     IVC     Any T   Any N   M1b  Any G</p>
          <p>[ ]            UNKNOWN STAGE</p>
          <p></p>
          <p>CLIN   PATH    STAGE GROUPING</p>
          <p>CARCINOID</p>
          <p>[ ]    [ ]     I       T1      N0      M0</p>
          <p>[ ]    [ ]     II      T2,3    N0      M0</p>
          <p>[ ]    [ ]     III     T4      N0      M0</p>
          <p>                       Any T   N1      M0</p>
          <p>[ ]    [ ]     IV      Any T   Any N   M1</p>
          <p>[ ]            UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p></p>
          <p>Carcinoma</p>
          <p></p>
          <p>REQUIRED FOR STAGING: Grade</p>
          <p>CLINICALLY SIGNIFICANT:Preoperative/Pretreatment CEA):___________</p>
          <p>Preoperative/Pretreatment CA 19-9: ___________</p>
          <p>Tumor Deposits (TD): ___________</p>
          <p>Microsatellite instability (MSI): ___________</p>
          <p>18q Loss of Heterozygosity (LOH): ___________</p>
          <p></p>
          <p>Carcinoid</p>
          <p></p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Serum Chromaganin A __________</p>
          <p></p>
          <p>GRADING SYSTEM 					GRADE</p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X: Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been</p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some</p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC DISTAL BILE DUCT STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>DISTAL BILE DUCT</p>
          <p>(Sarcoma and carcinoid tumors are not included)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis     Carcinoma in situ</p>
          <p>[ ]    [ ]     T1      Tumor confined to the bile duct histologically</p>
          <p>[ ]    [ ]     T2      Tumor invades beyond the wall of the bile duct</p>
          <p>[ ]    [ ]     T3      Tumor invades the gallbladder, pancreas, duodenum or</p>
          <p>                       other adjacent organs without involvement of the</p>
          <p>                       celiac axis, or the superior mesenteric artery</p>
          <p>[ ]    [ ]     T4      Tumor invades celiac axis, or the superior mesenteric</p>
          <p>                       artery</p>
          <p> </p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Regional lymph node metastasis</p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; </p>
          <p>                       use clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>[ ]    [ ]     0       Tis     N0      M0</p>
          <p>[ ]    [ ]     IA      T1      N0      M0</p>
          <p>[ ]    [ ]     IB      T2      N0      M0</p>
          <p>[ ]    [ ]     IIA     T3      N0      M0</p>
          <p>[ ]    [ ]     IIB     T1      N1      M0</p>
          <p>                       T2      N1      M0</p>
          <p>                       T3      N1      M0</p>
          <p>[ ]    [ ]     III     T4      Any N   M0</p>
          <p>[ ]    [ ]     IV      Any T   Any N   M1</p>
          <p>[ ]    [ ]     UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>   Tumor location: _________</p>
          <p></p>
          <p>   Carcinoembryonic antigen (CEA): _______</p>
          <p></p>
          <p>   CA 19-9: _______</p>
          <p></p>
          <p></p>
          <p>GRADING SYSTEM 					GRADE</p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>  [ ]NCCN </p>
          <p>  [ ]Other (describe):</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC INTRAHEPATIC BILE DUCT STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>INTRAHEPATIC BILE DUCTS</p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size: ___________________</p>
          <p> </p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p> </p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis     Carcinoma in situ (intraductal tumor)</p>
          <p>[ ]    [ ]     T1      Solitary tumor without vascular invasion</p>
          <p>[ ]    [ ]     T2a     Solitary tumor with vascular invasion</p>
          <p>[ ]    [ ]     T2b     Multiple tumors with or without vascular</p>
          <p>                       invasion </p>
          <p>[ ]    [ ]     T3      Tumor perforating the visceral peritoneum or </p>
          <p>                       involving the local extra hepatic structures </p>
          <p>                       by direct invasion</p>
          <p>[ ]    [ ]     T4      Tumor with periductal invasion</p>
          <p></p>
          <p>                       REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph node metastasis cannot be </p>
          <p>                       assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Regional lymph node metastasis present</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>[ ]    [ ]     0       Tis     N0      M0</p>
          <p>[ ]    [ ]     I       T1      N0      M0</p>
          <p>[ ]    [ ]     II      T2      N0      M0</p>
          <p>[ ]    [ ]     III     T3      N0      M0</p>
          <p>[ ]    [ ]     IVA     T4      N0      M0</p>
          <p>                       Any T   N1      M0</p>
          <p>[ ]    [ ]     IVB     Any T   Any N   M1</p>
          <p>[ ]    [ ]     UNKNOWN STAGE</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Tumor growth pattern: ____________________</p>
          <p>Primary sclerosing cholangitis: ____________________</p>
          <p>CA 19-9: ____________________</p>
          <p></p>
          <p>GRADING SYSTEM 					GRADE</p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been</p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some</p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC PERIHILAR BILE DUCT STAGING  7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>PERIHILAR BILE DUCTS</p>
          <p>(Sarcomas and carcinoid tumors are not included)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ] y-Clinical staging completed after neoadjuvant therapy</p>
          <p>    but before subsequent surgery</p>
          <p></p>
          <p>[ ] y-Pathologic staging completed after neoadjuvant therapy</p>
          <p>    AND subsequent surgery</p>
          <p></p>
          <p>Tumor Size: __________________</p>
          <p></p>
          <p> </p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis     Carcinoma in situ</p>
          <p>[ ]    [ ]     T1      Tumor confined to the bile duct with </p>
          <p>                       extension up to the muscle layer or fibrous </p>
          <p>                       tissue</p>
          <p>[ ]    [ ]     T2a     Tumor invades beyond the wall of the bile </p>
          <p>                       duct to surrounding adipose tissue</p>
          <p>[ ]    [ ]     T2b     Tumor invades adjacent hepatic parenchyma</p>
          <p>[ ]    [ ]     T3      Tumor invades unilateral branches of the </p>
          <p>                       portal vein or hepatic artery</p>
          <p>[ ]    [ ]     T4      Tumor invades main portal vein or its </p>
          <p>                       branches bilaterally; or the common hepatic </p>
          <p>                       artery; or the second-order biliary radicals </p>
          <p>                       bilaterally; or unilateral second-order </p>
          <p>                       biliary radicals with contralateral portal </p>
          <p>                       vein or hepatic artery involvement</p>
          <p></p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph node metastasis cannot be </p>
          <p>                       assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Regional lymph node metastasis (including </p>
          <p>                       nodes along the cystic duct, common bile </p>
          <p>                       duct, hepatic artery, and portal vein)</p>
          <p>[ ]    [ ]     N2      Metastasis to periaortic, pericaval, superior </p>
          <p>                       mesentery artery, and/or celiac artery lymph </p>
          <p>                       nodes</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p>                       STAGE GROUPING</p>
          <p>[ ]    [ ]     0       Tis     N0      M0</p>
          <p>[ ]    [ ]     I       T1      N0      M0</p>
          <p>[ ]    [ ]     II      T2a-b   N0      M0</p>
          <p>[ ]    [ ]     IIIA    T3      N0      M0</p>
          <p>[ ]    [ ]     IIIB    T1-3    N1      M0</p>
          <p>[ ]    [ ]     IVA     T4      N0-1    M0</p>
          <p>[ ]    [ ]     IVB     Any T   N2      M0</p>
          <p>                       Any T   Any N   M1</p>
          <p>[ ]    [ ]     UNKNOWN STAGE </p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Tumor location: ____________________</p>
          <p>Papillary variant: ____________________</p>
          <p>Tumor growth pattern: ____________________</p>
          <p>Primary sclerosing cholangitis: ____________________</p>
          <p>CA 19-9: ____________________</p>
          <p>Carcinoembryonic antigen (CEA): ____________________</p>
          <p></p>
          <p>GRADING SYSTEM 					GRADE</p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been</p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some</p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC BLADDER (URINARY) STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>URINARY BLADDER</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH     PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Ta      Non invasive papillary carcinoma</p>
          <p>[ ]    [ ]     Tis     Carcinoma in situ (flat tumor)</p>
          <p>[ ]    [ ]     T1      Tumor invades subepithelial connective tissue</p>
          <p>[ ]    [ ]     T2      Tumor invades muscularis propria</p>
          <p>[ ]    [ ]     T2a     Tumor Invades superficial muscularis </p>
          <p>                       propria (inner half)</p>
          <p>[ ]    [ ]     T2b     Tumor Invades deep muscularis propria (outer </p>
          <p>                       half)</p>
          <p>[ ]    [ ]     T3      Tumor invades perivesical tissue</p>
          <p>[ ]    [ ]             T3a     Microscopically</p>
          <p>[ ]    [ ]             T3b     Macroscopically (extravesical mass)</p>
          <p>[ ]    [ }     T4      Tumor invades any of the following: prostatic </p>
          <p>                       stroma, seminal vesicles, uterus,vagina, </p>
          <p>                       pelvic wall, abdominal wall</p>
          <p>[ ]    [ ]             T4a     Tumor invades prostatic stroma,</p>
          <p>                               uterus, vagina</p>
          <p>[ ]    [ ]             T4b     Tumor invades pelvic wall, abdominal </p>
          <p>                               wall</p>
          <p> </p>
          <p> </p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph node metastasis cannot be </p>
          <p>                       assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Single regional lymph node metastasis in the </p>
          <p>                       true pelvis (hypogastric, obturator,external </p>
          <p>                       iliac or presacral lymph node)</p>
          <p>[ ]    [ ]     N2      Multiple regional lymph node metastasis in </p>
          <p>                       the true pelvis (hypogastric,obturator, </p>
          <p>                       external iliac or presacral lymph node </p>
          <p>                       metastasis) </p>
          <p>[ ]    [ ]     N3      Lymph node metastasis to the common iliac </p>
          <p>                       lymph nodes</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p>STAGE GROUPING                        </p>
          <p>[ ]    [ ]     Oa      Ta      N0      M0</p>
          <p>[ ]    [ ]     Ois     Tis     N0      M0</p>
          <p>[ ]    [ ]     I       T1      N0      M0</p>
          <p>[ ]    [ ]     II      T2a     N0      M0</p>
          <p>[ ]    [ ]             T2b     N0      M0</p>
          <p>[ ]    [ ]     III     T3a     N0      M0</p>
          <p>[ ]    [ ]             T3b     N0      M0</p>
          <p>[ ]    [ ]             T4a     N0      M0</p>
          <p>[ ]    [ ]     IV      T4b     N0      M0</p>
          <p>[ ]    [ ]             Any T   N1-3    M0</p>
          <p>[ ]    [ ]             Any T   Any N   M1</p>
          <p>[ ]            Unknown Stage </p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Presence or absence of extranodal extension: ______________________</p>
          <p>Size of the largest tumor deposit in the lymph nodes: _____________</p>
          <p>World Health Organization/International Society of Urologic Pathology (WHO/ISUP) </p>
          <p>grade : _______________________________________</p>
          <p></p>
          <p>HISTOLOGIC GRADE: WHO/ISUP</p>
          <p>[ ] LOW GRADE</p>
          <p>[ ] HIGH GRADE</p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe)</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
          <p> </p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC BONE STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>BONE</p>
          <p>(Primary malignant lymphoma &amp; multiple myeloma are not included)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p>Laterality:</p>
          <p>          [ ] Left</p>
          <p>          [ ] Right</p>
          <p>          [ ] Bilateral</p>
          <p> </p>
          <p> </p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     T1      Tumor 8 cm or less in greatest dimension</p>
          <p>[ ]    [ ]     T2      Tumor more than 8 cm in greatest dimension</p>
          <p>[ ]    [ ]     T3      Discontinuous tumors in the primary bone site.  </p>
          <p> </p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Regional lymph node metastasis</p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]    [ ]     M0      No distant metastasis</p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p>[ ]    [ ]     M1a     Lung</p>
          <p>[ ]    [ ]     M1b     Other distant sites</p>
          <p> </p>
          <p>       STAGE GROUPING</p>
          <p>[ ]    [ ]     IA      T1      N0      M0      G1,2     Low grade     GX</p>
          <p>[ ]    [ ]     IB      T2      N0      M0      G1,2     Low grade     GX</p>
          <p>                       T3      N0      M0      G1,2     Low grade     GX</p>
          <p>[ ]    [ ]     IIA     T1      N0      M0      G3,4     High grade</p>
          <p>[ ]    [ ]     IIB     T2      N0      M0      G3,4     High grade</p>
          <p>[ ]    [ ]     III     T3      N0      M0      G3,4*    High grade</p>
          <p>[ ]    [ ]     IVA     Any T   N0      M1a     Any G</p>
          <p>[ ]    [ ]     IVB     Any T   N1      Any M   Any G</p>
          <p>                       Any T   Any N   M1b     Any G</p>
          <p> *Ewing' sarcoma is G4</p>
          <p>[ ]            Stage Unknown</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING:  None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>     Three dimensions of tumor size ___x___x___</p>
          <p>     Percentage necrosis post neoadjuvant systematic therapy </p>
          <p>      from pathology report: ______</p>
          <p>     Number of resected pulmonary metastases from pathology </p>
          <p>      report:_____  </p>
          <p></p>
          <p> Histologic Grade (G) (also known as overall grade)</p>
          <p> GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>[ ] Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ] Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ] Not Applicable</p>
          <p>[ ] Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>[ ] RX  Presence of residual tumor cannot be assessed.</p>
          <p>[ ] R0  No residual tumor</p>
          <p>[ ] R1  Microscopic residual tumor</p>
          <p>[ ] R2  Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]  Clinical stage was used in the treatment planning (describe):_______</p>
          <p>[ ]  National guidelines were used in treatment planning:</p>
          <p>     [ ]  NCCN</p>
          <p>     [ ]  Other</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
          <p></p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC BREAST STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>BREAST </p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p>Laterality:</p>
          <p>          [ ] Left</p>
          <p>          [ ] Right</p>
          <p>          [ ] Bilateral</p>
          <p> </p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis     Carcinoma in situ</p>
          <p>[ ]    [ ]     Tis     (DCIS) Ductal carcinoma in situ</p>
          <p>[ ]    [ ]     Tis     (LCIS) Lobular carcinoma in situ</p>
          <p>[ ]    [ ]     Tis     (Paget's) Paget's disease of the nipple with no </p>
          <p>                       tumor. Note: Paget's disease of the nipple is NOT</p>
          <p>                       associated with invasive carcinoma and/or carcinoma</p>
          <p>                       in situ (DCIS and/or LCIS) in the underlying breast</p>
          <p>                       parenchyma.  Carcinomas in the breast parenchyma</p>
          <p>                       associated with Paget's disease are categorized</p>
          <p>                       based on the size and characteristics of the</p>
          <p>                       parenchymal disease, although the presence of</p>
          <p>                       Paget's disease should still be noted.</p>
          <p>[ ]    [ ]     T1      Tumor &lt; or = 20 mm in greatest dimension</p>
          <p>[ ]    [ ]     T1mi    Tumor &lt; or = 1 mm in greatest dimension</p>
          <p>[ ]    [ ]     T1a     Tumor &gt;1 mm but &lt; or = 5 mm in greatest dimension</p>
          <p>[ ]    [ ]     T1b     Tumor &gt;5 mm but &lt; or = 10 mm in greatest dimension</p>
          <p>[ ]    [ ]     T1c     Tumor &gt;10 mm but &lt; or = 20 mm in greatest dimension</p>
          <p>[ ]    [ ]     T2      Tumor &gt;20 mm but &lt; or = 50 mm in greatest dimension</p>
          <p>[ ]    [ ]     T3      Tumor &gt;50 mm in greatest dimension</p>
          <p>[ ]    [ ]     T4      Tumor of any size with direct extension to the</p>
          <p>                       chest wall and/or skin,(ulceration or skin nodules)*</p>
          <p>[ ]    [ ]     T4a     Extension to chest wall, not including pectoralis</p>
          <p>                       muscle adherence/invasion</p>
          <p>[ ]    [ ]     T4b     Ulceration and/or ipsilateral satellite nodules</p>
          <p>                       and/or edema (including peau d/orange) of the</p>
          <p>                       skin which do not meet the criteria for</p>
          <p>                       inflammatory carcinoma</p>
          <p>[ ]    [ ]     T4c     Both T4a and T4b</p>
          <p>[ ]    [ ]     T4d     Inflammatory carcinoma**</p>
          <p></p>
          <p>      *Note:  Invasion of the dermis alone does not qualify as T4.</p>
          <p>     **Note:  Inflammatory carcinoma is restricted to cases with typical</p>
          <p>       skin changes involving a third or more of the skin of the breast.</p>
          <p>       while the histologic presence of invasive carcinoma invading </p>
          <p>       dermal lymphatics is supportive to the diagnosis, it is not</p>
          <p>       required nor is dermal lymphatic invasion without typical clinical</p>
          <p>       findings sufficient for a diagnosis of inflammatory breast cancer.</p>
          <p></p>
          <p>CLINICAL               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]            NX      Regional lymph nodes cannot be assessed</p>
          <p>                       (e.g. previously removed)   </p>
          <p>[ ]            N0      No regional lymph node metastases</p>
          <p>[ ]            N1      Metastases to movable ipsilateral level I,II</p>
          <p>                       axillary lymph node(s)</p>
          <p>[ ]            N2      Metastases in ipsilateral level I, II, axillary</p>
          <p>                       lymph nodes that are clinically fixed or matted</p>
          <p>                       or in clinically detected* ipsilateral internal</p>
          <p>                       mammary nodes in the absence of clinically evident </p>
          <p>                       axillary lymph node metastasis </p>
          <p>[ ]            N2a     Metastases in ipsilateral axillary lymph </p>
          <p>                       nodes fixed to one another (matted) or to </p>
          <p>                       other structures.</p>
          <p>[ ]            N2b     Metastases only in clinically detected*** </p>
          <p>                       ipsilateral internal mammary nodes and </p>
          <p>                       in the absence of clinically evident </p>
          <p>                       axillary lymph node metastasis.</p>
          <p>[ ]            N3      Metastases in ipsilateral infraclavicular </p>
          <p>                       (level III axillary) lymph node(s) with or</p>
          <p>                       without level I, II axillary lymph node </p>
          <p>                       involvement or in clinically detected* ipsilateral</p>
          <p>                       internal mammary lymph node(s) with clinically</p>
          <p>                       evident level I, II axillary lymph node </p>
          <p>                       metastases; or metastases in ipsilateral </p>
          <p>                       supraclavicular lymph node(s) with or </p>
          <p>                       without axillary or internal mammary lymph </p>
          <p>                       node involvement.</p>
          <p>[ ]            N3a     Metastases in ipsilateral infraclavicular lymph </p>
          <p>                       node(s).</p>
          <p>[ ]            N3b     Metastases in ipsilateral internal mammary lymph </p>
          <p>                       node(s) and axillary lymph node(s)</p>
          <p>[ ]            N3c     Metastases in ipsilateral supraclavicular lymph </p>
          <p>                       node(s)</p>
          <p>PATHOLOGIC CLASSIFICATION OF LYMPH NODES (pN)</p>
          <p>       [ ]     pNX     Regional lymph nodes cannot be assessed (e.g. </p>
          <p>                       previously removed or not removed for pathological </p>
          <p>                       study)</p>
          <p>       [ ]     pN0     No regional lymph node metastasis histologically, </p>
          <p>       [ ]     pN0(i-) No regional lymph node metastasis histologically,</p>
          <p>                       negative IHC.</p>
          <p>       [ ]     pN0(i+) Malignant cells in regional lymph node(s) no</p>
          <p>                       greater than 0.2 mm (detected by H&amp;E or IHC</p>
          <p>                       including ITC)</p>
          <p>       [ ]    pN0(mol-)No regional lymph node metastasis histologically,</p>
          <p>                       negative molecular findings (RT-PCR)</p>
          <p>       [ ]    pN0(mol+)Positive molecular findings (RT-PCR),but no</p>
          <p>                       Regional lymph node metastases detected by</p>
          <p>                       histology or IHC</p>
          <p>       [ ]     pN1     Micrometastasis in 1 to 3 axillary lymph node(s),</p>
          <p>                       and/or in internal mammary nodes with metastases</p>
          <p>                       detected by sentinel lymph node biopsy but not</p>
          <p>                       clinically detected</p>
          <p>       [ ]     pN1mi   Micrometastasis (greater than 0.2 mm, and/or more</p>
          <p>                       Than 200 cells, but more greater than 2.0 mm)</p>
          <p>       [ ]     pN1a    Metastasis in 1 to 3 axillary lymph nodes, at least</p>
          <p>                       One metastasis greater than 2.0 mm.</p>
          <p>       [ ]     pN1b    Metastasis in internal mammary nodes with </p>
          <p>                       micrometastases or macrometastases detected by</p>
          <p>                       sentinel lymph node biopsy but not clinically </p>
          <p>                       detected.</p>
          <p>       [ ]     pN1c    Metastasis in 1 to 3 axillary lymph nodes and in </p>
          <p>                       internal mammary lymph nodes with micrometastastes</p>
          <p>                       or macrometastases detected by sentinel lymph node</p>
          <p>                       biopsy by not clinically detected**</p>
          <p>                       but not clinically apparent.</p>
          <p>       [ ]     pN2     Metastasis in 4 to 9 axillary lymph nodes, or in </p>
          <p>                       clinically detected*** internal mammary lymph </p>
          <p>                       nodes in the absence of axillary lymph node</p>
          <p>                       metastasis.</p>
          <p>       [ ]     pN2a    Metastasis in 4 to 9 axillary lymph nodes (at </p>
          <p>                       least one tumor deposit greater than 2.0mm).</p>
          <p>       [ ]     pN2b    Metastasis in clinically detected*** internal </p>
          <p>                       mammary lymph nodes in the absence of axillary</p>
          <p>                       lymph node metastases.</p>
          <p>       [ ]     pN3     Metastasis in 10 or more axillary lymph nodes, or </p>
          <p>                       in infraclavicular (level III) lymph nodes, or in</p>
          <p>                       clinically detected*** ipsilateral internal mammary</p>
          <p>                       lymph nodes in the presence of 1 or more positive</p>
          <p>                       level I, II axillary lymph nodes; or in more than 3</p>
          <p>                       axillary lymph nodes and in internal mammary lymph</p>
          <p>                       nodes; with micrometastases or macrometastases</p>
          <p>                       detected by sentinel lymph node biopsy but not</p>
          <p>                       clinically detected***.or in ipsilateral</p>
          <p>                       supraclavicular lymph nodes.</p>
          <p>       [ ]     pN3a    Metastases in 10 or more axillary lymph nodes (at </p>
          <p>                       least one tumor deposit greater than 2.0mm) or </p>
          <p>                       metastases to the infraclavicular (level II)</p>
          <p>                       axillary lymph nodes.</p>
          <p>       [ ]     pN3b    Metastases in clinically detected*** ipsilateral </p>
          <p>                       internal mammary lymph nodes or more than 3</p>
          <p>                       axillary lymph nodes and in internal mammary lymph</p>
          <p>                       nodes with micrometastases or macrometastases</p>
          <p>                       detected by sentinel lymph node biopsy but not </p>
          <p>                       clinically detected***.</p>
          <p>       [ ]     pN3c    Metastasis in ipsilateral supraclavicular lymph </p>
          <p>                       nodes.</p>
          <p>      *Classification is based on axillary lymph node dissection with or</p>
          <p>       without sentinel lymph node biopsy.  Classification based solely on</p>
          <p>       sentinel lymph node biopsy without subsequent axillary lymph node</p>
          <p>       dissection is designated (sn) for "sentinel node, " for example</p>
          <p>       pNO(sn).</p>
          <p>     **Note: Not clinically detected is defined as no0t detected by</p>
          <p>       Imaging studies (excluding lymphoscintigraphy) or not detected</p>
          <p>       by clinical examination.</p>
          <p>    ***Note: Clinically detected is defined as detected by </p>
          <p>       imaging studies (excluding lymphoscintigraphy) or by clinical</p>
          <p>       examination and having characteristics highly suspicious for</p>
          <p>       malignancy or a presumed pathologic macrometastasis based on</p>
          <p>       fine needle aspiration biopsy with cytologic examination.</p>
          <p>       Confirmation of clinically detected metastatic disease by fine</p>
          <p>       needle aspiration without excision biopsy designated with an</p>
          <p>       (f) suffix, for example, cN3a(f).  Excisional biopsy of lymph</p>
          <p>       node or biopsy of a sentinel node, in the absence of assignment</p>
          <p>       of a pT, is classified as a clinical N, for example,cN1.</p>
          <p>       Information regarding the confirmation of the nodal status</p>
          <p>       will be designated in site specific factors as clinical, fine needle</p>
          <p>       aspiration, core biopsy, or sentinel lymph node biopsy.  Pathologic</p>
          <p>       classification (pNc) is used for excision or sentinel lymph node</p>
          <p>       biopsy only in conjunction with a pathologic T assignment.</p>
          <p>       Note:  Isolated tumor cell clusters (ITC) are defined as small</p>
          <p>       clusters of cells not greater than 0.2 mm, or single tumor cells,</p>
          <p>       or a cluster of fewer than 200 cells in a single histologic cross</p>
          <p>       section. ITCs may be detected by routine histology or by</p>
          <p>       Immunohistochemical (IHC) methods.  Notes containing only ITCs are</p>
          <p>       excluded from the total positive node count for purposes of N</p>
          <p>       classification but should be included in the total number of nodes</p>
          <p>       evaluated.</p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No clinical or radiographic evidence of distant</p>
          <p>                       metastases (no pathologic MO;  use clinical M to</p>
          <p>                       complete stage group)</p>
          <p>[ ]           cM0(i+)  No clinical or radiographic evidence of distant</p>
          <p>                       metastases, but deposits of molecularly or</p>
          <p>                       microscopically detected tumor cells in circulating</p>
          <p>                       blood, bone marrow or other non-regional nodal</p>
          <p>                       tissue that are no larger than 0.2 mm in a patient</p>
          <p>                       without symptoms or signs of metastases.</p>
          <p>[ ]    [ ]     M1      Distant detectable metastases as determined by</p>
          <p>                       classic clinical and radiographic means and/or</p>
          <p>                       histologically proven larger than 0.2 mm.</p>
          <p>                       Biopsy of metastatic site performed [ ]Y [ ]N</p>
          <p>                       Source of pathologic metastatic specimen _______</p>
          <p>                       </p>
          <p>CLIN   PATH    STAGE GROUPING</p>
          <p> </p>
          <p>[ ]    [ ]     0       Tis     N0      M0</p>
          <p>[ ]    [ ]     IA      T1*     N0      M0</p>
          <p>[ ]    [ ]     IB      T0      N1mi    M0</p>
          <p>[ ]    [ ]             T1*     N1      M0</p>
          <p>[ ]    [ ]     IIA     T0      N1**    M0</p>
          <p>[ ]    [ ]             T1*     N1**    M0</p>
          <p>[ ]    [ ]             T2      N0      M0</p>
          <p>[ ]    [ ]     IIB     T2      N1      M0</p>
          <p>[ ]    [ ]             T3      N0      M0</p>
          <p>[ ]    [ ]     IIIA    T0      N2      M0</p>
          <p>[ ]    [ ]             T1*     N2      M0</p>
          <p>[ ]    [ ]             T2      N2      M0</p>
          <p>[ ]    [ ]             T3      N1      M0</p>
          <p>[ ]    [ ]             T3      N2      M0</p>
          <p>[ ]    [ ]     IIIB    T4      N0      M0</p>
          <p>[ ]    [ ]             T4      N1      M0</p>
          <p>[ ]    [ ]             T4      N2      M0</p>
          <p>[ ]    [ ]     IIIC    Any T   N3      M0</p>
          <p>[ ]    [ ]     IV      Any T   Any N   M1</p>
          <p>[ ]            Stage Unknown </p>
          <p> </p>
          <p> *   T1 includes T1mi</p>
          <p> **  T0 and T1 tumors with nodal micrometastases only are excluded from</p>
          <p>     Stage IIA and are classified Stage IB.</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING:  None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p></p>
          <p>Paget's disease:_______________________________________________________</p>
          <p>Tumor grade (Scarf-Bloom-Richardson system):___________________________</p>
          <p>Estrogen receptor and test method (IHC, RTpPCR, other):________________</p>
          <p>Progesterone receptor and test method (IHC, RT-PCR, other):____________</p>
          <p>HER2 status and test method (IHC, FISH, CISH, RT-PCR, other):__________</p>
          <p>Method of lymph node assessment (e.g. clinical fine needle aspiration, </p>
          <p>   core biopsy, sentinel lymph node biopsy):___________________________</p>
          <p>IHC of regional lymph nodes:___________________________________________</p>
          <p>Molecular studies of regional lymph nodes:_____________________________</p>
          <p>Distant metastases method of detection (clinical, radiographic,</p>
          <p>   biopsy)_____________________________________________________________</p>
          <p>Circulating Tumor Cells (CTC) and method of detection (RT-PCR,</p>
          <p>   immunomagnetic separation, other):__________________________________</p>
          <p>Disseminated Tumor Cells (DTC:  bone marrow micrometastases) and method</p>
          <p>   of detection (RT-PCR, immunohistochemical, other):__________________</p>
          <p>Multi-gene signature score:____________________________________________</p>
          <p>Response to neoadjuvant therapy will be collected in the registry but</p>
          <p>   does not affect the post neoadjuvant stage:_________________________</p>
          <p></p>
          <p>Histologic Grade (G) (also known as overall grade)</p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>Checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>[ ] Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ] Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ] Not Applicable</p>
          <p>[ ] Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>[ ] RX  Presence of residual tumor cannot be assessed.</p>
          <p>[ ] R0  No residual tumor</p>
          <p>[ ] R1  Microscopic residual tumor</p>
          <p>[ ] R2  Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]  Clinical stage was used in the treatment planning (describe):_______</p>
          <p>[ ]  National guidelines were used in treatment planning</p>
          <p>     [ ] NCCN</p>
          <p>     [ ] Other:___________________________________________________________</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
          <p></p>
          <p></p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC CERVIX UTERI STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>CERVIX UTERI</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p></p>
          <p>CLIN   PATH   TNM     FIGO    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX              Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0              No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis     *       Carcinoma in situ (preinvasive tumor)</p>
          <p>[ ]    [ ]     T1      I       Cervical carcinoma confined to uterus</p>
          <p>                              (extension to corpus should be disregarded)</p>
          <p>[ ]    [ ]     T1a     IA      Invasive carcinoma diagnosed only by</p>
          <p>                               microscopy  Stromal invasion with a maximum</p>
          <p>                               depth of 5.0 mm measured from the base of</p>
          <p>                               the epithelium and a horizontal spread of</p>
          <p>                               7.0 mm or less. Vascular space involvement,</p>
          <p>                               venous or lymphatic, does not affect</p>
          <p>                               classification.</p>
          <p>[ ]    [ ]     T1a1    IA1     Measured stromal invasion 3.0 mm or less in</p>
          <p>                               depth &amp; 7.0 mm or less in horizontal spread.</p>
          <p>[ ]    [ ]     T1a2    IA2     Measured stromal invasion more than 3.0 mm</p>
          <p>                               and not more than 5.0 mm with a horizontal</p>
          <p>                               spread 7.0 mm or less.</p>
          <p>[ ]    [ ]     T1b     IB      Clinically visible lesion confined to the</p>
          <p>                               cervix or microscopic lesion greater than</p>
          <p>                               T1a/IA2</p>
          <p>[ ]    [ ]     T1b1    IB1     Clinically visible 4.0 cm or less in greatest</p>
          <p>                               dimension.</p>
          <p>[ ]    [ ]     T1b2    IB2     Clinically visible more than 4.0 cm in greatest</p>
          <p>                               dimension. </p>
          <p>[ ]    [ ]     T2      II      Cervical carcinoma invades beyond uterus</p>
          <p>                               but not to pelvic wall or lower third of</p>
          <p>                               vagina.</p>
          <p>[ ]    [ ]     T2a     IIA     Tumor without parametrial invasion</p>
          <p>[ ]    [ ]     T2a1    IIAI    Clinically visible lesion 4.0 cm or less in</p>
          <p>                               greatest dimension</p>
          <p>[ ]    [ ]     T2a2    IIA2    Clinically visible lesion more than 4.0 cm in</p>
          <p>                               greatest dimension</p>
          <p>[ ]    [ ]     T2b     IIB     Tumor with parametrial invasion</p>
          <p>[ ]    [ ]     T3      III     Tumor extends to pelvic wall and/or </p>
          <p>                               Involves lower 1/3 of vagina and/or causes</p>
          <p>                               hydronephrosis or nonfunctioning kidney</p>
          <p>[ ]    [ ]     T3a     IIIA    Tumor involves lower 1/3 vagina, no</p>
          <p>                               extension to pelvic wall</p>
          <p>[ ]    [ ]     T3b     IIIB    Tumor extends s to pelvic wall and/or</p>
          <p>                               causes hydronephrosis or nonfunctioning</p>
          <p>                               kidney</p>
          <p>[ ]    [ ]     T4      IVA     Tumor invades mucosa of the bladder or</p>
          <p>                               rectum, and/or extends beyond true pelvis</p>
          <p>                               (bullous edema is not sufficient to</p>
          <p>                               classify a tumor as T4.</p>
          <p>    *FIGO staging no longer includes Stage 0 (Tis)</p>
          <p>   **All macroscopically visible lesions - even with superficial invasion</p>
          <p>     Are T1b/IB.</p>
          <p> </p>
          <p>CLIN   PATH    TNM     FIGO   REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX              Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0              No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      IIIB    Regional lymph node metastasis</p>
          <p> </p>
          <p>CLIN   PATH    TNM     FIGO    DISTANT METASTASIS (M)</p>
          <p>[ ]    [ ]     M0              No distant metastasis</p>
          <p>[ ]    [ ]     M1      IVB     Distant metastasis (including peritoneal spread,   </p>
          <p>                               involvement of supraclavicular, mediastinal or</p>
          <p>                               paraaortic lymph nodes,lung,liver,or bone</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    STAGE GROUPING</p>
          <p>[ ]    [ ]     0*      Tis     N0      M0</p>
          <p>[ ]    [ ]     I       T1      N0      M0</p>
          <p>[ ]    [ ]     IA      T1a     N0      M0</p>
          <p>[ ]    [ ]     IA1     T1a1    N0      M0</p>
          <p>[ ]    [ ]     IA2     T1a2    N0      M0</p>
          <p>[ ]    [ ]     IB      T1b     N0      M0</p>
          <p>[ ]    [ ]     IB1     T1b1    N0      M0</p>
          <p>[ ]    [ ]     IB2     T1b2    N0      M0</p>
          <p>[ ]    [ ]     II      T2      N0      M0</p>
          <p>[ ]    [ [     IIA     T2a     N0      M0</p>
          <p>[ ]    [ ]     IIA1    T2a1    N0      M0</p>
          <p>[ ]    [ ]     IIA2    T2a2    N0      M0</p>
          <p>[ ]    [ ]     IIB     T2b     N0      M0</p>
          <p>[ ]    [ ]     III     T3      N0      M0</p>
          <p>[ ]    [ ]     IIIA    T3a     N0      M0</p>
          <p>[ ]]]  [ ]     IIIB    T3b     Any N   M0</p>
          <p>[ ]    [ ]             T1-3    N1      M0</p>
          <p>[ ]    [ ]     IVA     T4      Any N   M0</p>
          <p>[ ]    [ ]     IVB     Any T   Any N   M1</p>
          <p>[ ]    [ ]     Stage Unknown</p>
          <p>    FIGO no longer includes Stage 0 (Tis)</p>
          <p></p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING:  None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>    FIGO Stage:________________________________________________________</p>
          <p>    Pelvic nodal status and method of assessment:______________________</p>
          <p>    Paraaortic nodal status and method of assessment:_________________</p>
          <p>    Distant (mediastinal, scalene) nodal status and method of assessment</p>
          <p>_______________________________________________________________________</p>
          <p></p>
          <p>Histologic Grade (G) (also known as overall grade)</p>
          <p> </p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p></p>
          <p>Endometrioid adenocarcinomas should be graded according to the degree of </p>
          <p>differentiation of the adenocarcinoma as follows:</p>
          <p></p>
          <p>G1 5% or less of a non-squamous or non-morular solid growth pattern</p>
          <p>G2 6% to 50% of a non-squamous or non-morular solid growth pattern</p>
          <p>G3 More than 50% of a non-squamous or non-morular solid growth pattern</p>
          <p></p>
          <p>Notes on Pathologic Grading</p>
          <p>1. Notable nuclear atypia, inappropriate for the architectural grade, raises the </p>
          <p>grade by one.</p>
          <p>2. Serous, clear cell, and mixed mesodermal tumors are Grade 3.</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>Checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>[ ] Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ] Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ] Not Applicable</p>
          <p>[ ] Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>[ ] RX  Presence of residual tumor cannot be assessed.</p>
          <p>[ ] R0  No residual tumor</p>
          <p>[ ] R1  Microscopic residual tumor</p>
          <p>[ ] R2  Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]  Clinical stage was used in the treatment planning (describe):_______</p>
          <p>[ ]  National guidelines were used in treatment planning:</p>
          <p>     [ ]  NCCN</p>
          <p>     [ ]  Other</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC COLON AND RECTUM STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>COLON AND RECTUM</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p> </p>
          <p>(Sarcomas, lymphomas, and carcinoid tumors of the large intestine </p>
          <p>are excluded)</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:  ____________</p>
          <p></p>
          <p> </p>
          <p>CLIN   PATH            PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis     Carcinoma in situ, intraepithelial or </p>
          <p>                       invasion of lamina propria*</p>
          <p>[ ]    [ ]     T1      Tumor invades submucosa</p>
          <p>[ ]    [ ]     T2      Tumor invades muscularis propria</p>
          <p>[ ]    [ ]     T3      Tumor invades thru the muscularis propria </p>
          <p>                       into pericolorectal tissues</p>
          <p>[ ]    [ ]     T4a     Tumor penetrates to the surface of the </p>
          <p>                       visceral peritoneum**</p>
          <p>[ ]    [ ]     T4b     Tumor directly invades or is adherent to </p>
          <p>                       other organs or structures **,***</p>
          <p> </p>
          <p>* Note: Includes cancer cells confined within the glandular basement</p>
          <p>membrane (intraepithelial) or mucosal lamina propria (intramucosal) with no </p>
          <p>extension through the muscularis mucosae into the submucosa.</p>
          <p></p>
          <p>** Note: Direct invasion in T4 includes invasion of other organs or </p>
          <p>other segments of the colorectum as a result of direct extension </p>
          <p>through the serosa, as confirmed on microscopic examination (for </p>
          <p>example, invasion of the sigmoid colon by a carcinoma of the cecum) </p>
          <p>or, for cancers in a retro-peritoneal or subperitoneal location, </p>
          <p>direct invasion of other organs or structures by virtue of extension</p>
          <p>beyond the muscularis propria (i.e., respectively, a tumor on the </p>
          <p>posterior wall of the descending colon invading the left kidney or </p>
          <p>lateral abdominal wall; or a mid or distal rectal cancer with </p>
          <p>invasion of prostate, seminal vesicles, cervix or vagina).</p>
          <p></p>
          <p>*** Note: Tumor that is adherent to other organs or structures, </p>
          <p>grossly, is classified cT4b. However, if no tumor is present in the </p>
          <p>adhesion, microscopically, the classification should be pT1-4a </p>
          <p>depending on the anatomical depth of wall invasion. The V and</p>
          <p>L classifications should be used to identify the presence or absence </p>
          <p>of vascular or lymphatic invasion whereas the PN site-specific factor should be </p>
          <p>used for perineural invasion.</p>
          <p></p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Metastasis in 1 to 3 regional nodes</p>
          <p>[ ]    [ ]     N1a     Metastasis in 1 regional lymph node</p>
          <p>[ ]    [ ]     N1b     Metastasis in 2-3 regional lymph nodes</p>
          <p>[ ]    [ ]     N1c     Tumor deposit(s) in the subserosa, mesentery, </p>
          <p>                       or non-peritonealized pericolic or perirectal </p>
          <p>                       tissues without regional nodal metastasis</p>
          <p>[ ]    [ ]     N2      Metastasis in 4 or more regional lymph nodes</p>
          <p>[ ]    [ ]     N2a     Metastasis in 4 to 6 regional lymph nodes</p>
          <p>[ ]    [ ]     N2b     Metastasis in 7 or more regional lymph nodes</p>
          <p></p>
          <p>Note: A satellite peritumoral nodule in the pericolorectal adipose </p>
          <p>tissue of a primary carcinoma without histologic evidence of </p>
          <p>residual lymph node in the nodule may represent discontinuous </p>
          <p>spread, venous invasion with extravascular spread (V1/2) or a</p>
          <p>totally replaced lymph node (N1/2). Replaced nodes should be counted </p>
          <p>separately as positive nodes in the N category, whereas </p>
          <p>discontinuous spread or venous invasion should be classified and </p>
          <p>counted in the Site-Specific Factor category Tumor Deposits</p>
          <p>(TD).</p>
          <p></p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p>[ ]    [ ]     M1a     Metastasis confined to one organ or site(e.g. </p>
          <p>                       liver, lung, ovary, non-regional node)</p>
          <p>[ ]    [ ]     M1b     Metastasis in more than one organ/site/or the </p>
          <p>                       peritoneum</p>
          <p></p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    STAGE GROUPING                  DUKES*  MAC*</p>
          <p></p>
          <p>[ ]    [ ]     0       Tis     N0      M0      -        -</p>
          <p>[ ]    [ ]     I       T1      N0      M0      A        A</p>
          <p>	                T2      N0      M0               B1</p>
          <p>[ ]    [ ]     IIA     T3      N0      M0      B        B2</p>
          <p>[ ]    [ ]     IIB     T4a     N0      M0      B        B2</p>
          <p>[ ]    [ ]     IIC     T4b     N0      M0      B        B3</p>
          <p>[ ]    [ ]     IIIA    T1-T2   N1/N1C  M0      C        C1</p>
          <p>	                T1      N2a     M0      C        C1</p>
          <p>[ ]    [ ]     IIIB    T3-T4a  N1/N1C  M0      C        C2</p>
          <p>	                T2-T3   N2a     M0      C        C1/C2</p>
          <p>                       T1-T2   N2b     M0      C        C1</p>
          <p>[ ]    [ ]     IIIC    T4a     N2a     M0      C        C2</p>
          <p>                       T3-T4a  N2b     M0      C        C2</p>
          <p>                       T4b     N1/N2   M0      C        C3</p>
          <p>[ ]    [ ]     IVA     Any T   Any N   M1a     -        -</p>
          <p>[ ]    [ ]     IVB     Any T   Any N   M1b     -        -</p>
          <p>[ ]            STAGE UNKNOWN</p>
          <p></p>
          <p>*Dukes B is a composite of better (T3 N0 M0) and worse (T4 N0 M0) </p>
          <p>Prognostic groups, as is Dukes C (Any TN1 M0 and Any T N2 M0). MAC </p>
          <p>is the modified Astler-Coller classification.</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT: Preoperative/Pretreatment </p>
          <p>carcinoembryonic antigen (CEA) ng/ml: ___________</p>
          <p>Tumor Deposits (TD): ___________</p>
          <p>Circumferential Resection Margin (CRM): ___________</p>
          <p>Perineural Invasion (PN): ___________</p>
          <p>Microsatellite instability (MSI): ___________</p>
          <p>Tumor Regression Grade (with neoadjuvant </p>
          <p>therapy): ___________</p>
          <p>KRAS gene analysis: ___________</p>
          <p>18q Loss of Heterozygosity (LOH) assay: ___________</p>
          <p></p>
          <p>GRADING SYSTEM 					GRADE</p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been</p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some</p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC CONJUNCTIVA CARCINOMA STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>CONJUNCTIVA CARCINOMA</p>
          <p>Note: excludes melanoma and malignancies other than carcinoma.</p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p>Laterality:</p>
          <p> [ ] Left</p>
          <p> [ ] Right</p>
          <p> [ ] Bilateral</p>
          <p></p>
          <p></p>
          <p>CLIN  PATH     PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX   Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0   No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis  Carcinoma in situ</p>
          <p>[ ]    [ ]     T1   Tumor 5 mm or less in greatest dimension</p>
          <p>[ ]    [ ]     T2   Tumor more than 5 mm in greatest dimension, without </p>
          <p>                    invasion of adjacent structures</p>
          <p>[ ]    [ ]     T3   Tumor invades adjacent structures (excluding the </p>
          <p>                    orbit)</p>
          <p>[ ]    [ ]     T4   Tumor invades the orbit with or without further </p>
          <p>                    extension</p>
          <p>[ ]    [ ]     T4a  Tumor invades orbital soft tissues, without bone </p>
          <p>                    invasion</p>
          <p>[ ]    [ ]     T4b  Tumor invades bone</p>
          <p>[ ]    [ ]     T4c  Tumor invades adjacent paranasal</p>
          <p>[ ]    [ ]     T4d  Tumor invades brain</p>
          <p></p>
          <p>               REGIONAL LYMPH NODES  (N)</p>
          <p>[ ]    [ ]     NX   Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0   No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1   Regional lymph node metastasis</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0   No distant metastasis (no pathologic M0; use </p>
          <p>                    clinical M to complete stage group)</p>
          <p>[ ]    [ ]     M1   Distant metastasis</p>
          <p></p>
          <p>               STAGE GROUPING:</p>
          <p>No stage grouping is presently recommended by AJCC</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT: Ki-67 growth fraction</p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be </p>
          <p>                                                       assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>   [ ]NCCN </p>
          <p>   [ ]Other (describe):</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC CUTANEOUS SQUAMOUS CELL STAGING (SKIN) 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>CUTANEOUS SQUAMOUS CELL/OTHER CUTANEOUS CARCINOMA</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p>Laterality:</p>
          <p>          [ ] Left</p>
          <p>          [ ] Right</p>
          <p>          [ ] Midline </p>
          <p>          [ ] Bilateral</p>
          <p></p>
          <p> </p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis     Carcinoma in situ</p>
          <p>[ ]    [ ]     T1      Tumor 2 cm or less with less than two high risk </p>
          <p>                       features**</p>
          <p>[ ]    [ ]     T2      Tumor &gt;2 cm or tumor any size with two or more high risk      </p>
          <p>			  features**</p>
          <p>[ ]    [ ]     T3      Tumor invasion of maxilla, orbit, or temporal bone</p>
          <p>[ ]    [ ]     T4      Tumor invasion of skeleton (axial or appendicular)</p>
          <p>                       or perineural invasion of skull base</p>
          <p></p>
          <p>* Excludes cSCC of the eyelid - See Chapter 48.</p>
          <p>**High Risk Features for the Primary Tumor (T) Staging :</p>
          <p>   Depth/Invasion: &gt;2 mm thickness, Clark level greater than or equal to IV, </p>
          <p>   Perineural invasion. Anatomic Location: Primary site ear, primary site </p>
          <p>   hair-bearing lip. Differentiation: Poorly differentiated or undifferentiated</p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph node cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Mets in a single ipsilateral node, 3 cm or less</p>
          <p>[ ]    [ ]     N2      Mets in single ipsilateral node, &gt;3 cm but not &gt;6 cm; </p>
          <p>                       or multiple ipsilateral nodes, none &gt;6 cm, </p>
          <p>                       or in bilateral or contralateral nodes, none &gt;6 cm </p>
          <p>[ ]    [ ]     N2a     Mets in single ipsilat node &gt;3 cm but not &gt;6 cm</p>
          <p>[ ]    [ ]     N2b     Mets in multiple ipsilatateral nodes, none &gt;6 cm</p>
          <p>[ ]    [ ]     N2c     Mets in bilateral or contralateral nodes, none &gt;6 cm</p>
          <p>[ ]    [ ]     N3      Mets in lymph node &gt;6 cm in greatest dimension</p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            MX      Presence of distant metastasis cannot be assessed</p>
          <p>[ ]    [ ]     M0      No distant metastasis</p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p> </p>
          <p>STAGE GROUPING</p>
          <p>[ ]    [ ]     0       Tis     N0      M0</p>
          <p>[ ]    [ ]     I       T1      N0      M0</p>
          <p>[ ]    [ ]     II      T2      N0      M0</p>
          <p>[ ]    [ ]     III     T3      N0      M0</p>
          <p>[ ]    [ ]             T1      N1      M0</p>
          <p>[ ]    [ ]             T2      N1      M0</p>
          <p>[ ]    [ ]             T3      N1      M0</p>
          <p>[ ]    [ ]     IV      T1      N2      M0</p>
          <p>[ ]    [ ]             T2      N2      M0</p>
          <p>[ ]    [ ]             T3      N2      M0</p>
          <p>[ ]    [ ]             Any T   N3      M0</p>
          <p>[ ]    [ ]             T4      Any N   M0</p>
          <p>[ ]    [ ]             Any T   Any N   M1</p>
          <p>[ ]    [ ]     UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING:</p>
          <p>  Tumor thickness (in mm):  </p>
          <p>  Clark's Level:  </p>
          <p>  Presence / absence of perineural invasion:  </p>
          <p>  Primary site location on ear or hair-bearing lip:  </p>
          <p>  Histologic grade:  </p>
          <p>  Size of largest lymph node metastasis:  </p>
          <p>CLINICALLY SIGNIFICANT: No additional factors</p>
          <p></p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>   [ ]NCCN </p>
          <p>   [ ]Other (describe):</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC ESOPHAGUS AND ESOPHAGOGASTRIC STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>ESOPHAGUS AND ESOPHAGOGASTRIC JUNCTION</p>
          <p>(Nonmucosal cancers are not included)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p> </p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH            PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis     High grade dysplasia*</p>
          <p>[ ]    [ ]     T1      Tumor invades lamina propria, muscularis </p>
          <p>                       mucosae, or submucosa</p>
          <p>[ ]    [ ]     T1a     Tumor invades lamina propria or muscularis </p>
          <p>                       mucosae</p>
          <p>[ ]    [ ]     T1b     Tumor invades submucosa </p>
          <p>[ ]    [ ]     T2      Tumor invades muscularis propria</p>
          <p>[ ]    [ ]     T3      Tumor invades adventitia</p>
          <p>[ ]    [ ]     T4      Tumor invades adjacent structures</p>
          <p>[ ]    [ ]     T4a     Resectable tumor invading pleura, </p>
          <p>                       pericardium, or diaphragm</p>
          <p>[ ]    [ ]     T4b     Unresectable tumor invading other adjacent </p>
          <p>                       structures, such as aorta, vertebral body, </p>
          <p>                       trachea, etc.</p>
          <p></p>
          <p>*High-grade dysplasia includes all non-invasive neoplastic </p>
          <p>epithelium that was formerly called carcinoma in situ, a diagnosis </p>
          <p>that is no longer used for columnar mucosae anywhere in the </p>
          <p>gastrointestinal tract.</p>
          <p></p>
          <p>                       REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Regional lymph node metastases involving 1-2 nodes</p>
          <p>[ ]    [ ]     N2      Regional lymph node metastases involving 3-6 nodes</p>
          <p>[ ]    [ ]     N3      Regional lymph node metastases involving 7 or more </p>
          <p>                       nodes</p>
          <p></p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p>SQUAMOUS CELL CARCINOMA</p>
          <p>                                                      TUMOR</p>
          <p>CLIN   PATH    STAGE GROUPING                GRADE    LOCATION</p>
          <p>[ ]    [ ]     0       Tis(HGD)N0     M0     1        Any</p>
          <p>[ ]    [ ]     IA      T1      N0     M0     1,X      Any</p>
          <p>[ ]    [ ]     IB      T1      N0     M0     2-3      Any</p>
          <p>[ ]    [ ]             T2-3    N0     M0     1,X      Lower,X</p>
          <p>[ ]    [ ]     IIA     T2-3    N0     M0     1,X      Upper,Middle</p>
          <p>[ ]    [ ]             T2-3    N0     M0     2-3      Lower,X</p>
          <p>[ ]    [ ]     IIB     T2-3    N0     M0     2-3      Upper,Middle</p>
          <p>[ ]    [ ]             T1-2    N1     M0     Any      Any</p>
          <p>[ ]    [ ]     IIIA    T1-2    N2     M0     Any      Any</p>
          <p>[ ]    [ ]             T3      N1     M0     Any      Any</p>
          <p>[ ]    [ ]             T4a     N0     M0     Any      Any</p>
          <p>[ ]    [ ]     IIIB    T3      N2     M0     Any      Any</p>
          <p>[ ]    [ ]     IIIC    T4a     N1-2   M0     Any      Any</p>
          <p>[ ]    [ ]             T4b     Any    M0     Any      Any</p>
          <p>[ ]    [ ]             Any     N3     M0     Any      Any</p>
          <p>[ ]    [ ]     IV      Any     Any    M1     Any      Any</p>
          <p>[ ]    [ ]     UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>ADENOCARCINOMA</p>
          <p>* or mixed histology including a squamous component or NOS</p>
          <p>** Location of the primary cancer site is defined by the position of theupper </p>
          <p>(proximal) edge of the tumor in the esophagus</p>
          <p>                                                      </p>
          <p>CLIN   PATH    STAGE GROUPING                GRADE</p>
          <p>[ ]    [ ]     0       Tis(HGD)N0     M0     1,X</p>
          <p>[ ]    [ ]     IA      T1      N0     M0     1-2,X</p>
          <p>[ ]    [ ]     IB      T1      N0     M0     3</p>
          <p>[ ]    [ ]             T2      N0     M0     1-2,X</p>
          <p>[ ]    [ ]     IIA     T2      N0     M0     3</p>
          <p>[ ]    [ ]     IIB     T3      N0     M0     Any</p>
          <p>[ ]    [ ]             T1-2    N1     M0     Any</p>
          <p>[ ]    [ ]     IIIA    T1-2    N2     M0     Any</p>
          <p>[ ]    [ ]             T3      N1     M0     Any</p>
          <p>[ ]    [ ]             T4a     N0     M0     Any</p>
          <p>[ ]    [ ]     IIIB    T3      N2     M0     Any</p>
          <p>[ ]    [ ]     IIIC    T4a     N1-2   M0     Any</p>
          <p>[ ]    [ ]             T4b     Any    M0     Any</p>
          <p>[ ]    [ ]             Any     N3     M0     Any</p>
          <p>[ ]    [ ]     IV      Any     Any    M1     Any</p>
          <p>[ ]            UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>SQUAMOUS CELL CARCINOMA</p>
          <p></p>
          <p>REQUIRED FOR STAGING: </p>
          <p>Location-based on the position of the upper (proximal) edge of the tumor in </p>
          <p>the esophagus:</p>
          <p>    Upper or middle-cancers above lower border of interior pulmonary vein; </p>
          <p>    Lower-below inferior pulmonary vein)</p>
          <p></p>
          <p>Grade: ____</p>
          <p></p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Distance to proximal edge of tumor from incisors: ___________</p>
          <p>Distance to distal edge of tumor from incisors: ___________</p>
          <p>Number of regional nodes with extracapsular tumor: ___________</p>
          <p></p>
          <p>ADENOCARCINOMA</p>
          <p>REQUIRED FOR STAGING: </p>
          <p>Grade: ____</p>
          <p></p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Distance to proximal edge of tumor from incisors: ___________</p>
          <p>Distance to distal edge of tumor from incisors: ___________</p>
          <p>Number of regional nodes with extracapsular tumor: ___________</p>
          <p></p>
          <p></p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been</p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some</p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC EYELID CARCINOMA STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>EYELID CARCINOMA</p>
          <p></p>
          <p>7th Edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p>Laterality:</p>
          <p> [ ] Left</p>
          <p> [ ] Right</p>
          <p> [ ] Bilateral</p>
          <p></p>
          <p></p>
          <p>Clin    Path    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]    TX   Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]    TO   No evidence of primary tumor</p>
          <p>[ ]    [ ]    Tis  Carcinoma in situ</p>
          <p>[ ]    [ ]    T1   Tumor 5mm or less in greatest dimension</p>
          <p>                   not invading the tarsal plate or eyelid margin, </p>
          <p>[ ]    [ ]    T2a  Tumor more than 5mm, but not more than 10mm in </p>
          <p>                   greatest dimension. Or, any tumor that invades the </p>
          <p>                   tarsal plate or eyelid margin.</p>
          <p>[ ]    [ ]    T2b  Tumor more than 10mm, but not more than 20mm in </p>
          <p>                   greatest dimension. Or, involves full thickness </p>
          <p>                   eyelid.</p>
          <p>[ ]    [ ]    T3a  Tumor more than 20mm in greatest dimension.</p>
          <p>                   Or, any tumor that invades adjacent ocular, or </p>
          <p>                   orbital structures. Any T with perineural tumor </p>
          <p>                   invasion.</p>
          <p>[ ]    [ ]    T3b  Tumor complete resection requires enucleation, </p>
          <p>                   exenteration or bone resection.</p>
          <p>[ ]    [ ]    T4   Tumor is not resectable due to extensive invasion </p>
          <p>                   of ocular, orbital, craniofacial structures or </p>
          <p>                   brain.</p>
          <p></p>
          <p>                REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]    NX   Regional lymph nodes cannot be assessed</p>
          <p>[ ]           NO   No regional lymph node metastasis;based upon clinical </p>
          <p>                   evaluation or imaging</p>
          <p>       [ ]    N0   No reginal lymph node metastasis; based upon lymph </p>
          <p>                   node biopsy.</p>
          <p>[ ]    [ ]    N1   Regional lymph node metastasis</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]             M0   No distant metastasis (no pathologic M0; use </p>
          <p>                     clinical M to complete stage group)</p>
          <p>[ ]    [ ]      M1   Distant metastasis</p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>[ ]    [ ]   0      Tis     N0     M0</p>
          <p>[ ]    [ ]   IA     T1      N0     M0</p>
          <p>[ ]    [ ]   IB     T2a     N0     M0</p>
          <p>[ ]    [ ]   IC     T2b     N0     M0</p>
          <p>[ ]    [ ]   II     T3a     N0     M0</p>
          <p>[ ]    [ ]   III A  T3b     N0     M0</p>
          <p>[ ]    [ ]   III B  Any T   N1     M0</p>
          <p>[ ]    [ ]   III C  T4      Any N  M0</p>
          <p>[ ]    [ ]   IV     Any T   Any N  M1</p>
          <p>[ ]    [ ]   Stage unknown</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>  Sentinel Lymph Node Biopsy (SLNB) results: </p>
          <p>  Regional nodes identified on clinical or radiographic examination:</p>
          <p>  Perineural invasion: </p>
          <p>  Tumor necrosis: </p>
          <p>  Pagetoid spread: </p>
          <p>  More than 3 Mohs micrographic surgical layers required: </p>
          <p>  Immunosuppression - patient has HIV: </p>
          <p>  Immunosuppression - history of solid organ transplant or leukemia: </p>
          <p>  Prior radiation to the tumor field: </p>
          <p>  Excluding skin cancer, patient has history of two or more carcinomas: </p>
          <p>  Patient has Muir-Torre syndrome:</p>
          <p>  Patient has xeroderma pigmentosa: </p>
          <p></p>
          <p>For Eyelid Cutaneous Squamous Cell Carcinoma only (see cSCC, Chapter </p>
          <p>29):</p>
          <p>REQUIRED FOR STAGING:</p>
          <p>    Tumor thickness (in mm): </p>
          <p>    Clark's Level: </p>
          <p>    Presence / absence of perineural invasion: </p>
          <p>    Primary site location on ear or non-glabrous lip: </p>
          <p>    Histologic grade: </p>
          <p>    Size of largest lymph node metastasis: </p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be </p>
          <p>                                                       assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>   [ ]NCCN </p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC FALLOPIAN TUBE STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>FALLOPIAN TUBE</p>
          <p></p>
          <p>7th Edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p>Laterality:</p>
          <p>          [ ] Left</p>
          <p>          [ ] Right</p>
          <p>          [ ] Bilateral</p>
          <p></p>
          <p></p>
          <p></p>
          <p>CLIN   PATH   TNM     FIGO    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX             Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0             No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis     *      Carcinoma in situ (limited to tubal </p>
          <p>                              mucosa)</p>
          <p>[ ]    [ ]     T1      I      Tumor limited to the fallopian tube(s)</p>
          <p>[ ]    [ ]     T1a     IA     Tumor limited to one tube, without </p>
          <p>                              penetrating the serosal surface; no </p>
          <p>                              ascites</p>
          <p>[ ]    [ ]     T1b     IB     Tumor limited to both tubes, without </p>
          <p>                              penetrating the serosal surface; no </p>
          <p>                              ascites</p>
          <p>[ ]    [ ]     T1c     IC     Tumor limited to one or both tubes with </p>
          <p>                              extension onto or through the tubal </p>
          <p>                              serosa, or with malignant cells in </p>
          <p>                              ascites or peritoneal washings</p>
          <p>[ ]    [ ]     T2      II     Tumor involves one or both fallopian </p>
          <p>                              tubes with pelvic extension</p>
          <p>[ ]    [ ]     T2a     IIA    Extension and/or metastasis to the uterus </p>
          <p>                              and/or ovaries</p>
          <p>[ ]    [ ]     T2b     IIB    Extension to other pelvic structures</p>
          <p>[ ]    [ ]     T2c     IIC    Pelvic extension with malignant cells in </p>
          <p>                              ascites or peritoneal washings</p>
          <p>[ ]    [ ]     T3      III    Tumor involves one or both fallopian </p>
          <p>                              tubes, with peritoneal implants outside </p>
          <p>                              the pelvis</p>
          <p>[ ]    [ ]     T3a     IIIA   Microscopic peritoneal metastasis outside </p>
          <p>                              the pelvis</p>
          <p>[ ]    [ ]     T3b     IIIB   Macroscopic peritoneal metastasis outside </p>
          <p>                              the pelvis 2 cm or less in greatest </p>
          <p>                              dimension</p>
          <p>[ ]    [ ]     T3c     IIIC   Peritoneal metastasis outside the pelvis </p>
          <p>                              and more than 2 cm in diameter</p>
          <p></p>
          <p>* FIGO no longer includes Stage 0 (Tis)</p>
          <p>Note: Liver capsule metastasis is T3/Stage III; liver parenchymal </p>
          <p>Metastasis is M1/Stage IV. Pleural effusion must have positive cytology for </p>
          <p>M1/Stage IV.</p>
          <p></p>
          <p>                              REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX             Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0             No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1             Regional lymph node metastasis</p>
          <p></p>
          <p>                              DISTANT METASTASIS (M)</p>
          <p>[ ]            M0             No distant metastasis (no pathologic M0; </p>
          <p>                              use clinical M to complete stage group)</p>
          <p>[ ]    [ ]     M1             Distant metastasis</p>
          <p></p>
          <p>CLIN   PATH   TNM     STAGE GROUPING</p>
          <p>[ ]    [ ]     0*     Tis      N0      M0</p>
          <p>[ ]    [ ]     I      T1       N0      M0</p>
          <p>[ ]    [ ]     IA     T1a      N0      M0</p>
          <p>[ ]    [ ]     IB     T1b      N0      M0</p>
          <p>[ ]    [ ]     IC     T1c      N0      M0</p>
          <p>[ ]    [ ]     II     T2       N0      M0</p>
          <p>[ ]    [ ]     IIA    T2a      N0      M0</p>
          <p>[ ]    [ ]     IIB    T2b      N0      M0</p>
          <p>[ ]    [ ]     IIC    T2c      N0      M0</p>
          <p>[ ]    [ ]     III    T3       N0      M0</p>
          <p>[ ]    [ ]     IIIA   T3a      N0      M0</p>
          <p>[ ]    [ ]     IIIB   T3b      N0      M0</p>
          <p>[ ]    [ ]     IIIC   T3c      N0      M0</p>
          <p>                      Any T    N1      M0</p>
          <p>[ ]    [ ]     IV     Any T    Any N   M1</p>
          <p></p>
          <p>*FIGO no longer includes Stage 0 (Tis)</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>FIGO Stage: _________</p>
          <p>Tumor location : _________ (fimbria, isthmus, unknown)</p>
          <p>Pelvic and paraaortic nodal status: </p>
          <p>  Pelvic-__________</p>
          <p>  Paraaortic-__________</p>
          <p> (report as number of nodes removed/number of nodes involved with  tumor)</p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>   [ ]NCCN </p>
          <p>   [ ]Other (describe):</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC GALLBLADDER STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>GALLBLADDER</p>
          <p>(Carcinoid tumors and sarcomas are not included)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis     Carcinoma in situ</p>
          <p>[ ]    [ ]     T1      Tumor invades lamina propria or muscular layer</p>
          <p>[ ]    [ ]     T1a     Tumor invades lamina propria</p>
          <p>[ ]    [ ]     T1b     Tumor invades muscular layer </p>
          <p>[ ]    [ ]     T2      Tumor invades perimuscular connective tissue; no </p>
          <p>                       extension beyond serosa or into liver</p>
          <p>[ ]    [ ]     T3      Tumor perforates the serosa(visceral peritoneum) and/</p>
          <p>                       or one other adjacent organ or structure, such as the</p>
          <p>                       stomach, duodenum, colon, pancreas, omentum, or </p>
          <p>                       extrahepatic bile ducts</p>
          <p>[ ]    [ ]     T4      Tumor invades main portal vein or hepatic artery or </p>
          <p>                       invades two or more extrahepatic organs or structures</p>
          <p></p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Metastases to nodes along the cystic duct, common bile</p>
          <p>                       duct, hepatic artery, and/or portal vein</p>
          <p>[ ]    [ ]     N2      Metastases to periaotic, pericaval, superior mesentery</p>
          <p>                       artery and/or celiac artery lymph nodes</p>
          <p></p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0;</p>
          <p>                       use clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p>Distant metastasis</p>
          <p>               STAGE GROUPING</p>
          <p>[ ]    [ ]     0       Tis     N0      M0</p>
          <p>[ ]    [ ]     I       T1      N0      M0</p>
          <p>[ ]    [ ]     II      T2      N0      M0</p>
          <p>[ ]    [ ]     IIIA    T3      N0      M0</p>
          <p>[ ]    [ ]     IIIB    T1-3    N1      M0</p>
          <p>[ ]    [ ]     IVA     T4      N0-1    M0</p>
          <p>[ ]    [ ]     IVB     Any T   N2      M0</p>
          <p>                       Any T   Any N   M1</p>
          <p>[ ] UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p></p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>   Tumor location: ___________</p>
          <p></p>
          <p>   Specimen type: ____________</p>
          <p></p>
          <p>   Extent of liver resection: ____________</p>
          <p></p>
          <p>   Free peritoneal side vs hepatic side for T2: _________</p>
          <p></p>
          <p></p>
          <p>GRADING SYSTEM 					GRADE</p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>  [ ]NCCN </p>
          <p>  [ ]Other (describe):</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC GASTROINTESTINAL STROMAL TUMOR STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>GASTROINTESTINAL STROMAL TUMOR</p>
          <p>(This staging system is new for the seventh edition)</p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p></p>
          <p>		Stage Category Definitions for GIST</p>
          <p>		AT ALL SITES</p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     T1      Tumor 2 cm or less</p>
          <p>[ ]    [ ]     T2      Tumor more than 2 cm but not more than 5 cm</p>
          <p>[ ]    [ ]     T3      Tumor more than 5 cm but not more than 10 cm</p>
          <p>[ ]    [ ]     T4      Tumor more than 10 cm in greatest dimension</p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis*</p>
          <p>[ ]    [ ]     N1      Regional lymph node metastasis</p>
          <p></p>
          <p>* If regional node status is unknown, use N0, not NX</p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0;</p>
          <p>                       use clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>               GASTRIC GIST                 MITOTIC RATE</p>
          <p>[ ]    [ ]     IA      T1 or T2 N0      M0   Low</p>
          <p>[ ]    [ ]     IB      T3       N0      M0   Low</p>
          <p>[ ]    [ ]     II      T1       N0      M0   HIGH</p>
          <p>                       T2       N0      M0   HIGH</p>
          <p>                       T4       N0      M0   Low</p>
          <p>[ ]    [ ]     IIIA    T3       N0      M0   HIGH</p>
          <p>[ ]    [ ]     IIIB    T4       N0      M0   HIGH</p>
          <p>[ ]    [ ]     IV      Any T    N1      M0   Any rate</p>
          <p>                       Any T    Any N   M1   Any rate</p>
          <p>[ ] UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>               SMALL INTESTINE GIST         MITOTIC RATE</p>
          <p>(also used for Esophagus, Colorectal, Mesentery and Peritoneum)</p>
          <p>[ ]    [ ]     I       T1 or T2  N0      M0   Low</p>
          <p>[ ]    [ ]     II      T3        N0      M0   Low</p>
          <p>[ ]    [ ]     IIIA    T1        N0      M0   HIGH</p>
          <p>                       T4        N0      M0   Low</p>
          <p>[ ]    [ ]     IIIB    T2        N0      M0   HIGH</p>
          <p>                       T3        N0      M0   HIGH</p>
          <p>                       T4        N0      M0   HIGH</p>
          <p>[ ]    [ ]     IV      Any T     N1      M0   Any rate</p>
          <p>                       Any T     Any N   M1   Any rate</p>
          <p>[ ] UNKNOWN STAGE</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : Mitotic Rate</p>
          <p></p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>KIT Immunohistochemistry: _________</p>
          <p>Mutational status of KIT, PDGFRA: ________</p>
          <p></p>
          <p>Histologic Grade (G): </p>
          <p>Histologic grading, an ingredient in sarcoma staging, is not well suited to</p>
          <p>GISTs, because a majority of these tumors have low or relatively low mitotic</p>
          <p>rates below the thresholds used for soft tissue tumors, and because GISTs</p>
          <p>often manifest aggressive features with mitotic rates below the thresholds</p>
          <p>used for soft tissue grading (the lowest tier of mitotic rates for soft</p>
          <p>tissue sarcomas being 10 mitoses per 10 HPFs).  In GIST staging, the grade</p>
          <p>is replaced by mitotic activity.</p>
          <p></p>
          <p>[ ] GX  Grade cannot be assessed</p>
          <p>[ ] G1  Low grade;  mitotic rate &lt;5/50 HPF</p>
          <p>[ ] G2  High grade; mitotic rate &gt;5/50 HPF</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):___________</p>
          <p></p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>  [ ]NCCN </p>
          <p>  [ ]Other (describe):</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC GESTATIONAL TROPHOBLASTIC TUMOR STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>GESTATIONAL TROPHOBLASTIC TUMORS </p>
          <p></p>
          <p>7th Edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH   TNM  FIGO  Primary Tumor (T)</p>
          <p>[ ]    [ ]    TX         Primary tumor cannot be assessed </p>
          <p>[ ]    [ ]    T0         No evidence of primary tumor</p>
          <p>[ ]    [ ]    T1   I     Tumor confined to uterus</p>
          <p>[ ]    [ ]    T2   II    Tumor extends to other genital structures </p>
          <p>                         (ovary, tube, vagina, broad ligaments)by </p>
          <p>                         metastasis or direct extension</p>
          <p></p>
          <p>              REGIONAL LYMPH NODES (N)</p>
          <p>There is no regional nodal designation in the staging of these tumors. </p>
          <p>Nodal metastases should be classified as metastatic (M1) disease.</p>
          <p></p>
          <p>              DISTANT METASTASIS (M)</p>
          <p>[ ]           M0         No distant metastasis (no pathologic M0; use </p>
          <p>                         clinical M to complete stage group)</p>
          <p>[ ]   [ ]     M1         Distant metastasis</p>
          <p>[ ]   [ ]     M1a  III   Lung metastasis</p>
          <p>[ ]   [ ]     M1b  IV    All other distant metastasis</p>
          <p></p>
          <p>              STAGE GROUPING </p>
          <p>[ ]    [ ]    Stage   T        M        RISK SCORE </p>
          <p>[ ]    [ ]    I       T1       M0       Unknown </p>
          <p>[ ]    [ ]    IA      T1       M0       Low risk</p>
          <p>[ ]    [ ]    IB      T1       M0       High risk</p>
          <p>[ ]    [ ]    II      T2       M0       Unknown</p>
          <p>[ ]    [ ]    IIA     T2       M0       Low risk</p>
          <p>[ ]    [ ]    IIB     T2       M0       High risk</p>
          <p>[ ]    [ ]    III     Any T    M1a      Unknown</p>
          <p>[ ]    [ ]    IIIA    Any T    M1a      Low risk</p>
          <p>[ ]    [ ]    IIIB    Any T    M1a      High risk</p>
          <p>[ ]    [ ]    IV      Any T    M1b      Unknown</p>
          <p>              IVA     Any T    M1b      Low risk</p>
          <p>              IVB     Any T    M1b      High risk</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: Prognostic Risk Scoring Index</p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>  REQUIRED FOR STAGING: Prognostic Risk Scoring Index </p>
          <p>                        __________________________________________________</p>
          <p>                        :                  RISK SCORE </p>
          <p>  ______________________:_________________________________________________</p>
          <p>  PROGNOSTIC FACTOR     :     0      :     1     :     2      :    4 </p>
          <p>  ______________________:____________:___________:____________:___________</p>
          <p>  Age                   :    &lt; 40    : &gt; or = 40 :            : </p>
          <p>  ______________________:____________:___________:____________:___________</p>
          <p>  Antecedent pregnancy  :Hydatidiform: Abortion  :   Term     : </p>
          <p>                        :    mole    :           :  Pregnancy : </p>
          <p>  ______________________:____________:___________:____________:___________</p>
          <p>  Interval months from  :            :           :            : </p>
          <p>     index pregnancy    :   &lt; 4      :   4-6     :   7-12     :   &gt; 12 </p>
          <p>  ______________________:____________:___________:____________:___________</p>
          <p>  Pretreatment hCG      :      3     :   3   4   :    4   5   :       5 </p>
          <p>     (IU/mo)            :   &lt;10      : 10 -10    :  10 -10    :   &gt; 10 </p>
          <p>  ______________________:____________:___________:____________:___________</p>
          <p>  Largest tumor size,   :            :           :            : </p>
          <p>    including uterus    :  &lt; 3 cm    :  3-5 cm   :   &gt; 5 cm   : </p>
          <p>  ______________________:____________:___________:____________:___________</p>
          <p>  Site of metastases    :    Lung    : Spleen,   :  GI tract  :   Brain, </p>
          <p>                        :            : Kidney    :            :   Liver </p>
          <p>  ______________________:____________:___________:____________:___________</p>
          <p>  Number of metastases  :            :           :            : </p>
          <p>    identified          :            :   1-4     :    5-8     :   &gt; 8 </p>
          <p>  ______________________:____________:___________:____________:___________</p>
          <p>  Previous failed       :            :           :   Single   :Two or more</p>
          <p>    chemotherapy        :            :           :    drug    :   drugs </p>
          <p>  ______________________:____________:___________:____________:___________</p>
          <p></p>
          <p>  Low risk is a score of 6 or less. High risk is a score of 7 or greater.</p>
          <p>  TOTAL SCORE:</p>
          <p></p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>FIGO Stage: </p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>   [ ]NCCN </p>
          <p>   [ ]Other (describe):</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC KIDNEY STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>KIDNEY</p>
          <p>(Sarcomas and adenomas are excluded)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p>Laterality:</p>
          <p>          [ ] Left</p>
          <p>          [ ] Right</p>
          <p>          [ ] Bilateral</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH            PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     T1      Tumor 7.0 cm or less, limited to the kidney</p>
          <p>[ ]    [ ]     T1a     Tumor 4 cm or less limited to the kidney</p>
          <p>[ ]    [ ]     T1b     Tumor more than 4 cm but not more that 7 cm </p>
          <p>                       in greatest dimension, limited to the kidney.</p>
          <p>[ ]    [ ]     T2      Tumor more than 7.0 cm in greatest dimension,</p>
          <p>                       limited to kidney</p>
          <p>[ ]    [ ]     T2a     Tumor more than 7 cm but less than or equal </p>
          <p>                       to 10 cm in greatest dimension,limited to the </p>
          <p>                       kidney</p>
          <p>[ ]    [ ]     T2b     Tumor more than 10 cm, limited to the kidney</p>
          <p>[ ]    [ ]     T3      Tumor extends into major veins or perinephric </p>
          <p>                       tissues but not into the ipsilateral adrenal </p>
          <p>                       gland and not beyond Gerota's fascia</p>
          <p>[ ]    [ ]     T3a     Tumor grossly extends into the renal vein or </p>
          <p>                       its segmental (muscle containing) branches, </p>
          <p>                       or tumor invades perirenal and/or renal sinus </p>
          <p>                       fat but not beyond Gerota's fascia</p>
          <p>[ ]    [ ]     T3b     Tumor grossly extends into the vena cava </p>
          <p>                       below the diaphragm</p>
          <p>[ ]    [ ]     T3c     Tumor grossly extends into the vena cava </p>
          <p>                       above the diaphragm or invades the wall of </p>
          <p>                       the vena cava</p>
          <p>[ ]    [ ]     T4      Tumor invades beyond Gerota's fascia </p>
          <p>                       including contiguous extension into the</p>
          <p>                       ipsilateral adrenal gland)</p>
          <p></p>
          <p>               </p>
          <p>               REGIONAL LYMPH NODES (N) </p>
          <p>[ ]    [ ]     NX      Regional lymph node metastasis cannot be </p>
          <p>                       assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Regional lymph node metastasis </p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p>CLIN   PATH    STAGE GROUPING</p>
          <p>[ ]    [ ]     I       T1      N0      M0</p>
          <p>[ ]    [ ]     II      T2      N0      M0</p>
          <p>[ ]    [ ]     III     T1-2    N1      M0</p>
          <p>[ ]    [ ]             T3      N0-1    M0</p>
          <p>[ ]    [ ]     IV      T4      Any N   M0</p>
          <p>[ ]    [ ]             Any T   Any N   M1</p>
          <p>[ ]            Unknown Stage</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Invasion beyond capsule into fat or perisinus tissues:____________ </p>
          <p>Venous involvement: ______________________________________________</p>
          <p>Adrenal Extension:________________________________________________</p>
          <p>Fuhrman Grade:____________________________________________________</p>
          <p>Sarcomatoid features:_____________________________________________</p>
          <p>Histologic tumor necrosis: _______________________________________</p>
          <p>Extranodal extension: ____________________________________________</p>
          <p>Size of metastasis in lymph nodes: _______________________________</p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC LACRIMAL GLAND CARCINOMA STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>CARCINOMA OF THE LACRIMAL GLAND</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p>Laterality:</p>
          <p> [ ] Left</p>
          <p> [ ] Right</p>
          <p> [ ] Bilateral</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     T1      Tumor 2 cm or less in greatest dimension, with or</p>
          <p>                       without extraglandular extension into the orbital soft</p>
          <p>                       tissue.</p>
          <p>[ ]    [ ]     T2      Tumor more than 2 cm but not more than 4 cm in</p>
          <p>                       greatest dimension*</p>
          <p>[ ]    [ ]     T3      Tumor more than 4 cm in greatest dimension*</p>
          <p>[ ]    [ ]     T4      Tumor invades periosteum or orbital bone or adjacent</p>
          <p>                       structures</p>
          <p>[ ]    [ ]     T4a     Tumor invades periosteum</p>
          <p>[ ]    [ ]     T4b     Tumor invades orbital bone</p>
          <p>[ ]    [ ]     T4c     Tumor invades adjacent structures (brain,sinus,</p>
          <p>                       pterygoid fossa, temporal fossa)</p>
          <p></p>
          <p>  *As the maximum size of the lacrimal gland is 2cm, T2 and greater tumors</p>
          <p> will usually extend into the orbital soft tissue.</p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Regional lymph node metastasis</p>
          <p>  </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>No stage grouping is presently recommended</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>[ ] Ki-67 growth fraction _________</p>
          <p>[ ] Nuclear NM23 staining _________</p>
          <p></p>
          <p>GRADING SYSTEM</p>
          <p></p>
          <p>[ ] 2 grade system                        </p>
          <p>[ ] 3 grade system                        </p>
          <p>[ ] 4 grade system                        </p>
          <p>[ ] No 2,3,or 4 grade system is available </p>
          <p></p>
          <p>HISTOLOGIC GRADE</p>
          <p>[ ] Grade I or 1:   Well differentiated</p>
          <p>[ ] Grade II or 2:  Moderately differentiated: includes adenoid cystic</p>
          <p>                    carcinoma without basaloid (solid) pattern</p>
          <p>[ ] Grade III or 3: Poorly differentiated: includes adenoid cystic carcinoma</p>
          <p>                    with basaloid (solid pattern </p>
          <p>[ ] Grade IV or 4:  Undifferentiated</p>
          <p>[ ] Grade X:        Grade cannot be assessed</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
          <p></p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC LARYNX STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>LARYNX </p>
          <p>(Nonepithelial tumors such as those of lymphoid tissue, soft tissue,</p>
          <p>bone and cartilage are not included.)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p></p>
          <p> </p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis     Carcinoma in situ</p>
          <p> </p>
          <p>               *****SUPRAGLOTTIS*****</p>
          <p>[ ]    [ ]     T1      Limited to 1 subsite w/normal vocal cord mobility.</p>
          <p>[ ]    [ ]     T2      Invades mucosa of more than one adjacent subsite of           </p>
          <p>                       supraglottis or glottis or region outside the </p>
          <p>                       Supraglottis (e.g. mucosa of base of tongue, </p>
          <p>                       vallecula, medial wall of pyriform sinus) without </p>
          <p>                       fixation of the larynx.</p>
          <p>[ ]    [ ]     T3      Tumor limited to larynx w/vocal cord fixation </p>
          <p>                       and/or invades any of the following: postcricoid area,</p>
          <p>                       pre-epiglottic tissues, paraglottic space, and/or </p>
          <p>                       inner cortex of the thyroid cartilage.</p>
          <p>[ ]    [ ]     T4a     Moderately advanced local disease.</p>
          <p>                         Tumor invades through the thyroid cartilage; </p>
          <p>                         and/or invades beyond the larynx (e.g., trachea, </p>
          <p>                         soft tissues of neck including deep extrinsic muscle </p>
          <p>                         of the tongue, strap muscles, thyroid, or esophagus)</p>
          <p>[ ]    [ ]     T4b     Very advanced local disease.</p>
          <p>                         Tumor invades prevertebral space, encases </p>
          <p>                         carotid artery, or invades mediastinal</p>
          <p>                         structures.</p>
          <p>                       </p>
          <p>               *****GLOTTIS*****</p>
          <p>[ ]    [ ]     T1      Tumor limited to vocal cord(s) (may involve</p>
          <p>                       anterior/posterior commissures) with normal</p>
          <p>                       mobility</p>
          <p>[ ]    [ ]     T1a     Tumor limited to one vocal cord</p>
          <p>[ ]    [ ]     T1b     Tumor involves both vocal cords</p>
          <p>[ ]    [ ]     T2      Extends to supraglottic or subglottis, and/or</p>
          <p>                       with impaired vocal cord mobility</p>
          <p>[ ]    [ ]     T3      Tumor limited to the larynx with vocal cord</p>
          <p>                       fixation and/or invades paraglottic space, and/or </p>
          <p>                       inner cortex  of the thyroid cartilage.</p>
          <p>[ ]    [ ]     T4a     Moderately advanced local disease.</p>
          <p>                         Tumor invades through the outer cortex of the </p>
          <p>                         thyroid cartilage and/or invades tissues </p>
          <p>                         beyond the larynx (e.g., trachea, soft tissues</p>
          <p>                         of neck including deep extrinsic muscle of the</p>
          <p>                         tongue, strap muscles, thyroid, or esophagus)</p>
          <p>[ ]    [ ]     T4b    Very advanced local disease.</p>
          <p>                         Tumor invades prevertebral space, encases </p>
          <p>                         carotid artery, or invades mediastinal</p>
          <p>                         structures.</p>
          <p>                       </p>
          <p>               *****SUBGLOTTIS *****</p>
          <p>[ ]    [ ]     T1      Tumor limited to the subglottis</p>
          <p>[ ]    [ ]     T2      Extends to vocal cord w/normal or impaired </p>
          <p>                       mobility</p>
          <p>[ ]    [ ]     T3      Limited to larynx with vocal cord fixation</p>
          <p>[ ]    [ ]     T4a     Moderately advanced local disease.</p>
          <p>                         Tumor invades cricoid or thyroid cartilage </p>
          <p>                         and/or invades tissues beyond the larynx</p>
          <p>                         (e.g., trachea, soft tissues of neck</p>
          <p>                         including deep extrinsic muscles of the</p>
          <p>                         tongue, strap muscles, thyroid, or</p>
          <p>                         esophagus)</p>
          <p>[ ]    [ ]     T4b     Very advanced local disease.</p>
          <p>                         Tumor invades prevertebral space, encases </p>
          <p>                         carotid artery, or invades mediastinal</p>
          <p>                         structures.</p>
          <p>                       </p>
          <p>               REGIONAL LYMPH NODES (N)*</p>
          <p>[ ]    [ ]     NX      Regional lymph node cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Metastasis in a single ipsilateral node, 3 cm or less</p>
          <p>[ ]    [ ]     N2      Metastasis in single ipsilat node, &gt;3 cm but not &gt;6 cm; </p>
          <p>                       or multiple ipsilateral nodes, none &gt;6 cm, </p>
          <p>                       or in bilateral or contralat nodes, none &gt;6 cm </p>
          <p>[ ]    [ ]     N2a     Metastasis in single ipsilat node &gt;3 cm but not &gt;6 cm</p>
          <p>[ ]    [ ]     N2b     Metastasis in multiple ipsilat nodes, none &gt;6 cm</p>
          <p>[ ]    [ ]     N2c     Metastasis in bilateral or contralat nodes, none &gt;6 cm</p>
          <p>[ ]    [ ]     N3      Metastasis in lymph node &gt;6 cm in greatest dimension</p>
          <p> </p>
          <p>*Note: Metastases at level VII are considered regianla lymph node metastases</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            MX      Presence of distant metastasis cannot be assessed</p>
          <p>[ ]    [ ]     M0      No distant metastasis</p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p> </p>
          <p>STAGE GROUPING</p>
          <p>[ ]    [ ]     0       Tis     N0      M0</p>
          <p>[ ]    [ ]     I       T1      N0      M0</p>
          <p>[ ]    [ ]     II      T2      N0      M0</p>
          <p>[ ]    [ ]     III     T3      N0      M0</p>
          <p>[ ]    [ ]             T1      N1      M0</p>
          <p>[ ]    [ ]             T2      N1      M0</p>
          <p>[ ]    [ ]             T3      N1      M0</p>
          <p>[ ]    [ ]     IVA     T4a     N0      M0</p>
          <p>[ ]    [ ]             T4a     N1      M0</p>
          <p>[ ]    [ ]             T1      N2      M0</p>
          <p>[ ]    [ ]             T2      N2      M0</p>
          <p>[ ]    [ ]             T3      N2      M0</p>
          <p>[ ]    [ ]             T4a     N2      M0</p>
          <p>[ ]    [ ]     IVB     T4b     Any N   M0</p>
          <p>[ ]    [ ]             Any T   N3      M0</p>
          <p>[ ]    [ ]     IVC     Any T   Any N   M1</p>
          <p>[ ]    [ ]     UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Size of Lymph Nodes: </p>
          <p>Extracapsular Extension from Lymph Nodes for Head &amp; Neck: </p>
          <p>Head &amp; Neck Lymph Nodes Levels I-III: </p>
          <p>Head &amp; Neck Lymph Nodes Levels IV-V: </p>
          <p>Head &amp; Neck Lymph Nodes Levels VI-VII: </p>
          <p>Other Lymph Node Group: </p>
          <p>Clinical Location of cervical nodes: </p>
          <p>Extracapsular spread (ECS) Clinical: </p>
          <p>Extracapsular spread (ECS) Pathologic: </p>
          <p>Human Papillomavirus (HPV) Status: </p>
          <p>Tumor Thickness:</p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>   [ ]NCCN </p>
          <p>   [ ]Other (describe):</p>
          <p> </p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC LIP AND ORAL CAVITY STAGING 7TH. ED. ">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>LIP &amp; ORAL CAVITY</p>
          <p>(Nonepithelial tumors such as those of lymphoid tissue, soft</p>
          <p>tissue, bone and cartilage are excluded. Staging for mucosal </p>
          <p>melanoma of the lip and oral cavity is not included in this </p>
          <p>chapter.)  </p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p> </p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis     Carcinoma in situ</p>
          <p>[ ]    [ ]     T1      Tumor 2 cm or less in greatest dimension</p>
          <p>[ ]    [ ]     T2      Tumor &gt;2 cm but not more than 4 cm</p>
          <p>[ ]    [ ]     T3      Tumor &gt;4 cm in greatest dimension</p>
          <p>[ ]    [ ]     T4a     Moderately advanced local disease*</p>
          <p>                       (lip) Tumor invades through cortical bone, </p>
          <p>                          inferior alveolar nerve, floor of mouth, </p>
          <p>                          or skin of face, i.e., chin or nose.</p>
          <p>                       (oral cavity) Tumor invades adjacent structures</p>
          <p>                          only (e.g., through cortical bone, [mandible </p>
          <p>                          or maxilla] into deep [extrinsic] muscle of </p>
          <p>                          tongue [genioglossus, hyoglossus, palatoglossus, </p>
          <p>                          and styloglossus], maxillary sinus, skin of face) </p>
          <p>[ ]    [ ]     T4b     Very advanced local disease.</p>
          <p>                       Tumor invades masticator space, pterygoid plates, </p>
          <p>                       or skull base and/or encases internal carotid artery.</p>
          <p></p>
          <p>                *NOTE: Superficial erosion alone of bone/tooth </p>
          <p>                       socket by gingival primary is not sufficient to</p>
          <p>                       classify as T4.</p>
          <p> </p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph node metastasis cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Metastasis in single ipsilateral node, 3 cm or less.</p>
          <p>[ ]    [ ]     N2      Metastasis in single ipsilateral node &gt;3 cm but not &gt;6cm;</p>
          <p>                       or in multiple ipsilateral nodes, none &gt;6cm; </p>
          <p>                       or in bilateral or contralateral nodes, none &gt;6cm</p>
          <p>[ ]    [ ]     N2a     Metastasis in single ipsilateral node &gt;3 cm but not &gt;6cm</p>
          <p>[ ]    [ ]     N2b     Metastasis in multiple ipsilateral nodes, none &gt;6 cm</p>
          <p>[ ]    [ ]     N2c     Metastasis in bilateral or contralateral nodes, none &gt;6cm</p>
          <p>[ ]    [ ]     N3      Metastasis in lymph node &gt;6cm in greatest dimension</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p>               STAGE GROUPING  </p>
          <p>[ ]    [ ]     0       Tis     N0      M0</p>
          <p>[ ]    [ ]     I       T1      N0      M0</p>
          <p>[ ]    [ ]     II      T2      N0      M0</p>
          <p>[ ]    [ ]     III     T3      N0      M0</p>
          <p>[ ]    [ ]             T1      N1      M0 </p>
          <p>[ ]    [ ]             T2      N1      M0</p>
          <p>[ ]    [ ]             T3      N1      M0</p>
          <p>[ ]    [ ]     IVA     T4a     N0      M0</p>
          <p>[ ]    [ ]             T4a     N1      M0</p>
          <p>[ ]    [ ]             T1      N2      M0</p>
          <p>[ ]    [ ]             T2      N2      M0</p>
          <p>[ ]    [ ]             T3      N2      M0</p>
          <p>[ ]    [ ]             T4a     N2      M0</p>
          <p>[ ]    [ ]     IVB     Any T   N3      M0</p>
          <p>[ ]    [ ]             T4b     Any N   M0</p>
          <p>[ ]    [ ]     IVC     Any T   Any N   M1</p>
          <p>[ ]    [ ]     UNKNOWN STAGE</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Size of Lymph Nodes: </p>
          <p>Extracapsular Extension from Lymph Nodes for Head &amp; Neck: </p>
          <p>Head &amp; Neck Lymph Nodes Levels I-III: </p>
          <p>Head &amp; Neck Lymph Nodes Levels IV-V: </p>
          <p>Head &amp; Neck Lymph Nodes Levels VI-VII: </p>
          <p>Other Lymph Node Group: </p>
          <p>Clinical Location of cervical nodes: </p>
          <p>Extracapsular spread (ECS) Clinical: </p>
          <p>Extracapsular spread (ECS) Pathologic: </p>
          <p>Human Papillomavirus (HPV) Status: </p>
          <p>Tumor Thickness: </p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>   [ ]NCCN </p>
          <p>   [ ]Other (describe):</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC LIVER STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>LIVER</p>
          <p>(Excluding intrahepatic bile ducts; Sarcomas and tumors metastatic to the</p>
          <p>Liver are not included.)</p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     T1      Solitary tumor without vascular invasion</p>
          <p>[ ]    [ ]     T2      Solitary tumor with vascular invasion or multiple</p>
          <p>                       tumors none more than 5 cm</p>
          <p>[ ]    [ ]     T3a     Multiple tumors more than 5 cm</p>
          <p>[ ]    [ ]     T3b     Single tumor or multiple tumors of any size involving</p>
          <p>                       a major branch of the portal vein or hepatic vein</p>
          <p>[ ]    [ ]     T4      Tumor(s)with direct invasion of adjacent organs other</p>
          <p>                       than the gallbladder or with perforation of visceral</p>
          <p>                       peritoneum</p>
          <p> </p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Regional lymph node metastasis</p>
          <p> </p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0;</p>
          <p>                       use clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>[ ]    [ ]     I       T1      N0      M0</p>
          <p>[ ]    [ ]     II      T2      N0      M0</p>
          <p>[ ]    [ ]     IIIA    T3a     N0      M0</p>
          <p>[ ]    [ ]     IIIB    T3b     N0      M0</p>
          <p>[ ]    [ ]     IIIC    T4      N0      M0</p>
          <p>[ ]    [ ]     IVA     Any T   N1      M0</p>
          <p>               IVB     Any T   Any N   M1</p>
          <p>[ ]            UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p></p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>Alpha Fetoprotein (AFP): __________</p>
          <p>Fibrosis Score: _________</p>
          <p>Hepatitis Serology: ___________</p>
          <p>Creatinine*:__________</p>
          <p>Bilirubin*: __________</p>
          <p>Prothrombin* time international normalized ratio (INR): ______</p>
          <p>  * Part of the Model for End Stage Liver Disease score</p>
          <p></p>
          <p></p>
          <p>GRADING SYSTEM 					GRADE</p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>  [ ]NCCN </p>
          <p>  [ ]Other (describe):</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC LUNG STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>LUNG</p>
          <p>(Carcinoid tumors are included. Sarcomas and </p>
          <p>other rare tumor are not included).</p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p></p>
          <p>Laterality:</p>
          <p>          [ ] Left</p>
          <p>          [ ] Right</p>
          <p>          [ ] Bilateral</p>
          <p></p>
          <p>CLIN   PATH            PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis     Tis Carcinoma in situ</p>
          <p>[ ]    [ ]     T1      Tumor &lt; or = 3 cm in greatest dimension, surrounded by </p>
          <p>                       lung or visceral pleura, without bronchoscopic</p>
          <p>                       evidence of invasion more proximal than the </p>
          <p>                       lobar bronchus (i.e. not in the main bronchus)*</p>
          <p>[ ]    [ ]     T1a     Tumor &lt; or = 2 cm in greatest dimension</p>
          <p>[ ]    [ ]     T1b     Tumor &gt;2 cm but &lt; or = 3 cm in greatest dimension </p>
          <p>[ ]    [ ]     T2      Tumor &gt;3 cm but &lt; or = 7 cm or tumor with any of the </p>
          <p>                       following features (T2 tumors with these </p>
          <p>                       features are classified T2A if &lt; or = 5 cm) </p>
          <p>                       Involves main bronchus, &gt; or = 2 cm distal to the </p>
          <p>                       carina</p>
          <p>                       Invades visceral pleura (PL1 or PL2) </p>
          <p>                       Associated with atelectasis or </p>
          <p>                       obstructive pneumonitis that extends to the </p>
          <p>                       hilar region but does not involve the entire </p>
          <p>                       lung</p>
          <p>[ ]    [ ]     T2a     Tumor &gt;3 cm but &lt; or = 5 cm in greatest dimension</p>
          <p>[ ]    [ ]     T2b     Tumor &gt;5 cm but &lt; or = 7 cm in greatest dimension</p>
          <p>[ ]    [ ]     T3      Tumor &gt;7 cm or one that directly invades any of </p>
          <p>                       the following: parietal pleural (PL3) chest wall</p>
          <p>                       (including superior sulcus tumors), </p>
          <p>                       diaphragm, phrenic nerve, mediastinal pleura,</p>
          <p>                       partietal pericardium; or tumor in the main </p>
          <p>                       bronchus (&lt; 2 cm distal to the carina* but </p>
          <p>                       without involvement of the carina; or </p>
          <p>                       associated atelectasis or obstructive </p>
          <p>                       pneumonitis of the entire lung or separate </p>
          <p>                       tumor nodule(s) in the same lobe</p>
          <p>[ ]    [ ]     T4      Tumor of any size that invades any of the following:                                                                                                                                                        </p>
          <p>                       mediastimum, heart, great vessels, trachea, </p>
          <p>                       recurrent laryngeal nerve, esophagus, vertebral </p>
          <p>                       body, carina, separate tumor nodule(s) in a </p>
          <p>                       different ipsilateral lobe </p>
          <p></p>
          <p>* The uncommon superficial tumor of any size with its invasive component</p>
          <p>limited to the bronchial wall, which may extend proximal to the main</p>
          <p>bronchus, is also classified T1a</p>
          <p> </p>
          <p>                       REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Metastasis in ipsilateral peribronchial and/or </p>
          <p>                       ipsilateral hilar lymph nodes and intrapulmonary</p>
          <p>                       nodes including involvement by direct extension</p>
          <p>[ ]    [ ]     N2      Metastasis to ipsilateral mediastinal and/or</p>
          <p>                       subcarinal lymph node(s)</p>
          <p>[ ]    [ ]     N3      Metastasis in contralateral mediastinal, contralateral </p>
          <p>                       hilar, ipsilateral or contralateral scalene or </p>
          <p>                       supraclavicular lymph node(s)</p>
          <p> </p>
          <p> </p>
          <p>                       DISTANT METASTASIS (M)</p>
          <p>[ ]    [ ]     M0      No distant metastasis</p>
          <p>[ ]    [ ]     M1      Distant metastasis </p>
          <p>[ ]    [ ]     M1a     Separate tumor nodules(s) in a contralateral lobe;</p>
          <p>                       tumor with pleural nodules or malignant pleural (or</p>
          <p>                       pericardial) effusion**</p>
          <p>[ ]    [ ]     M1b     Distant metastasis (in extrathoracic organs)</p>
          <p></p>
          <p>** Most pleural (and pericardial) effusions with lung cancer are due to tumor.  </p>
          <p>In a few patients, however, multiple cytopathologic examinations </p>
          <p>of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody </p>
          <p>and is not an exudate. Where these elements and clinical judgement dictate that </p>
          <p>the effusion is not related to the tumor, the effusion should be excluded as a </p>
          <p>staging element and the patient should be classified as M0.  </p>
          <p> </p>
          <p>CLIN   PATH    STAGE GROUPING</p>
          <p>[ ]    [ ]     Occult  TX      N0      M0</p>
          <p>[ ]    [ ]     0       Tis     N0      M0</p>
          <p>[ ]    [ ]     IA      T1a     N0      M0</p>
          <p>                       T1b     N0      M0</p>
          <p>[ ]    [ ]     IB      T2a     N0      M0</p>
          <p>[ ]    [ ]     IIA     T2b     N0      M0</p>
          <p>                       T1a     N1      M0</p>
          <p>                       T1b     N1      M0</p>
          <p>                       T2a     N1      M0</p>
          <p>[ ]    [ ]     IIB     T2b     N1      M0</p>
          <p>                       T3      N0      M0</p>
          <p>[ ]    [ ]     IIIA    T1a     N2      M0</p>
          <p>                       T1b     N2      M0</p>
          <p>                       T2a     N2      M0</p>
          <p>                       T2b     N2      M0</p>
          <p>                       T3      N1      M0</p>
          <p>                       T3      N2      M0</p>
          <p>                       T4      N0      M0</p>
          <p>                       T4      N1      M0</p>
          <p>[ ]    [ ]     IIIB    T1a     N3      M0</p>
          <p>                       T1b     N3      M0</p>
          <p>                       T2a     N3      M0</p>
          <p>                       T2b     N3      M0</p>
          <p>                       T3      N3      M0</p>
          <p>                       T4      N2      M0</p>
          <p>                       T4      N3      M0                  </p>
          <p>[ ]    [ ]     IV      Any T   Any N   M1a</p>
          <p>                       Any T   Any N   M1b</p>
          <p>[ ]    [ ]             Stage Unknown</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING:  None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Pleural/Elastic Layer-Invasion (based on H&amp;E and elastic stains)</p>
          <p>________________________________________________________________</p>
          <p>Separate Tumor Nodules:_________________________________________</p>
          <p></p>
          <p>General Notes:  For identification of special cases of TNM or pTNM</p>
          <p>classifications, the "n" suffix and "y", "r" and "a" prefixes are used.</p>
          <p>Although they do not affect the stage grouping, they indicate cases </p>
          <p>needing separate analysis.</p>
          <p></p>
          <p> Histologic Grade (G) (also known as overall grade)</p>
          <p></p>
          <p>GRADING SYSTEM 					GRADE</p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>[ ] Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ] Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ] Not Applicable</p>
          <p>[ ] Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>[ ] RX  Presence of residual tumor cannot be assessed.</p>
          <p>[ ] R0  No residual tumor</p>
          <p>[ ] R1  Microscopic residual tumor</p>
          <p>[ ] R2  Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]  Clinical stage was used in the treatment planning (describe):_______</p>
          <p>[ ]  National guidelines were used in treatment planning:</p>
          <p>     [ ]  NCCN</p>
          <p>     [ ]  Other</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC LYMPHOID NEOPLASMS HODGKIN AND NON-HODGKIN 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>I</STATUS>
        <BOILERPLATE_TEXT>
          <p>LYMPHOID NEOPLASM (HODGKINS AND NON-HODGKIN LYMPHOMA)</p>
          <p>      (Excludes ocular adnexal lymphoma)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p></p>
          <p>ANATOMIC STAGE/PROGNOSTIC GROUPS</p>
          <p>[ ]    Stage I    Involvement of a single lymphatic site (i.e. nodal region,</p>
          <p>                  Waldeyer's ring, thymus or spleen)(I); or localized</p>
          <p>                  involvement of a single extralymphatic oragan or site in</p>
          <p>                  the absence of any lymph node involvement (IE) (rare in</p>
          <p>                  Hodgkin lymphoma).      </p>
          <p></p>
          <p>[ ]    Stage II   Involvement of two or more lymph node regions on the same</p>
          <p>                  side of the diaphragm (II); or localized involvement of a</p>
          <p>                  single extralymphatic organ or site in association with</p>
          <p>                  regional lymph node involvement with or without involvement</p>
          <p>                  of other lymph node regions on the same side of the</p>
          <p>                  diaphgram (IIE). The number of regions involved may be</p>
          <p>                  indicated by a subscript, as in, for example, II3.</p>
          <p></p>
          <p>[ [    Stage III  Involvement of lymph node regions on both sides of the</p>
          <p>                  diaphgram (III), which also may be accompanied by</p>
          <p>                  extralymphatic extension in association with adjacent lymph</p>
          <p>                  node involvement (IIIE) or by involvement of the spleen</p>
          <p>                  (IIIS) or both (IIIE,S). Splenic involvement is designated</p>
          <p>                  by the letter S.</p>
          <p></p>
          <p>[ ]    Stage IV   Diffuse or disseminated involvement of one or more</p>
          <p>                  extralymphatic organs, with or without associated lymph</p>
          <p>                  node involvement; or isolated extralymphatic organ</p>
          <p>                  involvement in the absence of adjacent regional lymph node</p>
          <p>                  involvement, but in conjunction with disease in distant</p>
          <p>                  site(s). Stage IV includes any involvement of the liver or</p>
          <p>                  bone marrow, lungs (other than by direct extension from</p>
          <p>                  another site), or cerebrospinal fluid.</p>
          <p></p>
          <p>[ ]    Unknown Stage</p>
          <p></p>
          <p>Modifiers of Group:</p>
          <p>[ ] E Extranodal</p>
          <p>[ ] S Spleen</p>
          <p></p>
          <p>A &amp; B Classification (Symptoms):</p>
          <p>[ ] A Asymptomatic</p>
          <p>[ ] B Symptoms; fevers, night sweats, weight loss</p>
          <p></p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p> Associated with HIV/AIDS [ ]</p>
          <p> Symptoms at diagnosis (B Symptoms): ______________________________________</p>
          <p> International Prognostic Index (IPI) score: ________</p>
          <p> Follicular Lymphoma Prognostic Index (FLIPI) score: ________</p>
          <p> International Prognostic Score (IPS): ________</p>
          <p></p>
          <p></p>
          <p></p>
          <p>[ ] T-Cell</p>
          <p>[ ] B-cell (pre B, B precursor)</p>
          <p>[ ] Null cell (non T-non B)</p>
          <p>[ ] NK cell (natural killer cell)</p>
          <p>[ ] Cell type not determined, not stated or not applicable. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
          <p></p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC LYMPHOID NEOPLASM HODGKIN AND NON HODGKIN 7TH ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>LYMPHOID NEOPLASM (HODGKINS AND NON-HODGKIN LYMPHOMA)</p>
          <p>(Excludes ocular adnexal lymphoma)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>SITE</p>
          <p>[ ]    NODAL</p>
          <p>[ ]    EXTRANODAL</p>
          <p>       MULTIPLE NODAL CHAINS   [ ]Y  [ ] N</p>
          <p> </p>
          <p>LATERALITY (IF APPLICABLE)</p>
          <p>[ ]    BILATERAL</p>
          <p>[ ]    LEFT</p>
          <p>[ ]    RIGHT</p>
          <p> </p>
          <p>HISTOPATHOLOGIC TYPE</p>
          <p>[ ]    WORKING FORMULATION</p>
          <p>[ ]    REAL CLASSIFICATION</p>
          <p>[ ]    T-CELL AND PUTATIVE NK-CELL NEOPLASMS</p>
          <p></p>
          <p></p>
          <p>ANATOMIC STAGE/PROGNOSTIC GROUPS</p>
          <p></p>
          <p>[ ]    Stage I    Involvement of a single lymphatic site (i.e. nodal region,</p>
          <p>                  Waldeyer's ring, thymus or spleen)(I); or localized</p>
          <p>                  involvement of a single extralymphatic oragan or site in</p>
          <p>                  the absence of any lymph node involvement (IE) (rare in</p>
          <p>                  Hodgkin lymphoma).      </p>
          <p></p>
          <p>[ ]    Stage II   Involvement of two or more lymph node regions on the same</p>
          <p>                  side of the diaphragm (II); or localized involvement of a</p>
          <p>                  single extralymphatic organ or site in association with</p>
          <p>                  regional lymph node involvement with or without involvement</p>
          <p>                  of other lymph node regions on the same side of the</p>
          <p>                  diaphgram (IIE). The number of regions involved may be</p>
          <p>                  indicated by a subscript, as in, for example, II3.</p>
          <p></p>
          <p>[ [    Stage III  Involvement of lymph node regions on both sides of the</p>
          <p>                  diaphgram (III), which also may be accompanied by</p>
          <p>                  extralymphatic extension in association with adjacent lymph</p>
          <p>                  node involvement (IIIE) or by involvement of the spleen</p>
          <p>                  (IIIS) or both (IIIE,S). Splenic involvement is designated</p>
          <p>                  by the letter S.</p>
          <p></p>
          <p>[ ]    Stage IV   Diffuse or disseminated involvement of one or more</p>
          <p>                  extralymphatic organs, with or without associated lymph</p>
          <p>                  node involvement; or isolated extralymphatic organ</p>
          <p>                  involvement in the absence of adjacent regional lymph node</p>
          <p>                  involvement, but in conjunction with disease in distant</p>
          <p>                  site(s). Stage IV includes any involvement of the liver or</p>
          <p>                  bone marrow, lungs (other than by direct extension from</p>
          <p>                  another site), or cerebrospinal fluid.</p>
          <p></p>
          <p>[ ]    Unknown Stage</p>
          <p></p>
          <p>Modifiers of Group:</p>
          <p>[ ] E Extranodal</p>
          <p>[ ] S Spleen</p>
          <p></p>
          <p>A &amp; B Classification (Symptoms):</p>
          <p>[ ] A Asymptomatic</p>
          <p>[ ] B Symptoms; fevers, night sweats, weight loss</p>
          <p></p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p> Associated with HIV/AIDS [ ]</p>
          <p> Symptoms at diagnosis (B Symptoms): ______________________________________</p>
          <p></p>
          <p> </p>
          <p>Prognostic Factors</p>
          <p>       </p>
          <p>Ann Arbor Stage    Adverse Risk                           Score</p>
          <p>Ann Arbor Stage    III or IV                              1 point [ ]</p>
          <p>LDH                Greater than max normal value          1 point [ ]</p>
          <p>Age                60 or older                            1 point [ ]</p>
          <p>Extranodal Disease More than 1 site of extranodal disease 1 point [ ]</p>
          <p>Performance status Depressed performance status           1 point [ ]</p>
          <p>                   ECOG 2 or greater                          </p>
          <p> </p>
          <p>IPI Score</p>
          <p>[ ] 0-1 point      Low</p>
          <p>[ ] 2 points       Low Intermediate</p>
          <p>[ ] 3 points       High Intermediate</p>
          <p>[ ] 4-5 points     High</p>
          <p></p>
          <p></p>
          <p>[ ] T-Cell</p>
          <p>[ ] B-cell (pre B, B precursor)</p>
          <p>[ ] Null cell (non T-non B)</p>
          <p>[ ] NK cell (natural killer cell)</p>
          <p>[ ] Cell type not determined, not stated or not applicable. </p>
          <p></p>
          <p></p>
          <p></p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p>    </p>
          <p>Reproduced with permission and under license from the AJCC</p>
          <p></p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC PRIMARY CUTANEOUS LYMPHOMA 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>PRIMARY CUTANEOUS LYMPHOMA</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)SKIN</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T1      Limited patches*, papules, and/or plaques** covering</p>
          <p>                       &lt;10% of the skin surface. May further stratify into</p>
          <p>                       T1a (patch only) vs T1b (plaque +/- patch). </p>
          <p>[ ]    [ ]     T2      Patches, papules or plaques covering 10% or greater of</p>
          <p>                       the skin surface. May further stratify into T2a (patch</p>
          <p>                       only) vs T2b (plaque +/- patch).</p>
          <p>[ ]    [ ]     T3      One or more tumors***(size 1cm or less in diameter)</p>
          <p>[ ]    [ ]     T4      Confluence of erythema covering 80% or greater body</p>
          <p>                       surface area</p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Clinically abnormal peripheral lymph nodes; no</p>
          <p>                       histologic confirmation</p>
          <p>[ ]    [ ]     N0      No clinically abnormal peripheral lymph nodes^;</p>
          <p>                       biopsy not required.</p>
          <p>[ ]    [ ]     N1      Clinically abnormal peripheral lymph nodes;</p>
          <p>                       histopathology Dutch grade 1 or NCI LN0-2.</p>
          <p>[ ]    [ ]     N1a      Clone negative#</p>
          <p>[ ]    [ ]     N1b      Clone positive#</p>
          <p>[ ]    [ ]     N2      Clinically abnormal peripheral lymph nodes;</p>
          <p>                       histopathology Dutch grade 2 or NCI LN3.</p>
          <p>[ ]    [ ]     N2a      Clone negative#</p>
          <p>[ ]    [ ]     N2b      Clone positive#</p>
          <p>[ ]    [ ]     N3      Clinically abnormal peripheral lymph nodes;</p>
          <p>                       histopathology Dutch grade 3-4 or NCI LN4; clone</p>
          <p>                       positive or negative</p>
          <p></p>
          <p>                DISTANT METASTASIS (M) VISCERAL</p>
          <p>[ ]            M0      No visceral organ involvement (no pathologic M; use</p>
          <p>                       clinical M to complete stage group)</p>
          <p>[ ]    [ ]     M1      Visceral involvement (must have pathology</p>
          <p>                       confirmation^^ and organ involved should be specified)</p>
          <p></p>
          <p>                PERIPHERAL BLOOD INVOLVEMENT (B)</p>
          <p>[ ]    [ ]     B0      Absence of significant blood involvement; &lt; or = %5 of</p>
          <p>                       peripheral blood lymphocytes are atypical(Sezary)</p>
          <p>                       cells ^^</p>
          <p>[ ]    [ ]     B0a      Clone negative#</p>
          <p>[ ]    [ ]     B0b      Clone positive#</p>
          <p>[ ]    [ ]     B1      Low blood tumor burden: &gt;5% of peripheral blood</p>
          <p>                       lymphocytes are atypical (Sezary) cells but does not</p>
          <p>                       meet the criteria of B2.</p>
          <p>[ ]    [ ]     B2      High blood tumor burden: greater than or equal to</p>
          <p>                       100/uL Sezary cells^^^ with positive clone# </p>
          <p></p>
          <p>Notes:</p>
          <p></p>
          <p>  * For skin, patch indicates any size skin lesion without significant</p>
          <p>    elevation or induration. Presence/absence of hypo-or hyperpigmentation,</p>
          <p>    scale, crusting, and/or poikiloderma should be noted.</p>
          <p></p>
          <p> ** For skin, plaque indicates any size skin lesion that is elevated or</p>
          <p>    indurated. Presence or absence of scale, crusting, and/or poikiloderma</p>
          <p>    should be noted. Histologic features such as folliculotropism or large-</p>
          <p>    cell transformation (&gt;25% large cells), CD30+ or CD30-, and clinical</p>
          <p>    features such as ulceration are important to document.</p>
          <p></p>
          <p>*** For skin, tumor indicates at least one 1cm diameter solid or nodular</p>
          <p>    lesion with evidence of depth and/or vertical growth.  Note total number</p>
          <p>    of lesions, total volume of lesions, largest size lesion, and region of</p>
          <p>    body involved. Also note if histologic evidence of large-cell</p>
          <p>    transformation has occurred. Phenotyping for CD30 is encouraged.</p>
          <p></p>
          <p>  ^ For node, abnormal peripheral lymph node(s) indicates any palpable</p>
          <p>    peripheral node that on physical examination is firm, irregular,</p>
          <p>    clustered, fixed or 1.5cm or larger in diameter. Node groups examined on</p>
          <p>    physical examination include cervical, supraclavicular, epitrochlear,</p>
          <p>    axillary and inguinal. Central nodes, which are not generally amenable to</p>
          <p>    pathologic assessment, are not currently considered in nodal</p>
          <p>    classification unless used to establish N3 histopathologically.</p>
          <p></p>
          <p> ^^ For viscera, spleen and liver may be diagnosed by imaging criteria.</p>
          <p></p>
          <p>^^^ For blood, Sezary cells are defined as lymphocytes with hyperconvoluted</p>
          <p>    cerebriform nuclei. If Sezary cells are not able to be used to determine</p>
          <p>    tumor burden for B2, then one of the following modified ISCL criteria</p>
          <p>    along with a positive clonal rearrangement of the TCR may be used</p>
          <p>    instead: (1) expanded CD4+ or CD3+ cells with CD4/CD8 ratio of 10 or</p>
          <p>    more. (2) expanded CD4+ cells with abnormal immunophenotype including loss</p>
          <p>    of CD7 or CD26.</p>
          <p>  # A T-cell clone is defined by PCR or Southern blot analysis of the T-cell</p>
          <p>    receptor gene.</p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>[ ]    [ ]     IA      T1      N0      M0      B0,1</p>
          <p>[ ]    [ ]     IB      T2      N0      M0      B0,1</p>
          <p>[ ]    [ ]     IIA     T1,2    N1,2    M0      B0,1</p>
          <p>[ ]    [ ]     IIB     T3      N0-2    M0      B0,1</p>
          <p>[ ]    [ ]     III     T4      N0-2    M0      B0,1</p>
          <p>[ ]    [ ]     IIIA    T4      N0-2    M0      B0</p>
          <p>[ ]    [ ]     IIIB    T4      N0-2    M0      B1</p>
          <p>[ ]    [ ]     IVA1    T1-4    N0-2    M0      B2</p>
          <p>[ ]    [ ]     IVA2    T1-4    N3      M0      B0-2</p>
          <p>[ ]    [ ]     IVB     T1-4    N0-3    M1      B0-2</p>
          <p>[ ]    [ ]     STAGE UNKNOWN</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: Peripheral blood involvement: ________</p>
          <p>CLINICALLY SIGNIFICANT: None</p>
          <p></p>
          <p>GRADING </p>
          <p>[ ] T-Cell</p>
          <p>[ ] B-cell (pre B, B precursor)</p>
          <p>[ ] Null cell (non T-non B)</p>
          <p>[ ] NK cell (natural killer cell)</p>
          <p>[ ] Cell type not determined, not stated or not applicable. </p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC LYMPHOID NEOPLASM OCULAR ADNEXAL LYMPHOMA 7TH. ED ">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>OCULAR ADNEXAL LYMPHOMA</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p>Laterality:</p>
          <p> [ ] Left</p>
          <p> [ ] Right</p>
          <p> [ ] Bilateral</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Lymphoma extent not specified</p>
          <p>[ ]    [ ]     T0      No evidence of lymphoma</p>
          <p>[ ]    [ ]     T1      Lymphoma involving the conjunctiva alone without</p>
          <p>                       orbital involvement.</p>
          <p>[ ]    [ ]     T1a     Bulbar conjunctiva only</p>
          <p>[ ]    [ ]     T1b     Palpebral conjunctiva +/- fornix +/- caruncle</p>
          <p>[ ]    [ ]     T1c     Extensive conjunctival involvement</p>
          <p>[ ]    [ ]     T2      Lymphoma with orbital involvement +/- any conjunctival</p>
          <p>                       involvement.</p>
          <p>[ ]    [ ]     T2a     Anterior orbital involvement (+/- conjunctival</p>
          <p>                       involvement</p>
          <p>[ ]    [ ]     T2b     Anterior orbital involvement (+/- conjunctival</p>
          <p>                       involvement + lacrimal involvement)</p>
          <p>[ ]    [ ]     T2c     Posterior orbital involvement (+/- conjunctival</p>
          <p>                       involvement +/- anterior involvement and +/- any</p>
          <p>                       extraocular muscle involvement)</p>
          <p>[ ]    [ ]     T2d     Nasolacrimal drainage system involvement (+/-</p>
          <p>                       conjunctival involvement but not including</p>
          <p>                       nasopharynx)</p>
          <p>[ ]    [ ]     T3      Lymphoma with pre-septal eyelid involvement (defined</p>
          <p>                       below*) +/- orbital involvement +/- any conjunctival</p>
          <p>                       involvement.</p>
          <p>[ ]    [ ]     T4      Orbital adnexal lymphoma extending beyond orbit to</p>
          <p>                       adjacent structures such as bone and brain.</p>
          <p>[ ]    [ ]     T4a     Involvement of nasopharynx</p>
          <p>[ ]    [ ]     T4b     Osseous involvement (including periosteum)</p>
          <p>[ ]    [ ]     T4c     Involvement of maxillofacial, ethmoidal and /or</p>
          <p>                       frontal sinuses</p>
          <p>[ ]    [ ]     T4d     Intracranial spread</p>
          <p></p>
          <p>*Note: Ocular Adnexal Lymphoma is defined as involving eyelid if the OAL</p>
          <p>infiltrates preseptal tissues such as dermis or orbicularis muscle of the</p>
          <p>anterior eyelid skin.</p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No evidence of lymph node involvement</p>
          <p>[ ]    [ ]     N1      Involvement of ipsilateral regional lymph nodes*</p>
          <p>[ ]    [ ]     N2      Involvement of contralateral or bilateral regional</p>
          <p>                       lymph nodes*</p>
          <p>[ ]    [ ]     N3      Involvement of peripheral lymph nodes not draining</p>
          <p>                       ocular adnexal region</p>
          <p>[ ]    [ ]     N4      Involvement of central lymph nodes</p>
          <p>  *The regional lymph nodes included preauricular (parotid), submandibular,</p>
          <p>   and cervical</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No evidence of involvement of other extranodal site</p>
          <p>                       (no pathologic M0; use clinical M to complete stage</p>
          <p>                       group) </p>
          <p>[ ]    [ ]     M1a     Noncontiguous involvement of tissues or organs</p>
          <p>                       external to the ocular adnexa (e.g., parotid glands,</p>
          <p>                       submandibular gland, lung, liver, spleen, kidney,</p>
          <p>                       breast etc.)</p>
          <p>[ ]    [ ]     M1b     Lymphomatous involvement of the bone marrow</p>
          <p>[ ]    [ ]     M1c     Both M1a and M1b involvement</p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>No stage grouping is presently recommended.</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p> Tumor cell growth fraction (Ki-67, MIB-1):_________________</p>
          <p> Serum lactate dehydrogenase (LDH) at diagnosis: ___________</p>
          <p> History of rheumatoid arthritis [ ]</p>
          <p> History of Sjogren's syndrome [ ]</p>
          <p> History of connective tissue disease [ ]</p>
          <p> History of recurrent dry eye syndrome (sicca syndrome) [ ]</p>
          <p> Any evidence of a viral infection (e.g. Hepatitis C or HIV [ ]</p>
          <p> Any evidence of bacterial infection (e.g. Helicobacter pylori)[ ]</p>
          <p> Any evidence of an infection caused by other micro-organisms (e.g. chlamydia</p>
          <p>  psittaci) [ ]</p>
          <p></p>
          <p></p>
          <p>HISTOLOGIC GRADE</p>
          <p>Grades are given only to follicular lymphomas as described by the 2002 WHO </p>
          <p>classification for malignant lymphomas as follows:</p>
          <p>[ ] Grade 1:  1-5 centroblasts per 10 high power field</p>
          <p>[ ] Grade 2:  Between 5 and 15 centroblasts per 10 high power fields</p>
          <p>[ ] Grade 3a: More than 15 centroblasts per 10 high power fields but with</p>
          <p>              admixed centrocytes</p>
          <p>[ ] Grade 3b: More than 15 centroblasts per 10 high power fields but without</p>
          <p>              centrocytes</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
          <p></p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC MELANOMA OF SKIN STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>MELANOMA OF THE SKIN</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p> </p>
          <p>Tumor size:  _____________</p>
          <p></p>
          <p>Laterality</p>
          <p></p>
          <p>[ ] Left</p>
          <p>[ ] Right</p>
          <p>[ ] Bilateral</p>
          <p></p>
          <p></p>
          <p></p>
          <p>CLIN   PATH           PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX     Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0     No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis    Melanoma in situ</p>
          <p>[ ]    [ ]     T1     Melanoma less than or equal to 1.0 mm in thickness </p>
          <p>[ ]    [ ]      T1a     without ulceration and mitosis &lt;1/mm2</p>
          <p>[ ]    [ ]      T1b     with ulceration and mitosis, &lt; or equal to 1/mm2</p>
          <p>[ ]    [ ]     T2     Melanoma 1.01-2.0 mm</p>
          <p>[ ]    [ ]      T2a     without ulceration</p>
          <p>[ ]    [ ]      T2b     with ulceration</p>
          <p>[ ]    [ ]     T3     Melanoma 2.01-4.0 mm</p>
          <p>[ ]    [ ]      T3a     without ulceration</p>
          <p>[ ]    [ ]      T3b     with ulceration</p>
          <p>[ ]    [ ]     T4     Tumor &gt; 4.0 mm </p>
          <p>[ ]    [ ]      T4a     without ulceration</p>
          <p>[ ]    [ ]      T4b     with ulceration</p>
          <p></p>
          <p>                       REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      1 lymph node</p>
          <p>       [ ]      N1a     micrometastasis*</p>
          <p>       [ ]      N1b     macrometastasis**</p>
          <p>       [ ]     N2      2-3 nodes</p>
          <p>       [ ]      N2a     micrometastasis*</p>
          <p>       [ ]      N2b     macrometastasis**</p>
          <p>[ ]    [ ]      N2c     in-transit met(s) without metastatic nodes </p>
          <p>[ ]    [ ]     N3      Clinical:1 or more nodes with in transit met(s)/</p>
          <p>                       satellite(s); pathologic 4 or more metastatic</p>
          <p>                       nodes, or matted nodes, or in transit met(s)/</p>
          <p>                       satellite(s) with metastatic node(s).</p>
          <p></p>
          <p>     *Micrometastases are diagnosed after sentinel lymph node biopsy</p>
          <p>      and completion lymphadenectomy (if performed).</p>
          <p>    **Macrometastases are defined as clinically detectable nodal</p>
          <p>      Metastases confirmed by therapeutic lymphadenectomy or when nodal</p>
          <p>      Metastasis exhibits gross extracapsular extension.</p>
          <p></p>
          <p>                       DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M; use </p>
          <p>                       Clinical M to complete stage group)</p>
          <p>[ ]    [ ]     M1a     Metastasis to skin, subcutaneous tissue or distant </p>
          <p>                       lymph nodes</p>
          <p>[ ]    [ ]     M1b     Metastasis to lung</p>
          <p>[ ]    [ ]     M1c     Metastasis to all other visceral sites or distant </p>
          <p>                       metastasis at any site combined with an elevated </p>
          <p>                       serum (LDH)</p>
          <p></p>
          <p></p>
          <p>CLINICAL STAGE GROUPING</p>
          <p>CLIN</p>
          <p>[ ]    0     Tis     N0         M0</p>
          <p>[ ]    IA    T1a     N0         M0</p>
          <p>[ ]    IB    T1b     N0         M0</p>
          <p>             T2A     N0         M0</p>
          <p>[ ]    IIA   T2b     N0         M0</p>
          <p>             T3a     N0         M0</p>
          <p>[ ]    IIB   T3b     N0         M0</p>
          <p>             T4a     N0         M0</p>
          <p>[ ]    IIC   T4b     N0         M0</p>
          <p>[ ]    III   Any T   N1 or &gt;N1  M0</p>
          <p>[ ]    IV    Any T   Any N      M1</p>
          <p>[ ]    Stage Unknown</p>
          <p></p>
          <p>     *Clinical staging includes microstaging of the primary melanoma</p>
          <p>      and clinical/radiologic evaluation for metastases.  By convention</p>
          <p>      it should be used after complete excision of the primary melanoma</p>
          <p>      with clinical assessment for regional and distant metastases.</p>
          <p></p>
          <p></p>
          <p></p>
          <p>PATHOLOGIC STAGING</p>
          <p></p>
          <p>PATH</p>
          <p>[ ]     0      Tis     N0     M0</p>
          <p>[ ]     IA     T1a     N0     M0</p>
          <p>[ ]     IB     T1b     N0     M0</p>
          <p>               T2a     N0     M0</p>
          <p>[ ]     IIA    T2b     N0     M0</p>
          <p>               T3a     N0     M0</p>
          <p>[ ]     IIB    T3b     N0     M0</p>
          <p>               T4a     N0     M0</p>
          <p>[ ]     IIC    T4b     N0     M0</p>
          <p>[ ]     IIIA   T1-4a   N1a    M0</p>
          <p>               T1-4a   N2a    M0</p>
          <p>[ ]     IIIB   T1-4b   N1a    M0</p>
          <p>               T1-4b   N2a    M0</p>
          <p>               T1-4a   N1b    M0</p>
          <p>               T1-4a   N2b    M0</p>
          <p>[ ]     IIIC   T1-4b   N1b    M0</p>
          <p>               T1-4b   N2b    M0</p>
          <p>               T1-4b   N2c    M0</p>
          <p>               Any T   N3     M0</p>
          <p>[ ]     IV     Any T   Any N  M1</p>
          <p></p>
          <p>    *Pathologic staging includes microstaging of the primary melanoma</p>
          <p>     and pathologic information about the regional lymph nodes after</p>
          <p>     partial or complete lymphadenectomy.  Pathologic Stage 0 or Stage</p>
          <p>     IA patients are the exception, they do not require pathologic</p>
          <p>     evaluation of their lymph nodes.</p>
          <p></p>
          <p>[ ]  Stage Unknown</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING:  None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>   Measured thickness (depth):____________________________________</p>
          <p>   Ulceration:____________________________________________________</p>
          <p>   Serum lactate dehydrogenase (LDH)______________________________</p>
          <p>   Mitotic Rate:__________________________________________________</p>
          <p>   Tumor infiltrating lymphocytes (TIL):__________________________</p>
          <p>   Level of invasion:_____________________________________________</p>
          <p>   Vertical growth plate:_________________________________________</p>
          <p>   Regression:____________________________________________________</p>
          <p></p>
          <p>Histologic Grade (G) (also known as overall grade)</p>
          <p>Histologic grading is not used in the staging of Melanoma.</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>Checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>[ ] Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ] Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ] Not Applicable</p>
          <p>[ ] Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>[ ] RX  Presence of residual tumor cannot be assessed.</p>
          <p>[ ] R0  No residual tumor</p>
          <p>[ ] R1  Microscopic residual tumor</p>
          <p>[ ] R2  Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]  Clinical stage was used in the treatment planning (describe):_______</p>
          <p>[ ]  National guidelines were used in treatment planning:</p>
          <p>     [ ]  NCCN</p>
          <p>     [ ]  Other</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
          <p></p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC MELANOMA OF CONJUNCTIVA STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>MALIGNANT MELANOMA OF THE CONJUNCTIVA</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p>Laterality:</p>
          <p> [ ] Left</p>
          <p> [ ] Right</p>
          <p> [ ] Bilateral</p>
          <p></p>
          <p>CLINICAL            PRIMARY TUMOR (T)</p>
          <p>*Quadrants are defined by clock hours, starting at the limbus (e.g.</p>
          <p>      6,9,12,3)extending from the central cornea, to and beyond the eyelid</p>
          <p>      margins. This will bisect the caruncle.</p>
          <p></p>
          <p>[ ]         TX      Primary tumor cannot be assessed</p>
          <p>[ ]         T0      No evidence of primary tumor</p>
          <p>[ ]         Tis     Melanoma confined to the conjunctival epithelium</p>
          <p>[ ]         T1      Malignant conjunctival melanoma of the bulbar conjunctiva</p>
          <p>[ ]         T1a     Less than or equal to 1 quadrant*</p>
          <p>[ ]         T1b     More than 1 but less than or equal to 2 quadrants</p>
          <p>[ ]         T1c     More than 2 but less than or equal to 3 quadrants</p>
          <p>[ ]         T1d     Greater than 3 quadrants</p>
          <p>[ ]         T2      Malignant conjunctival melanoma of the non-bulbar</p>
          <p>                    (palpebral, forniceal, caruncular)</p>
          <p>[ ]         T2a     Non-caruncular, less than or equal to 1 quadrant</p>
          <p>[ ]         T2b     Non-caruncular, greater than 1 quadrant</p>
          <p>[ ]         T2c     Any caruncular, less than or equal to 1 quadrant</p>
          <p>[ ]         T2d     Any caruncular, greater than 1 quadrant</p>
          <p>[ ]         T3      Any malignant conjunctival melanoma with local invasion</p>
          <p>[ ]         T3a     Globe</p>
          <p>[ ]         T3b     Eyelid</p>
          <p>[ ]         T3c     Orbit</p>
          <p>[ ]         T3d     Sinus</p>
          <p>[ ]         T4      Tumor invades the central nervous system</p>
          <p></p>
          <p>PATHOLOGIC          PRIMARY TUMOR (pT)</p>
          <p>[ ]        pTX      Primary tumor cannot be assessed</p>
          <p>[ ]        pT0      No evidence of primary tumor</p>
          <p>[ ]        pTis     Melanoma confined to the conjunctival epithelium**</p>
          <p>[ ]        pT1a     Melanoma of the bulbar conjunctiva not more than 0.5mm in</p>
          <p>                    thickness with invasion of the substantia propria</p>
          <p>[ ]        pT1b     Melanoma of the bulbar conjunctiva more than 0.5mm but</p>
          <p>                    not more than 1.5mm in thickness with invasion of the</p>
          <p>                    substantia propria</p>
          <p>[ ]        pT1c     Melanoma of the bulbar conjunctiva greater than 1.5mm in</p>
          <p>                    thickness with invasion of the substantia propria</p>
          <p>[ ]        pT2a     Melanoma of the palpebral, forniceal or caruncular</p>
          <p>                    conjunctiva not more than 0.5mm in thickness with</p>
          <p>                    invasion of the substantia propria</p>
          <p>[ ]        pT2b     Melanoma more than 0.5 but not greater than 1.5mm in</p>
          <p>                    thickness with invasion of the substantia propria</p>
          <p>[ ]        pT2c     Melanoma of the palpebral, forniceal or caruncular</p>
          <p>                    conjunctiva greater than 1.5mm in thickness with invasion</p>
          <p>                    of the substantia propria.</p>
          <p>[ ]        pT3      Melanoma invades the eye, eyelid, nasolacrimal system or</p>
          <p>                    orbit</p>
          <p>[ ]        pT4      Melanoma invades the central nervous system</p>
          <p></p>
          <p>** Note: pT(is) melanoma insitu (includes the term primary acquired</p>
          <p>melanosis) with atypia replacing greater than 75% of the normal epithelial</p>
          <p>thickness, with cytologic features of epithelioid cells, including abdundant</p>
          <p>cytoplasm, vesicular nuclei or prominent nucleoli, and/or presence of</p>
          <p>intraepithelial nest of atypical cells.</p>
          <p></p>
          <p>CLINICAL            REGIONAL LYMPH NODES (N)</p>
          <p>[ ]         NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]         N0a     No regional lymph node metastasis, biopsy performed</p>
          <p>[ ]         N0b     No regional lymph node metastasis, biopsy not performed</p>
          <p>[ ]         N1      Regional lymph node metastasis</p>
          <p></p>
          <p>PATHOLOGIC          REGIONAL LYMPH NODES (pN)</p>
          <p>[ ]        pNx      Regional lymph nodes cannot be assessed</p>
          <p>[ ]        pN0      No regional lymph node metastasis</p>
          <p>[ ]        pN1      Regional lymph node metastasis present</p>
          <p> </p>
          <p> </p>
          <p>DISTANT METASTASIS (M)</p>
          <p>[ ]         M0     No distant metastasis (no pathologic M0; use </p>
          <p>                   clinical M to complete stage group) </p>
          <p>[ ]    [ ]  M1     Distant metastasis</p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>No stage grouping is presently recommended</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>Measured thickness (depth):_______________</p>
          <p></p>
          <p></p>
          <p>HISTOLOGIC GRADE</p>
          <p>Histologic grade represents the origin of the primary tumor:</p>
          <p>[ ]   Grade 0: Primary acquired melanosis without cellular atypia</p>
          <p>[ ]   Grade 1: Conjunctival nevus</p>
          <p>[ ]   Grade 2: Primary acquired melanosis with cellular atypia (epithelial</p>
          <p>               disease only)</p>
          <p>[ ]   Grade 3: Primary acquired melanosis with epithelial cellular atypia and</p>
          <p>               invasive melanoma</p>
          <p>[ ]   Grade 4: De novo malignant melanoma</p>
          <p>[ ]   Grade X: Origin cannot be assessed</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
          <p></p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC MELANOMA OF UVEA STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>MALIGNANT MELANOMA OF THE UVEA</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p></p>
          <p>Tumor Size: Category classification (1-4) for ciliary body and choroid uveal</p>
          <p>melanoma based on thickness and diameter:</p>
          <p></p>
          <p></p>
          <p>*Thickness(mm)</p>
          <p>        &gt;15.0 _____________________________________4__________4__________4</p>
          <p>    12.1-15.0 ___________________________3_________3__________4__________4</p>
          <p>     9.1-12.0 _________3________3________3_________3__________3__________4</p>
          <p>     6.1- 9.0 _2_______2________2________2_________3__________3__________4</p>
          <p>     3.1- 6.0 _1_______1________1________2_________2__________3__________4</p>
          <p>         &lt;3.0 _1_______1________1________1_________2__________2__________4</p>
          <p></p>
          <p>           &lt;/=3.0  3.1-6.0  6.1-9.0  9.1-12.0  12.1-15.0  15.1-18.0  &gt;18.0</p>
          <p>             Largest basal diameter(mm)</p>
          <p></p>
          <p>Laterality:</p>
          <p> [ ] Left</p>
          <p> [ ] Right</p>
          <p> [ ] Bilateral</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>ALL UVEAL MELANOMAS</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p></p>
          <p>IRIS**</p>
          <p>[ ]    [ ]     T1      Tumor limited to the iris</p>
          <p>[ ]    [ ]     T1a     Tumor limited to the iris not more than 3 clock hours</p>
          <p>                       in size</p>
          <p>[ ]    [ ]     T1b     Tumor limited to iris more than 3 clock hours in size</p>
          <p>[ ]    [ ]     T1c     Tumor limited to iris with secondary glaucoma</p>
          <p>[ ]    [ ]     T2      Tumor confluent with or extending into the ciliary</p>
          <p>                        body, choroid or both</p>
          <p>[ ]    [ ]     T2a     Tumor confluent with or extending into the ciliary</p>
          <p>                        body, choroid or both, with secondary glaucoma</p>
          <p>[ ]    [ ]     T3      Tumor confluent with or extending into the ciliary</p>
          <p>                        body, choroid or both, with sclera extension</p>
          <p>[ ]    [ ]     T3a     Tumor confluent with or extending into the ciliary</p>
          <p>                        body, choroid or both, with sclera extension and</p>
          <p>                        secondary glaucoma</p>
          <p>[ ]    [ ]     T4      Tumor with extrascleral extension</p>
          <p>[ ]    [ ]     T4a     Tumor with extrascleral extension less than or equal</p>
          <p>                        to 5 mm in diameter</p>
          <p>[ ]    [ ]     T4b     Tumor with extrascleral extension more than 5 mm in</p>
          <p>                        diameter</p>
          <p></p>
          <p>**Iris melanomas originate from, and are predominantly located in, this</p>
          <p>Region of the uvea. If less than half of the tumor volume is located within</p>
          <p>The iris, the tumor may have originated in the ciliary body and consideration</p>
          <p>should be given to classifying it accordingly.</p>
          <p></p>
          <p>CILIARY BODY AND CHOROID (SEE TUMOR CLASSIFICATION TABLE ABOVE)</p>
          <p>[ ]    [ ]     T1      Tumor size category 1</p>
          <p>[ ]    [ ]     T1a     Tumor size category 1 with ciliary body involvement</p>
          <p>                       and extraocular extension</p>
          <p>[ ]    [ ]     T1b     Tumor size category 1 with ciliary body involvement</p>
          <p>[ ]    [ ]     T1c     Tumor size category 1 without ciliary body involvement</p>
          <p>                       but with extraocular extension less than or equal to</p>
          <p>                       5 mm in diameter</p>
          <p>[ ]    [ ]     T1d     Tumor size category 1 with ciliary body involvement</p>
          <p>                       and extraocular extension less than or equal to 5 mm</p>
          <p>                       in diameter</p>
          <p>[ ]    [ ]     T2      Tumor size category 2</p>
          <p>[ ]    [ ]     T2a     Tumor size category 2 without ciliary body involvement</p>
          <p>                       and extraocular extension</p>
          <p>[ ]    [ ]     T2b     Tumor size category 2 with ciliary body involvement</p>
          <p>[ ]    [ ]     T2c     Tumor size category 2 without ciliary body involvement</p>
          <p>                       but with extraocular extension less than or equal to 5</p>
          <p>                       mm in diameter.</p>
          <p>[ ]    [ ]     T2d     Tumor size category 2 with ciliary body involvement</p>
          <p>                       and extraocular extension less than or equal to 5 mm</p>
          <p>                       in diameter</p>
          <p>[ ]    [ ]     T3      Tumor size category 3</p>
          <p>[ ]    [ ]     T3a     Tumor size category 3 without ciliary body involvement</p>
          <p>                       and extraocular extension</p>
          <p>[ ]    [ ]     T3b     Tumor size category 3 with ciliary body involvement</p>
          <p>[ ]    [ ]     T3c     Tumor size category 3 without ciliary body involvement</p>
          <p>                       but with extraocular extension less than or equal to 5</p>
          <p>                       mm in diameter</p>
          <p>[ ]    [ ]     T3d     Tumor size category 3 with ciliary body involvement</p>
          <p>                       and extraocular extension less than or equal to 5 mm</p>
          <p>                       in diameter</p>
          <p>[ ]    [ ]     T4      Tumor size category 4</p>
          <p>[ ]    [ ]     T4a     Tumor size category 4 without ciliary body involvement</p>
          <p>                       and extraocular extension</p>
          <p>[ ]    [ ]     T4b     Tumor size category 4 with ciliary body involvement</p>
          <p>[ ]    [ ]     T4c     Tumor size category 4 without ciliary body involvement</p>
          <p>                       but with extraocular extension less than or equal to </p>
          <p>                       5 mm in diameter</p>
          <p>[ ]    [ ]     T4d     Tumor size category 4 with ciliary body involvement</p>
          <p>                       and extraocular extension less than or equal to 5 mm</p>
          <p>                       in diameter</p>
          <p>[ ]    [ ]     T4e     Any tumor size category with extraocular extension</p>
          <p>                       more than 5mm in diameter</p>
          <p></p>
          <p>*Clinical: In clinical practice, the largest tumor basal diameter may be</p>
          <p>estimated in optic disc diameters (dd,average: 1dd=1.5mm). Tumor thickness</p>
          <p>may be estimated in diopters (average: 2.5 diopters = 1mm). However,</p>
          <p>techniques such as ultrasonography and fundus photography are used to provide</p>
          <p>more accurate measurements. Ciliary body involvement can be evaluated by the</p>
          <p>slit-lamp, ophthalmoscopy, gonioscopy and transillumination. However, high</p>
          <p>frequency ultrasonography (ultrasound biomicroscopy) is used for more</p>
          <p>accurate assessment. Extension through the sclera is evaluated visually</p>
          <p>before and during surgery, and with ultrasonography, computed tomography or</p>
          <p>magnetic resonance imaging.</p>
          <p></p>
          <p>Pathologic: When histopathologic measurements are recorded after fixation,</p>
          <p>tumor diameter and thickness may be underestimated because of tissue</p>
          <p>shrinkage.</p>
          <p></p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Regional lymph node metastasis</p>
          <p> </p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p>[ ]    [ ]     M1a     Largest diameter of the largest metastasis 3cm or less</p>
          <p>[ ]    [ ]     M1b     Largest diameter of the largest metastasis 3.1-8.0 cm</p>
          <p>[ ]    [ ]     M1c     Largest diameter of the largest metastasis 8.1cm or more</p>
          <p></p>
          <p></p>
          <p>Distant metastasis</p>
          <p>               STAGE GROUPING</p>
          <p>[ ]    [ ]     I       T1a     N0      M0</p>
          <p>[ ]    [ ]     IIA     T1b-d   N0      M0</p>
          <p>[ ]    [ ]             T2a     N0      M0</p>
          <p>[ ]    [ ]     IIB     T2b     N0      M0</p>
          <p>                       T3a     N0      M0</p>
          <p>[ ]    [ ]     IIIA    T2c-d   N0      M0</p>
          <p>[ ]    [ ]             T3b-c   N0      M0</p>
          <p>[ ]    [ ]             T4a     N0      M0</p>
          <p>[ ]    [ ]     IIIB    T3d     N0      M0</p>
          <p>[ ]    [ ]             T4b-c   N0      M0</p>
          <p>[ ]    [ ]     IIIC    T4d-e   N0      M0</p>
          <p>[ ]    [ ]     IV      Any T   N1      M0</p>
          <p>[ ]    [ ]             Any T   Any N   M1a-c</p>
          <p>[ ] UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : Tumor height and largest diameter</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>Measured thickness (height) __________________________________</p>
          <p>Chromosomal alternations _____________________________________</p>
          <p>Gene expression profile ______________________________________</p>
          <p>Positron emission tomography/computed tomography _____________</p>
          <p>Confocal indocyanine green angiography _______________________</p>
          <p>Mitotic count per 40 high power fields (HPF) _________________</p>
          <p>Mean diameter of the ten largest nucleoli (MLN) ______________</p>
          <p>Presence of extravascular matrix patterns ____________________</p>
          <p>Microvascular density (MVD) __________________________________</p>
          <p>Insulin-like growth factor 1 receptor (IGF1-R) _______________</p>
          <p>Tumor-infiltrating lymphocytes _______________________________</p>
          <p>Tumor-infiltrating macrophages _______________________________</p>
          <p>HLA Class 1 expression _______________________________________</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC MERKEL CELL CARCINOMA STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>MERKEL CELL CARCINOMA</p>
          <p>(Staging for Merkel Cell of the eyelid is not included in this chapter; see </p>
          <p>Carcinoma of the Eyelid form)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p>Laterality:</p>
          <p> [ ] Left</p>
          <p> [ ] Right</p>
          <p> [ ] Bilateral</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor (e.g., nodal/metastatic</p>
          <p>                       presentation without associated primary)</p>
          <p>[ ]    [ ]     Tis     In situ primary tumor </p>
          <p>[ ]    [ ]     T1      Less than or equal to 2 cm maximum tumor dimension</p>
          <p>[ ]    [ ]     T2      Greater than 2 cm but not more than 5 cm maximum tumor</p>
          <p>                       dimension</p>
          <p>[ ]    [ ]     T3      Over 5 cm maximum tumor dimension</p>
          <p>[ ]    [ ]     T4      Primary tumor invades bone, muscle, fascia or</p>
          <p>                       cartilage</p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]            NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]            N0      No regional lymph node metastasis</p>
          <p>                        Nodes negative by clinical exam* (no pathologic node</p>
          <p>                        exam performed)</p>
          <p>       [ ]              Nodes negative by pathologic exam</p>
          <p>[ ]    [ ]     N1      Metastasis in regional lymph nodes(s)</p>
          <p>       [ ]     N1a      Micrometastasis **</p>
          <p>[ ]    [ ]     N1b      Macrometastasis***</p>
          <p>[ ]    [ ]     N2      In transit Metastasis****</p>
          <p></p>
          <p>*Clinical detection of nodal disease may be via inspection, palpation and/or </p>
          <p>imaging</p>
          <p>**Isolated tumor cells in a lymph node are classified as micrometastases (N1a) </p>
          <p>and thepresence of isolated tumor cells recorded using the prognostic factor. </p>
          <p>Micrometastases are diagnosed after sentinel or elective lymphadenectomy</p>
          <p>***Macrometastases are defined as clinically detectable nodal metastases </p>
          <p>confirmed by therapeutic lymphadenectomy or needle biopsy</p>
          <p>****In transit metastasis: a tumor distinct from the primary lesion and located </p>
          <p>either 1)between the primary lesion and the draining regional lymph nodes or 2) </p>
          <p>distal to the primary lesion </p>
          <p></p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Metastasis beyond regional lymph nodes</p>
          <p>[ ]    [ ]     M1a      Metastasis to skin, subcutaneous tissues or distant</p>
          <p>                        lymph nodes</p>
          <p>[ ]    [ ]     M1b      Metastasis to lung</p>
          <p>[ ]    [ ]     M1c      Metastasis to all other visceral sites</p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p></p>
          <p>Clinical</p>
          <p>[ ]         0       Tis     N0        M0</p>
          <p>[ ]         IB      T1      N0        M0</p>
          <p>[ ]         IIB     T2/T3   N0        M0</p>
          <p>[ ]         IIC     T4      N0        M0</p>
          <p>[ ]         IIIB    Any T   N1/N1b/N2 M0</p>
          <p>[ ]         IV      Any T   Any N     M1</p>
          <p>[ ] STAGE UNKNOWN</p>
          <p></p>
          <p>Note: Isolated tumor cells should be considered positive nodes.</p>
          <p></p>
          <p>Pathologic</p>
          <p>[ ]         0       Tis     N0        M0</p>
          <p>[ ]         IA      T1      pN0       M0</p>
          <p>[ ]         IB      T1      cN0       M0</p>
          <p>[ ]         IIA     T2/T3   pN0       M0</p>
          <p>[ ]         IIB     T2/T3   cN0       M0</p>
          <p>[ ]         IIC     T4      N0        M0</p>
          <p>[ ]         IIIA    Any T   N1a       M0</p>
          <p>[ ]         IIIB    Any T   N2/N1b/N2 M0</p>
          <p>[ ]         IV      Any T   Any N     M1</p>
          <p>[ ] STAGE UNKNOWN</p>
          <p></p>
          <p>Note: Isolated tumor cells should be considered positive nodes.</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>Measured thickness (depth) _____________________________________</p>
          <p>Tumor Base Transection Status __________________________________</p>
          <p>Profound Immune Suppression ____________________________________</p>
          <p>Tumor Infiltrating Lymphocytes in the Primary tumor (TIL)_______</p>
          <p>Growth Pattern of Primary Tumor ________________________________</p>
          <p>Size of tumor nests in regional lymph nodes ____________________</p>
          <p>Clinical Status of Regional Lymph nodes ________________________</p>
          <p>Regional Lymph nodes Pathological Extracapsular extension ______</p>
          <p>Isolated Tumor cell in Regional lymph nodes ____________________</p>
          <p></p>
          <p>GRADING SYSTEM</p>
          <p>Histologic grade is not used in staging of Merkel cell carcinoma.</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
          <p></p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC MUCOSAL MELANOMA OF HEAD AND NECK STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>MUCOSAL MELANOMA OF THE HEAD AND NECK </p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p>Tumor Size:__________</p>
          <p></p>
          <p>Laterality:</p>
          <p> [ ] Left</p>
          <p> [ ] Right</p>
          <p> [ ] Bilateral</p>
          <p></p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     T3      Mucosal disease</p>
          <p>[ ]    [ ]     T4A     Moderately advanced disease</p>
          <p>[ ]    [ ]              Tumor involving deep soft tissue, cartilage, bone or</p>
          <p>                        overlying skin</p>
          <p>[ ]    [ ]     T4B     Very advanced disease</p>
          <p>[ ]    [ ]              Tumor involving brain, dura, skull base, lower</p>
          <p>                        cranial nerves (IX,X,XI,XII), masticator space,</p>
          <p>                        carotid artery, prevertebral space, or mediastinal</p>
          <p>                        structures.</p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Regional lymph node metastasis present</p>
          <p> </p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p>Distant metastasis</p>
          <p>               STAGE GROUPING</p>
          <p>[ ]    [ ]     III     T3      N0      M0</p>
          <p>[ ]    [ ]     IVA     T4a     N0      M0</p>
          <p>                       T3-T4a  N1      M0</p>
          <p>[ ]    [ ]     IVB     T4b     Any N   M0</p>
          <p>[ ]    [ ]     IVC     Any T   Any N   M1</p>
          <p></p>
          <p>[ ] UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>Size of Lymph Nodes _________________</p>
          <p>Extracapsular Extension from Lymph Nodes for Head &amp; Neck __________</p>
          <p>Head &amp; Neck Lymph Nodes Levels I-III ___________</p>
          <p>Head &amp; Neck Lymph Nodes Levels IV-V  ___________</p>
          <p>Head &amp; Neck Lymph Nodes Levels VI-VII___________</p>
          <p>Other Lymph Nodes Group ___________________________________________</p>
          <p>Clinical Location of cervical nodes _______________________________</p>
          <p>Extracapsular spread (ECS) Clinical _______________________________</p>
          <p>Extracapsular spread (ECS) Pathologic _____________________________</p>
          <p>Tumor Thickness ___________________________________________________</p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC NASAL CAVITY AND PARANASAL SINUS STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>NASAL CAVITY AND PARANASAL SINUSES</p>
          <p>(Nonepithelial tumors such as those of lymphoid tissue, soft tissue, bone and</p>
          <p>cartilage are not included. Staging for mucosal melanoma of the nasal cavity</p>
          <p>and paranasal sinuses is not included - See Mucosal Melanoma of the Head &amp;</p>
          <p> Neck form)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p>Laterality:</p>
          <p> [ ] Left</p>
          <p> [ ] Right</p>
          <p> [ ] Bilateral</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis     Carcinoma in situ</p>
          <p></p>
          <p>               Maxillary Sinus</p>
          <p>[ ]    [ ]     T1      Tumor limited to maxillary sinus mucosa with no</p>
          <p>                       erosion or destruction of bone</p>
          <p>[ ]    [ ]     T2      Tumor causing bone erosion or destruction including</p>
          <p>                       extension into the hard palate and/or middle nasal</p>
          <p>                       meatus, except extension to posterior wall of</p>
          <p>                       maxillary sinus and pterygoid plates</p>
          <p>[ ]    [ ]     T3      Tumor invades any of the following; bone of the</p>
          <p>                       posterior wall of maxillary sinus, subcutaneous</p>
          <p>                       tissues, floor or medial wall of orbit, pterygoid</p>
          <p>                       fossa, ethmoid sinuses</p>
          <p>[ ]    [ ]     T4a     Moderately advanced local disease.</p>
          <p>                        Tumor invades anterior orbital contents, skin of</p>
          <p>                        cheek, pterygoid plates, infratemporal fossa,</p>
          <p>                        cribriform plate, sphenoid or frontal sinuses.</p>
          <p>[ ]    [ ]     T4b     Very advanced local disease.</p>
          <p>                        Tumor invades any of the following; orbital apex,</p>
          <p>                        dura, brain, middle cranial fossa, cranial nerves</p>
          <p>                        other than maxillary division of trigeminal nerve</p>
          <p>                        (V2), nasopharynx or clivus.</p>
          <p></p>
          <p>               Nasal Cavity and Ethmoid Sinus</p>
          <p>[ ]    [ ]     T1      Tumor restricted to any one subsite, with or without</p>
          <p>                       bony invasion</p>
          <p>[ ]    [ ]     T2      Tumor invading two subsites in a single region or</p>
          <p>                       extending to involve an adjacent region within the</p>
          <p>                       nasoethmoidal complex, with or without bony invasion</p>
          <p>[ ]    [ ]     T3      Tumor extends to invade the medial wall or floor of</p>
          <p>                       the orbit, maxillary sinus, palate or cribriform plate</p>
          <p>[ ]    [ ]     T4a     Moderately advanced local disease</p>
          <p>                        Tumor invades any of the following; anterior orbital</p>
          <p>                        contents, skin of nose or cheek, minimal extension to</p>
          <p>                        anterior cranial fossa, pterygoid plates, phenoid or</p>
          <p>                        frontal sinuses.</p>
          <p>[ ]    [ ]     T4b     Very advanced local disease</p>
          <p>                        Tumor invades any of the following; orbital apex,</p>
          <p>                        dura, brain, middle cranial fossa, cranial nerves</p>
          <p>                        other than (V2), nasopharynx or clivus.</p>
          <p></p>
          <p> </p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Metastasis in a single ipsilateral lymph node, 3cm or</p>
          <p>                       less in greatest dimension</p>
          <p>[ ]    [ ]     N2      Metastasis in a single ipsilateral lymph node, more</p>
          <p>                       than 3 cm but not more than 6 cm in greatest</p>
          <p>                       dimension, or in multiple ipsilateral lymph nodes,</p>
          <p>                       none more than 6 cm in greatest dimension, or in</p>
          <p>                       bilateral or contralateral lymph nodes, none more than</p>
          <p>                       6 cm in greatest dimension.</p>
          <p>[ ]    [ ]     N2a     Metastasis in a single ipsilateral lymph nodes, more</p>
          <p>                       than 3 cm but not more than 6 cm in greatest dimension</p>
          <p>[ ]    [ ]     N2b     Metastasis in multiple ipsilateral lymph nodes, none</p>
          <p>                       more than 6 cm in greatest dimension</p>
          <p>[ ]    [ ]     N2c     Metastasis in bilateral or contralateral lymph nodes,</p>
          <p>                       none more than 6cm in greatest dimension.</p>
          <p>[ ]    [ ]     N3      Metastasis in a lymph node, more than 6 cm in</p>
          <p>                       greatest dimension.</p>
          <p> </p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>[ ]    [ ]     0       Tis     N0      M0</p>
          <p>[ ]    [ ]     I       T1      N0      M0</p>
          <p>[ ]    [ ]     II      T2      N0      M0</p>
          <p>[ ]    [ ]     III     T3      N0      M0</p>
          <p>                       T1      N1      M0</p>
          <p>                       T2      N1      M0</p>
          <p>                       T3      N1      M0</p>
          <p>[ ]    [ ]     IVA     T4A     N0      M0</p>
          <p>                       T4A     N1      M0</p>
          <p>                       T2      N2      M0</p>
          <p>                       T3      N2      M0</p>
          <p>                       T4A     N2      M0</p>
          <p>[ ]    [ ]     IVB     T4B     Any N   M0</p>
          <p>                       Any T   N3      M0</p>
          <p>[ ]    [ ]     IVC     Any T   Any N   M2</p>
          <p>[ ]    [ ]     UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>Size of Lymph Nodes: ________________</p>
          <p>Extracapsular Extension from Lymph Nodes for Head &amp; Neck__________</p>
          <p>Head &amp; Neck lymph Nodes Levels I-III _____________</p>
          <p>Head &amp; Neck lymph Nodes Levels IV-V  _____________</p>
          <p>Head &amp; Neck lymph Nodes Levels VI-VII_____________</p>
          <p>Other Lymph Nodes Group___________________________</p>
          <p>Clinical Location of cervical nodes ______________</p>
          <p>Extracapsular spread (ECS) Clinical ______________</p>
          <p>Extracapsular spread (ECS) Pathological __________</p>
          <p>Human Papillomavirus (HPF) Status ________________</p>
          <p>Tumor Thickness ______________</p>
          <p></p>
          <p></p>
          <p>GRADING SYSTEM</p>
          <p>[ ] 2 grade system                        </p>
          <p>[ ] 3 grade system                        </p>
          <p>[ ] 4 grade system                        </p>
          <p>[ ] No 2,3,or 4 grade system is available </p>
          <p></p>
          <p>HISTOLOGIC GRADE:</p>
          <p>[ ] Grade X Grade cannot be assessed</p>
          <p>[ ] Grade 1 Well differentiated</p>
          <p>[ ] Grade 2 Moderately differentiated</p>
          <p>[ ] Grade 3 Poorly differentiated</p>
          <p>[ ] Grade 4 Undifferentiated</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe): </p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
          <p></p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC NEUROENDOCRINE TUMOR STAGING 7TH. ED. ">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>NEUROENDOCRINE TUMOR </p>
          <p>Gastric, small bowel, colonic, rectal and ampulla of vater carcinoid tumors</p>
          <p>(well differentiated neuroendocrine tumors and well differentiated neuro </p>
          <p>endocrine carcinomas); carcinoid tumors of the appendix (see Chap. 13) and </p>
          <p>neuroendocrine tumor of the pancreas (see Chap. 24) are not included. </p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p> Stomach</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis     Carcinoma in situ/dysplasia (tumor size &lt;0.5mm)</p>
          <p>                       confined to  mucosa</p>
          <p>[ ]    [ ]     T1      Tumor invades lamina propria or submucosa and size &lt;/= 1cm</p>
          <p>                       in size</p>
          <p>[ ]    [ ]     T2      Tumor invades muscularis propria or &gt; 1cm in size</p>
          <p>[ ]    [ ]     T3      Tumor penetrates subserosa</p>
          <p>[ ]    [ ]     T4      Tumor invades visceral peritoneum (serosa) or other</p>
          <p>                       organs of adjacent structures.</p>
          <p></p>
          <p>For any T, add (m) for multiple tumors</p>
          <p></p>
          <p> Duodenum/Ampulla/Jejunum/Ileum</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     T1      Tumor invades lamina propria or submucosa and size &lt;/= 1cm</p>
          <p>                       (small intestinal tumors); tumor &lt;/= 1 cm </p>
          <p>                       (ampullary tumors)</p>
          <p>[ ]    [ ]     T2      Tumor invades muscularis propria or size &gt; 1cm</p>
          <p>                       (small intestinal tumors); tumor &gt; 1cm </p>
          <p>                       (ampullary tumors)</p>
          <p>[ ]    [ ]     T3      Tumor invades through the muscularis propria into</p>
          <p>                       subserosal tissue without penetration of overlying</p>
          <p>                       serosa (jejunal or ileal tumors) or invades pancreas</p>
          <p>                       or retroperitoneum (ampullary or duodenal tumors) or</p>
          <p>                       into nonperitonealized tissues.</p>
          <p>[ ]    [ ]     T4      Tumor invades visceral peritoneum (serosa) or invades </p>
          <p>			  other organs.</p>
          <p></p>
          <p>For any T, add (m) for multiple tumors</p>
          <p>*Tumor limited to ampulla of Vater for ampullary gangliocytic paraganglioma</p>
          <p></p>
          <p> Colon or Rectum</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     T1      Tumor invades lamina propria or submucosa and &lt;/= 2 cm</p>
          <p>[ ]    [ ]     T1a     Tumor size &lt; 1 cm in greatest dimension </p>
          <p>[ ]    [ ]     T1b     Tumor size 1 to 2 cm in greatest dimension </p>
          <p>[ ]    [ ]     T2      Tumor invades muscularis propria or size &gt; 2 cm</p>
          <p>                       with invasion of lamina propria of submucosa</p>
          <p>[ ]    [ ]     T3      Tumor invades through the muscularis propria into the</p>
          <p>                       subserosa, or into non-peritonealized pericolic or</p>
          <p>                       perirectal tissues</p>
          <p>[ ]    [ ]     T4      Tumor invades peritoneum of other organs </p>
          <p></p>
          <p>For any T, add (m) for multiple tumors</p>
          <p></p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p> Stomach; Duodenum/Ampulla/Jejunum/Ileum; Colon or Rectum</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Regional lymph node metastasis</p>
          <p></p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>Stomach; Duodenum/Ampulla/Jejunum/Ileum; Colon or Rectum</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>[ ]    [ ]     0       Tis*     N0      M0</p>
          <p>[ ]    [ ]     I       T1       N0      M0</p>
          <p>[ ]    [ ]     IIA     T2       N0      M0</p>
          <p>[ ]    [ ]     IIB     T3       N0      M0</p>
          <p>[ ]    [ ]     IIIA    T4       N0      M0</p>
          <p>[ ]    [ ]     IIIB    Any T    N1      M0</p>
          <p>[ ]    [ ]     IV      Any T    Any N   M1</p>
          <p></p>
          <p>[ ]            UNKNOWN STAGE</p>
          <p>*Note: Tis applies only to stomach</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>Pre-operative plasma chromogranin A level (CgA)________________</p>
          <p>Urinary 5-hydroxyindolacetic acid (5-HIAA) level ______________</p>
          <p>Mitotic count _________________________________________________</p>
          <p></p>
          <p>GRADING SYSTEM					GRADE</p>
          <p>[ ] 2 grade system 					[ ] Grade I or 1                       </p>
          <p>[ ] 3 grade system       				[ ] Grade II or 2                 </p>
          <p>[ ] No 2 or 3 grade system is available 		[ ] Grade III or 3</p>
          <p></p>
          <p>HISTOLOGIC GRADE</p>
          <p>                       Mitotic count (10 HPF)*    Ki-67 index (%)**</p>
          <p>[ ]   Grade 1:         less than 2                less than or equal to 2</p>
          <p>[ ]   Grade 2:         2-20                       3-20</p>
          <p>[ ]   Grade 3:         greater than 20            greater than 20</p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC ORBIT SARCOMA STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>Sarcoma of the Orbit</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p>Laterality:</p>
          <p> [ ] Left</p>
          <p> [ ] Right</p>
          <p> [ ] Bilateral</p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     T1      Tumor 15 mm or less in greatest dimension</p>
          <p>[ ]    [ ]     T2      Tumor more than 15 mm in greatest dimension without</p>
          <p>                       invasion of the globe or bony wall</p>
          <p>[ ]    [ ]     T3      Tumor of any size with invasion of orbital tissues</p>
          <p>                       and/or bony walls.</p>
          <p>[ ]    [ ]     T4      Tumor invasion of globe or periorbital structure, such</p>
          <p>                       as eyelids, temporal fossa, nasal cavity and paranasal</p>
          <p>                       sinuses, and/or central nervous system.</p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Regional lymph node metastasis</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>No stage grouping is presently recommended</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT : None</p>
          <p></p>
          <p>GRADING SYSTEM</p>
          <p></p>
          <p>[ ] 2 grade system                        </p>
          <p>[ ] 3 grade system                        </p>
          <p>[ ] 4 grade system                        </p>
          <p>[ ] No 2,3,or 4 grade system is available </p>
          <p></p>
          <p>HISTOLOGIC GRADE</p>
          <p>[ ] Grade I or 1: Well differentiated</p>
          <p>[ ] Grade II or 2: Moderately differentiated</p>
          <p>[ ] Grade III or 3: Poorly differentiated</p>
          <p>[ ] Grade IV or 4: Undifferentiated</p>
          <p>[ ] Grade X: Grade cannot be assessed</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC OVARY AND PRIMARY PERITONEAL CARCINOMA STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>OVARY AND PRIMARY PERITONEAL CARCINOMA</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>Tumor size:  _____________</p>
          <p></p>
          <p>Laterality</p>
          <p></p>
          <p>[ ] Left</p>
          <p>[ ] Right</p>
          <p>[ ] Bilateral</p>
          <p></p>
          <p> </p>
          <p>CLIN   PATH    FIGO    TNM     PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]             TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]             T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     I       T1      Tumor limited to ovaries (one or both)</p>
          <p>[ ]    [ ]     IA      T1a     Tumor limited to one ovary; capsule intact,</p>
          <p>                               no tumor on ovarian surface. No</p>
          <p>                               malignant cells in ascites or peritoneal</p>
          <p>                               washings.</p>
          <p>[ ]    [ ]     IB      T1b     Tumor limited to both ovaries capsules</p>
          <p>                               Intact, no tumor on ovarian surface.  No</p>
          <p>                               Malignant cells in ascites or peritoneal</p>
          <p>                               washings</p>
          <p>[ ]    [ ]     IC      T1c     Tumor limited to 1 or both ovaries with</p>
          <p>                               any of the following: capsule ruptured,</p>
          <p>                               tumor on ovarian surface, malignant</p>
          <p>                               cells in ascites or peritoneal washings</p>
          <p>[ ]    [ ]     II      T2      Tumor involves one or both ovaries with</p>
          <p>                               pelvic extension and/or implants.</p>
          <p>[ ]    [ ]     IIA     T2a     Extension and/or implants on uterus and/or</p>
          <p>                               tubes. No malignant cells in ascites or</p>
          <p>                               peritoneal washings.</p>
          <p>[ ]    [ ]     IIB     T2b     Extension to and/or implants on other</p>
          <p>                               pelvic tissues. No malignant cells in</p>
          <p>                               ascites or peritoneal washings.</p>
          <p>[ ]    [ ]     IIC     T2c     Pelvic extension and/or implants </p>
          <p>                              (2a or 2b) with malignant cells in ascites</p>
          <p>                               or peritoneal washings.</p>
          <p>[ ]    [ ]     III     T3      Tumor involves 1 or both ovaries, with</p>
          <p>                               microscopically confirmed peritoneal</p>
          <p>                               metastasis outside pelvis.</p>
          <p>[ ]    [ ]     IIIA    T3a     Microscopic peritoneal metastasis beyond</p>
          <p>                               pelvis (no macroscopic tumor)</p>
          <p>[ ]    [ ]     IIIB    T3b     Macroscopic peritoneal metastasis beyond</p>
          <p>                               pelvis 2 cm or less in greatest dimension.</p>
          <p>[ ]    [ ]     IIIC    T3c     Peritoneal metastasis beyond pelvis &gt;2 cm</p>
          <p>                               in greatest dimension and/or regional lymph node  </p>
          <p>                               metastasis</p>
          <p></p>
          <p>    Note:  Liver capsule metastasis T3/Stage III:  liver parenchymal</p>
          <p>    metastasis M1/Stage IV.  Pleural effusion must have positive </p>
          <p>    cytology for M1/Stage IV.</p>
          <p> </p>
          <p>                               REGIONAL LYMPH NODES (N)</p>
          <p>CLIN   PATH    FIGO   TNM</p>
          <p>[ ]    [ ]            NX       Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]            N0       No regional lymph node metastasis</p>
          <p>[ ]    [ ]     IIIC   N1       Regional lymph node metastasis</p>
          <p> </p>
          <p>                               DISTANT METASTASIS (M)</p>
          <p>[ ]                   M0       No distant metastasis (no pathologic M0;</p>
          <p>                               use clinical M to complete stage group)</p>
          <p>[ ]    [ ]     IV     M1       Distant metastasis</p>
          <p> </p>
          <p></p>
          <p>STAGE GROUPING</p>
          <p>CLIN   PATH</p>
          <p>[ ]    [ ]     I       T1      N0      M0      Stage I</p>
          <p>[ ]    [ ]     IA      T1a     N0      M0      Stage IA</p>
          <p>[ ]    [ ]     IB      T1b     N0      M0      Stage IB</p>
          <p>[ ]    [ ]     IC      T1c     N0      M0      Stage IC</p>
          <p>[ ]    [ ]     II      T2      N0      M0      Stage II</p>
          <p>[ ]    [ ]     IIA     T2a     N0      M0      Stage IIA</p>
          <p>[ ]    [ ]     IIB     T2b     N0      M0      Stage IIB</p>
          <p>[ ]    [ ]     IIC     T2c     N0      M0      Stage IIC</p>
          <p>[ ]    [ ]     III     T3      N0      M0      Stage III</p>
          <p>[ ]    [ ]     IIIA    T3a     N0      M0      Stage IIIA</p>
          <p>[ ]    [ ]     IIIB    T3b     N0      M0      Stage IIIB</p>
          <p>[ ]    [ ]     IIIC    T3c     N0      M0      Stage IIIC</p>
          <p>[ ]    [ ]             Any T   N1      M0</p>
          <p>[ ]    [ ]     IV      Any T   Any N   M1      Stage IV</p>
          <p>[ ]    Stage Unknown</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>FIGO:________________________________________________________</p>
          <p>Gross residual tumor after primary cyto-reductive surgery:___</p>
          <p>_______________________________(present, absent, unknown, "y"</p>
          <p>   meaning patient received chemotherapy prior to surgery)</p>
          <p>Residual tumor volume after primary cyto-reductive surgery:__</p>
          <p>_____(no gross, ?1cm, &gt;1cm, unknown, "y" meaning patient</p>
          <p>   received chemotherapy prior to surgery)</p>
          <p>Residual tumor location following primary cyto-reductive</p>
          <p>   Surgery:_______("y" indicates patient received chemotherapy</p>
          <p>   Prior to surgery)</p>
          <p>Malignant ascites volume:_______________</p>
          <p></p>
          <p>Histologic Grade (G)</p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>[ ] Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ] Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ] Not Applicable</p>
          <p>[ ] Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>[ ] RX  Presence of residual tumor cannot be assessed.</p>
          <p>[ ] R0  No residual tumor</p>
          <p>[ ] R1  Microscopic residual tumor</p>
          <p>[ ] R2  Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]  Clinical stage was used in the treatment planning (describe):_______</p>
          <p>[ ]  National guidelines were used in treatment planning:</p>
          <p>     [ ]  NCCN</p>
          <p>     [ ]  Other</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC PANCREAS-EXOCRINE AND ENDOCRINE STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>PANCREAS</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis     Carcinoma in situ*</p>
          <p>[ ]    [ ]     T1      Tumor limited to pancreas, 2 cm or less in greatest</p>
          <p>                       dimension</p>
          <p>[ ]    [ ]     T2      Tumor limited to pancreas, more than 2 cm in greatest</p>
          <p>                       dimension</p>
          <p>[ ]    [ ]     T3      Tumor extends beyond the pancreas but without </p>
          <p>                       involvement of the celiac axis or the superior </p>
          <p>                       mesenteric artery</p>
          <p>[ ]    [ ]     T4      Tumor involves the celiac axis or the superior</p>
          <p>                       mesenteric artery (unresectable primary tumor)</p>
          <p></p>
          <p>   *This also includes the "PanInIII" classification</p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Regional lymph node metastasis</p>
          <p> </p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0;</p>
          <p>                       use clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>[ ]    [ ]     0       Tis     N0      M0</p>
          <p>[ ]    [ ]     IA      T1      N0      M0</p>
          <p>[ ]    [ ]     IB      T2      N0      M0</p>
          <p>[ ]    [ ]     IIA     T3      N0      M0</p>
          <p>[ ]    [ ]     IIB     T1      N1      M0</p>
          <p>                       T2      N1      M0</p>
          <p>                       T3      N1      M0</p>
          <p>[ ]    [ ]     III     T4      Any N   M0</p>
          <p>[ ]    [ ]     IV      Any T   Any N   M1</p>
          <p>[ ]            UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>   Preoperative CA 19-9: ____</p>
          <p>   Preoperative Carcinoembryonic antigen (CEA): _______</p>
          <p>   Preoperative plasma chromogranin A level (CgA) (endocrine pancreas):____</p>
          <p>   Mitotic count (endocrine pancreas): _______</p>
          <p></p>
          <p>GRADING SYSTEM 					GRADE</p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>  [ ]NCCN </p>
          <p>  [ ]Other (describe):</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC PENIS STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>PENIS</p>
          <p>(Primary urethral cardinomas and melanomas are not included)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH            PRIMARY TUMOR</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis     Carcinoma in situ</p>
          <p>[ ]    [ ]     Ta      Noninvasive verrucous carcinoma*</p>
          <p>[ ]    [ ]     T1a     Tumor invades subepithelial connective tissue </p>
          <p>                       without lymph vascular invasion and is not </p>
          <p>                       poorly differentiated (i.e., grade 3-4)</p>
          <p>[ ]    [ ]     T1b     Tumor invades subepithelial connective tissue </p>
          <p>                       with LVI or is poorly differentiated</p>
          <p>[ ]    [ ]     T2      Tumor invades corpus spongiosum or cavernosum</p>
          <p>[ ]    [ ]     T3      Tumor invades urethra</p>
          <p>[ ]    [ ]     T4      Tumor invades other adjacent structures</p>
          <p></p>
          <p>*Note: Broad pushing penetration (invasion) is permitted - destructive invasion </p>
          <p>is against this diagnosis</p>
          <p> </p>
          <p>                       REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed*</p>
          <p>[ ]            N0       No palpable or visibly enlarged inguinal </p>
          <p>                       lymph nodes*</p>
          <p>       [ ]     N0      No regional lymph node metastasis**</p>
          <p>[ ]            N1      Palpable mobile unilateral inguinal node*</p>
          <p>       [ ]     N1      Metastasis in a single inguinal lymph node**</p>
          <p>[ ]            N2      Palpable mobile multiple or bilateral </p>
          <p>                       inguinal lymph nodes *</p>
          <p>       [ ]     N2      Metastasis in multiple or bilateral inguinal </p>
          <p>                       lymph nodes**</p>
          <p>[ ]            N3      Palpable fixed inguinal nodal mass or pelvic </p>
          <p>                       lymphadenopathy unilateral or bilateral*</p>
          <p>       [ ]     N3      Extranodal extension of lymph node metastasis </p>
          <p>                       or pelvic lymph node(s)unilateral or </p>
          <p>                       bilateral**</p>
          <p>                * Based upon palpation, imaging</p>
          <p>                **Based upon biopsy, or surgical excision</p>
          <p></p>
          <p>              DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis*</p>
          <p></p>
          <p>            *Note: Lymph node metastasis outside of the true pelvis </p>
          <p>             in addition to visceral or bone sites.</p>
          <p></p>
          <p></p>
          <p>       STAGE GROUPING</p>
          <p>[ ]    [ ]     0       Tis     N0      M0</p>
          <p>[ ]    [ ]             Ta      N0      M0</p>
          <p>[ ]    [ ]     I       T1a     N0      M0</p>
          <p>[ ]    [ ]     II      T1b     N0      M0</p>
          <p>[ ]    [ ]             T2      N0      M0</p>
          <p>[ ]    [ ]             T3      N0      M0</p>
          <p>[ ]    [ ]     IIIA    T1-3    N1      M0</p>
          <p>[ ]    [ ]     IIIB    T1-3    N2      M0</p>
          <p>[ ]    [ ]     IV      T4      Any N   M0</p>
          <p>[ ]    [ ]             Any T   N3      M0</p>
          <p>                       Any T   Any N   M1</p>
          <p>[ ]            Unknown Stage</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Involvement of corpus spongiosum ___________________________</p>
          <p>Involvement of corpus cavernosum ___________________________</p>
          <p>Percent of tumor that is poorly differentiated ____________________</p>
          <p>Verrucous carcinoma depth of invasion ________________________</p>
          <p>Size of largest lymph node metastasis _________________________</p>
          <p>Extranodal/extracapsular extension ___________________________</p>
          <p>HPV Status ______________________________________________</p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC PHARYNX STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>PHARYNX</p>
          <p>(Nonepithelial tumors such as those of lymphoid tissue, soft tissue, </p>
          <p>bone, and cartilage are not included.  Staging of mucosal melanoma of </p>
          <p>the pharynx is not included)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p></p>
          <p>CLIN   PATH            PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis     Carcinoma in situ</p>
          <p> </p>
          <p>               *****NASOPHARYNX*****</p>
          <p>[ ]    [ ]     T1      Tumor confined to the nasopharynx, or extends to                                      </p>
          <p>                       oropharynx and/or nasal cavity without parapharyngeal </p>
          <p>                       extension* </p>
          <p>[ ]    [ ]     T2      Tumor with parapharyngeal extension* </p>
          <p>[ ]    [ ]     T3      Tumor involves bony structures of skull base </p>
          <p>                       and/or paranasal sinuses </p>
          <p>[ ]    [ ]     T4      Tumor with intracranial extension and/or involvement of </p>
          <p>                       cranial nerves, hypopharynx, orbit, or with extension to                    </p>
          <p>                       the infratemporal fossa/masticator space.</p>
          <p></p>
          <p>* Parapharyngeal extension denotes posterolateral infiltration of tumor.</p>
          <p>                       </p>
          <p>               *****OROPHARYNX*****</p>
          <p>[ ]    [ ]     T1      Tumor 2 cm or less in greatest dimension.</p>
          <p>[ ]    [ ]     T2      Tumor more than 2 cm but not more than 4 cm in greatest </p>
          <p>                       dimension</p>
          <p>[ ]    [ ]     T3      Tumor &gt;4 cm in greatest dimension or extention to lingual </p>
          <p>                       surface of epiglottis</p>
          <p>[ ]    [ ]     T4a     Moderately advanced local disease.</p>
          <p>                         Tumor invades the larynx, extrinsic muscle of </p>
          <p>                         tongue, medial pterygoid, hard palate, or </p>
          <p>                         mandible* </p>
          <p>[ ]    [ ]     T4b     Very advanced local disease.</p>
          <p>                         Tumor invades lateral pterygoid muscle, </p>
          <p>                         pterygoid plates, lateral nasopharynx, or skull</p>
          <p>                         base or encases carotid artery.</p>
          <p></p>
          <p>* Mucosal extension to lingual surface of epiglottis from primary tumors of </p>
          <p>the base of the tongue and vallecula does not constitute invasion of larynx.</p>
          <p>                       </p>
          <p>               *****HYPOPHARYNX*****</p>
          <p>[ ]    [ ]     T1      Tumor limited to 1 subsite of hypopharynx and/or </p>
          <p>                       2 cm or less in greatest dimension.</p>
          <p>[ ]    [ ]     T2      Tumor invades more than 1 subsite of hypopharynx or</p>
          <p>                       an adjacent site, or measures &gt;2 cm but not &gt;4 cm in          </p>
          <p>                       greatest dimension without fixation of hemilarynx.</p>
          <p>[ ]    [ ]     T3      Tumor &gt;4 cm in greatest dimension or with fixation of </p>
          <p>                       hemilarynx or extension to esophagus.</p>
          <p>[ ]    [ ]     T4a     Moderately advanced local disease.</p>
          <p>                         Tumor invades thyroid/cricoid cartilage, hyoid </p>
          <p>                         bone, thyroid gland, or central compartment soft</p>
          <p>                         tissue* </p>
          <p>[ ]    [ ]     T4b     Very advanced local disease.</p>
          <p>                         Tumor invades prevertebral fascia, encases </p>
          <p>                         carotid artery, or involves mediastinal</p>
          <p>                         structures.</p>
          <p>* Central compartment soft tissue includes prelaryngeal strap muscles and</p>
          <p>subcutaneous fat.                       </p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)   NASOPHARYNX</p>
          <p>The distribution and the prognostic impact of regional lymph node spread </p>
          <p>from nasopharynx cancer, particularly of the undifferentiated type, are </p>
          <p>different from those of other head and neck mucosal cancers and justify </p>
          <p>the use of a different N classification scheme.</p>
          <p></p>
          <p>[ ]    [ ]     NX      Regional lymph node cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Unilateral metastasis in lymph node(s) 6 cm or less </p>
          <p>                         in greatest dimension, above the supraclavicular </p>
          <p>                         fossa and/or unilateral or bilateral, retropharyngeal </p>
          <p>                         lymph nodes, 6 cm or less in greatest dimension*</p>
          <p>[ ]    [ ]     N2      Bilateral metastasis in lymph node(s) 6 cm or less in </p>
          <p>                         greatest dimension, above the supraclavicular fossa*</p>
          <p>[ ]    [ ]     N3      Metastasis in a lymph node(s)* &gt;6 cm and/or extention to </p>
          <p>                       supraclivicular fossa </p>
          <p>[ ]    [ ]     N3a     Greater than 6 cm in dimension</p>
          <p>[ ]    [ ]     N3b     Extension to the supraclavicular fossa**</p>
          <p> </p>
          <p>* Note: Midline nodes are considered ipsilateral nodes.</p>
          <p>**Supraclavicular zone or fossa is relevant to the staging of </p>
          <p>nasopharyngeal carcinoma and is the triangular region originally described</p>
          <p>by Ho. It is defined by three points: </p>
          <p>       (1) the superior margin of the sternal end of the clavicle, </p>
          <p>       (2) the superior margin of the lateral end of the clavicle, </p>
          <p>       (3) the point where the neck meets the shoulder; </p>
          <p>   Note that this would include caudal portions of Levels IV and VB.</p>
          <p>   All cases with lymph nodes (whole or part) in the fossa are considered N3b. </p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N) OROPHARYNX and HYPOPHARYNX</p>
          <p>[ ]    [ ]     NX      Regional lymph node cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Metastasis in a single ipsilateral node, 3 cm or less</p>
          <p>[ ]    [ ]     N2      Metastasis in single ipsilat node, &gt;3 cm but not &gt;6 cm </p>
          <p>                       or in multiple ipsilateral nodes, none &gt;6 cm  </p>
          <p>                       or in bilateral or contralateral lymph nodes, none &gt;6 cm  </p>
          <p>[ ]    [ ]     N2a     Metastasis in single ipsilateral lymph node &gt;3 cm, </p>
          <p>                       but not &gt;6 cm  </p>
          <p>[ ]    [ ]     N2b     Metastasis in multiple ipsilateral lymph nodes, </p>
          <p>                       none &gt;6 cm  </p>
          <p>[ ]    [ ]     N2c     Metastasis in bilateral or contralateral lymph nodes, </p>
          <p>                       none &gt;6 cm  </p>
          <p>[ ]    [ ]     N3      Metastasis in lymph node &gt;6 cm in greatest dimension</p>
          <p></p>
          <p>* Metastases at Level VII are considered regional lymph node metastases.</p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis</p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p> </p>
          <p>CLIN   PATH    NASOPHARYNX STAGE GROUPING</p>
          <p>[ ]    [ ]     0       Tis     N0      M0</p>
          <p>[ ]    [ ]     I       T1      N0      M0</p>
          <p>[ ]    [ ]     II      T1      N1      M0</p>
          <p>[ ]    [ ]             T2      N0      M0</p>
          <p>[ ]    [ ]             T2      N1      M0</p>
          <p>[ ]    [ ]     III     T1      N2      M0</p>
          <p>[ ]    [ ]             T2      N2      M0</p>
          <p>[ ]    [ ]             T3      N0      M0</p>
          <p>[ ]    [ ]             T3      N1      M0</p>
          <p>[ ]    [ ]             T3      N2      M0</p>
          <p>[ ]    [ ]     IVA     T4      N0      M0</p>
          <p>[ ]    [ ]             T4      N1      M0</p>
          <p>[ ]    [ ]             T4      N2      M0</p>
          <p>[ ]    [ ]     IVB     Any T   N3      M0</p>
          <p>[ ]    [ ]     IVC     Any T   Any N   M1</p>
          <p>[ ]    [ ]     UNKNOWN STAGE</p>
          <p> </p>
          <p>               OROPHARYNX AND HYPOPHARYNX STAGE GROUPING </p>
          <p>[ ]    [ ]     0       TIS     N0      M0</p>
          <p>[ ]    [ ]     I       T1      N0      M0</p>
          <p>[ ]    [ ]     II      T2      N0      M0</p>
          <p>[ ]    [ ]     III     T3      N0      M0</p>
          <p>[ ]    [ ]             T1      N1      M0</p>
          <p>[ ]    [ ]             T2      N1      M0</p>
          <p>[ ]    [ ]             T3      N1      M0</p>
          <p>[ ]    [ ]     IVA     T4a     N0      M0</p>
          <p>[ ]    [ ]             T4a     N1      M0</p>
          <p>[ ]    [ ]             T1      N2      M0</p>
          <p>[ ]    [ ]             T2      N2      M0</p>
          <p>[ ]    [ ]             T3      N2      M0</p>
          <p>[ ]    [ ]             T4a     N2      M0</p>
          <p>[ ]    [ ]     IVB     T4b     AnyN    M0</p>
          <p>                       AnyT    N3      M0</p>
          <p>[ ]    [ ]     IVC     Any T   Any N   M1</p>
          <p>[ ]    [ ]     UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Size of Lymph Nodes: </p>
          <p>Extracapsular Extension from Lymph Nodes for Head &amp; Neck: </p>
          <p>Head &amp; Neck Lymph Nodes Levels I-III: </p>
          <p>Head &amp; Neck Lymph Nodes Levels IV-V: </p>
          <p>Head &amp; Neck Lymph Nodes Levels VI-VII: </p>
          <p>Other Lymph Node Group: </p>
          <p>Clinical Location of cervical nodes: </p>
          <p>Extracapsular spread (ECS) Clinical: </p>
          <p>Extracapsular spread (ECS) Pathologic: </p>
          <p>Human Papillomavirus (HPV) Status: </p>
          <p>Tumor Thickness:</p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>   [ ]NCCN </p>
          <p>   [ ]Other (describe):</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC PLEURAL MESOTHELIOMA STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>PLEURAL MESOTHELIOMA</p>
          <p></p>
          <p> 7th edition AJCC Cancer Staging Manual</p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p>Laterality:</p>
          <p>          [ ] Left</p>
          <p>          [ ] Right</p>
          <p>          [ ] Bilateral</p>
          <p></p>
          <p>CLIN   PATH            PRIMARY TUMOR (T)</p>
          <p>                       IMIG Staging System for Diffuse Malignant </p>
          <p>                       Pleural Mesothelioma (MPM)</p>
          <p> </p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     T1      Tumor limited to the ipsilateral parietal </p>
          <p>                       pleura, with or without focal mediastinal </p>
          <p>                       pleura and with or without diaphragmatic </p>
          <p>                       pleural involvement</p>
          <p>[ ]    [ ]     T1a     No involvement of the visceral pleura</p>
          <p>[ ]    [ ]     T1b     Tumor also involving the visceral pleura</p>
          <p>[ ]    [ ]     T2      Tumor involving each of the ipsilateral </p>
          <p>                       pleural surfaces (parietal, mediastinal, </p>
          <p>                       diaphragmatic and visceral pleura) with</p>
          <p>                       at least one of the following features:</p>
          <p>                       -invasion of diaphragmatic muscle</p>
          <p>                       -extension of tumor from visceral pleura</p>
          <p>                       into the underlying pulmonary parenchyma</p>
          <p>[ ]    [ ]     T3      Locally advanced but potentially resectable</p>
          <p>                       tumor. Tumor involving all of the ipsilateral </p>
          <p>                       pleural surfaces, with at least 1 of the </p>
          <p>                       following features:</p>
          <p>                       -involvement of the endothroacic fascia</p>
          <p>                       -extension into mediastinal fat</p>
          <p>                       -solitary, completely resectable focus</p>
          <p>                        of tumor extending into the soft tissues </p>
          <p>                        of the chest wall</p>
          <p>                       -non-transmural involvement of the pericardium</p>
          <p>[ ]    [ ]     T4      Locally advanced technically unresectable tumor</p>
          <p>                       Tumor involving all of the ipsilateral pleural </p>
          <p>                       surfaces, with at least one of the following:</p>
          <p>                       -diffuse extension or multifocal masses of </p>
          <p>                        tumor in the chest wall, with or without </p>
          <p>                        associated rib destruction </p>
          <p>                       -direct transdiaphragmatic extension of tumor</p>
          <p>                        to the peritoneum</p>
          <p>                       -direct extension of tumor to the contralateral</p>
          <p>                        pleura</p>
          <p>                       -direct extension of tumor to mediastinal </p>
          <p>                        organ(s)</p>
          <p>                       -direct extension of tumor into the spine</p>
          <p>                       -tumor extending through to the internal </p>
          <p>                        surface of the pericardium with or without</p>
          <p>                        a pericardial effusion, or tumor involving</p>
          <p>                        the myocardium                                                                                                                                                   </p>
          <p>                        </p>
          <p>                       REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Metastasis in the ipsilateral bronchopulmonary </p>
          <p>                       or hilar lymph node(s)</p>
          <p>[ ]    [ ]     N2      Metastasis in the subcarinal or the ipsilateral</p>
          <p>                       mediastinal lymph node(s) including the </p>
          <p>                       ipsilateral internal mammary and </p>
          <p>                       peridiaphragmatic nodes </p>
          <p>[ ]    [ ]     N3      Metastasis in contralateral mediastinal,</p>
          <p>                       contralateral internal mammary, ipsilateral or</p>
          <p>                       contralateral supraclavicular lymph node(s)</p>
          <p>                       </p>
          <p>                       DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use</p>
          <p>                       clinical M to complete stage group).</p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p>                                           </p>
          <p> </p>
          <p>               STAGE GROUPING</p>
          <p>[ ]    [ ]     I       T1      N0       M0</p>
          <p>[ ]    [ ]     IA      T1a     N0       M0</p>
          <p>[ ]    [ ]     IB      T1b     N0       M0</p>
          <p>[ ]    [ ]     II      T2      N0       M0</p>
          <p>[ ]    [ ]     III     T1,T2   N1       M0</p>
          <p>                       T1,T2   N2       M0</p>
          <p>                       T3      N0,N1,N2 M0</p>
          <p>[ ]    [ ]     IV      T4      Any N    M0</p>
          <p>                       Any T   N3       M0</p>
          <p>                       Any T   Any N    M1</p>
          <p>[ ]            Stage Unknown</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING:  None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Histological subtype:  [ ] epithelioid  [ ]mixed or biphasic</p>
          <p>                       [ ] sarcomatoid  [ ]desmoplastic</p>
          <p></p>
          <p>History of asbestosis exposure:  [ ]Yes   [ ]No</p>
          <p></p>
          <p>Presence or absence of chest pain:  [ ]Present  [ ]Absent</p>
          <p></p>
          <p>FDG-PET SUV: _____ </p>
          <p></p>
          <p> Histologic Grade (G) (also known as overall grade)</p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>[ ] Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ] Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ] Not Applicable</p>
          <p>[ ] Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>[ ] RX  Presence of residual tumor cannot be assessed.</p>
          <p>[ ] R0  No residual tumor</p>
          <p>[ ] R1  Microscopic residual tumor</p>
          <p>[ ] R2  Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]  Clinical stage was used in the treatment planning (describe):_______</p>
          <p>[ ]  National guidelines were used in treatment planning:</p>
          <p>     [ ]  NCCN</p>
          <p>     [ ]  Other</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
          <p></p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC PROSTATE STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>PROSTATE</p>
          <p>(Sarcomas and transitional cell carcinomas are excluded.</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]            T1      Clinically inapparent, neither palpable nor </p>
          <p>                       visible by imaging</p>
          <p>[ ]            T1a     Incidental finding in 5% or less of resected </p>
          <p>                       tissue</p>
          <p>[ ]            T1b     Incidental finding in more than 5% of</p>
          <p>                       tissue resected</p>
          <p>[ ]            T1c     Tumor identified by needle biopsy (e.g., </p>
          <p>                       because of elevated PSA)</p>
          <p>[ ]            T2      Tumor confined within prostate*</p>
          <p>       [ ]    pT2      Organ confined </p>
          <p>[ ]            T2a     Tumor involves one half of one lobe or less</p>
          <p>       [ ]    pT2a     Unilateral, one-half of one side or less</p>
          <p>[ ]            T2b     Tumor involves more than one-half of one lobe </p>
          <p>                       but not both lobes</p>
          <p>       [ ]    pT2b     Unilateral, involving more than one-half of </p>
          <p>                       side but not both sides</p>
          <p>[ ]            T2c     Tumor involves both lobes</p>
          <p>       [ ]    pT2c     Bilateral Disease</p>
          <p>[ ]            T3      Tumor extends through the prostate capsule**</p>
          <p>       [ ]    pT3      Extraprostatic extension</p>
          <p>[ ]            T3a     Extracapsular extension (unilateral or </p>
          <p>                       bilateral)</p>
          <p>       [ ]    pT3a     Extraprostatic extension or microscopic </p>
          <p>                       invasion of bladder neck ***</p>
          <p>[ ]            T3b     Tumor invades seminal vesicle(s)</p>
          <p>       [ ]    pT3b     Seminal vesicle invasion</p>
          <p>[ ]            T4      Tumor is fixed or invades adjacent structures </p>
          <p>                       other than seminal vesicles: such as external </p>
          <p>                       sphincter, rectum, bladder, levator muscles, </p>
          <p>                       and/or pelvic wall</p>
          <p>       [ ]    pT4      Invasion of rectum, levator muscles and/or </p>
          <p>                       pelvic wall</p>
          <p></p>
          <p>            Note: There is no pathologic T1 classification.</p>
          <p>           *Note: Tumor found in one or both lobes by needle biopsy, </p>
          <p>                  but not palpable or reliably visible by imaging, is </p>
          <p>                  classified as T1c.</p>
          <p>          **Note: Invasion into the prostatic apex or into (but not </p>
          <p>                  beyond) the prostatic capsule is classified not as T3 </p>
          <p>                  but as T2.</p>
          <p>         ***Note: Positive surgical margin should be indicated by an </p>
          <p>                  R1 descriptor (residual microscopic disease).</p>
          <p></p>
          <p></p>
          <p>CLIN  PATH    REGIONAL LYMPH NODES  (N)</p>
          <p>[ ]            NX      Regional lymph were not assessed</p>
          <p>       [ ]    pNX      Regional nodes not sampled</p>
          <p>[ ]            N0      No regional lymph node metastasis</p>
          <p>       [ ]    pN0      No positive regional lymph nodes</p>
          <p>[ ]    [ ]    pN1      Metastasis in regional node(s)</p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis</p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p>[ ]    [ ]     M1a     Non-regional lymph nodes</p>
          <p>[ ]    [ ]     M1b     Bone(s)</p>
          <p>[ ]    [ ]     M1c     Other sites (with or without bone disease)</p>
          <p> </p>
          <p>      *Note: When more than one site of metastasis is present, the </p>
          <p>             most advanced category is used. pM1c is most advanced</p>
          <p></p>
          <p>CLIN   PATH    STAGE GROUPING           PSA             GLEASON</p>
          <p>[ ]    [ ]     I       T1a-c  N0   M0   PSA&lt;10          GL &lt;or =6</p>
          <p>[ ]    [ ]             T2     N0   M0   PSA&lt;10          GL &lt;or =6</p>
          <p>[ ]    [ ]             T1-2a  N0   M0   PSA X           GL  X</p>
          <p>[ ]    [ ]     IIA     T1a-c  N0   M0   PSA&lt;20          GL  7</p>
          <p>                       T1a-c  N0   M0   PSA &gt;or=10 &lt;20  GL &lt; or =6</p>
          <p>                       T2a    N0   M0   PSA &gt;or=10 &lt;20  GL &lt; or =6</p>
          <p>                       T2a    N0   M0   PSA &lt; 20        Geason 7</p>
          <p>                       T2b    N0   M0   PSA &lt; 20        GL &lt; or =7</p>
          <p>                       T2b    N0   M0   PSA X           GL X</p>
          <p>[ ]    [ ]     IIB     T2c    N0   M0   Any PSA         Any Gleason</p>
          <p>                       T1-2   N0   M0   PSA &gt; or =20    Any Gleason</p>
          <p>                       T1-2   N0   M0   Any PSA         GL &gt; or =8</p>
          <p>[ ]    [ ]     III     T3a-b  N0   M0   Any PSA         Any Gleason</p>
          <p>[ ]    [ ]     IV      T4     N0   M0   Any PSA         Any Gleason</p>
          <p>                       Any T  N1   M0   Any PSA         Any Gleason</p>
          <p>                       Any T  Any NM1   Any PSA         Any Gleason</p>
          <p>[ ]            Unknown Stage</p>
          <p></p>
          <p>*When either PSA or Gleason is not available, grouping should be determined by T </p>
          <p> stage and/or either PSA or Gleason as available.</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: Prostate Specific Antigen: _____</p>
          <p>Gleason score:  _________</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Gleason primary and secondary patterns: ___________________________</p>
          <p>Gleason Tertiary Pattern: _________________________________________</p>
          <p>Clinical Staging procedures performed: ____________________________</p>
          <p>Number of biopsy cores examined: __________________________________</p>
          <p>Number of biopsy cores positive for cancer: _______________________</p>
          <p></p>
          <p>Histologic Grade (G)</p>
          <p>Grading system</p>
          <p>[ ] Gleason X Gleason score cannot be processed</p>
          <p>[ ] Gleason &lt; OR = 6 Well differentiated (slight anaplasia)</p>
          <p>[ ] Gleason 7 Moderately differentiated (moderate anaplasia)</p>
          <p>[ ] Gleason 8-10 Poorly differentiated/undifferentiated (marked anaplasia)</p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p></p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC RENAL PELVIS AND URETER STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>RENAL PELVIS AND URETER</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p>Laterality:</p>
          <p> [ ] Left</p>
          <p> [ ] Right</p>
          <p> [ ] Bilateral</p>
          <p></p>
          <p> </p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Ta      Papillary noninvasive carcinoma</p>
          <p>[ ]    [ ]     Tis     Carcinoma in situ</p>
          <p>[ ]    [ ]     T1      Tumor invades subepithelial connective tissue</p>
          <p>[ ]    [ ]     T2      Tumor invades muscularis </p>
          <p>[ ]    [ ]     T3      (For Renal Pelvis only) Tumor invades beyond</p>
          <p>                       muscularis into peripelvic fat or renal </p>
          <p>                       parenchyma </p>
          <p>[ ]    [ ]     T3      (For Ureter only) Tumor invades beyond </p>
          <p>                       muscularis into periureteric fat</p>
          <p>[ ]    [ ]     T4      Tumor invades adjacent organs or through the </p>
          <p>                       kidney into perinephric fat</p>
          <p> </p>
          <p>               REGIONAL LYMPH NODES (N)*</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Mets in single LN, 2 cm or less in greatest</p>
          <p>                       dimension</p>
          <p>[ ]    [ ]     N2      Mets in single LN more than 2 cm but less </p>
          <p>                       than 5 cm or multiple lymph nodes, none more </p>
          <p>                       than 5 cm</p>
          <p>[ ]    [ ]     N3      Metastasis in lymph node more 5 cm in </p>
          <p>                       greatest dimension</p>
          <p> </p>
          <p>             *Note: Laterality does not affect the N classification</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>[ ]    [ ]     0a      Ta      N0      M0</p>
          <p>[ ]    [ ]     0is     Tis     N0      M0</p>
          <p>[ ]    [ ]     I       T1      N0      M0</p>
          <p>[ ]    [ ]     II      T2      N0      M0</p>
          <p>[ ]    [ ]     III     T3      N0      M0</p>
          <p>[ ]    [ ]     IV      T4      N0      M0</p>
          <p>[ ]    [ ]             Any T   N1      M0</p>
          <p>[ ]    [ ]             Any T   N2      M0</p>
          <p>[ ]    [ ]             Any T   N3      M0</p>
          <p>[ ]    [ ]             Any T   Any N   M1</p>
          <p>[ ]    [ ]     Unknown Stage</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>Renal parenchymal invasion: _______________________________________</p>
          <p>World Health Organization/International Society of Urologic Pathology (WHO/ISUP) </p>
          <p>grade: _______________________________________</p>
          <p></p>
          <p>HISTOLOGIC GRADE: WHO/ISUP</p>
          <p>[ ] LOW GRADE</p>
          <p>[ ] HIGH GRADE</p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC RETINOBLASTOMA STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>RETINOBLASTOMA</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p>Laterality:</p>
          <p> [ ] Left</p>
          <p> [ ] Right</p>
          <p> [ ] Bilateral</p>
          <p></p>
          <p>CLINICAL            PRIMARY TUMOR (T)</p>
          <p>[ ]         TX      Primary tumor cannot be assessed</p>
          <p>[ ]         T0      No evidence of primary tumor</p>
          <p>[ ]         T1      Tumor no more than 2/3 the volume of the eye with no</p>
          <p>                    vitreous or subretinal seeding.</p>
          <p>[ ]         T1a     No tumor in either eye is greater than 3mm in largest</p>
          <p>                    dimension or located closer than 1.5mm to the optic nerve</p>
          <p>                    or fovea.</p>
          <p>[ ]         T1b     At least one tumor is greater than 3mm in largest</p>
          <p>                    dimension or located closer than 1.5mm to the optic nerve</p>
          <p>                    or fovea. No retinal detachment or subretinal fluid</p>
          <p>                    beyond 5mm from the base of the tumor.</p>
          <p>[ ]         T1c     At least one tumor is greater than 3mm in largest</p>
          <p>                    dimension or located closer than 1.5mm to the optic nerve</p>
          <p>                    or fovea, with retinal detachment of subretinal fluid</p>
          <p>                    beyond 5mm from the base of the tumor.</p>
          <p>[ ]         T2      Tumor no more than 2/3 the volume of the eye with</p>
          <p>                    vitreous or subretinal seeding. Can have retinal</p>
          <p>                    detachment.</p>
          <p>[ ]         T2a     Focal vitreous and/or subretinal seeding of fine</p>
          <p>                    aggregates of tumor cells is present, but no large clumps</p>
          <p>                    or "snowballs" of tumor cells. </p>
          <p>[ ]         T2b     Massive vitreous and/or subretinal seeding is present,</p>
          <p>                    defined as diffuse clumps or "snowballs" of tumor cells</p>
          <p>[ ]         T3      Severe intraocular disease</p>
          <p>[ ]         T3a     Tumor fills more than 2/3 of the eye</p>
          <p>[ ]         T3b     One or more complications present, which may include</p>
          <p>                    tumor-associated neovascular or angle closure glaucoma,</p>
          <p>                    tumor extension into the anterior segment, hyphema,</p>
          <p>                    vitreous hemorrhage or orbital cellulitis.</p>
          <p>[ ]         T4      Extraocular disease detected by imaging studies</p>
          <p>[ ]         T4a     Invasion of optic nerve</p>
          <p>[ ]         T4b     Invasion into the orbit</p>
          <p>[ ]         T4c     Intracranial extension not past chiasm</p>
          <p>[ ]         T4d     Intracranial extension past chiasm</p>
          <p></p>
          <p>PATHOLOGIC          PRIMARY TUMOR (pT)</p>
          <p>[ ]        pTX      Primary tumor cannot be assessed</p>
          <p>[ ]        pT0      No evidence of primary tumor</p>
          <p>[ ]        pT1      Tumor confined to eye with no optic nerve or choroidal</p>
          <p>                    Invasion.</p>
          <p>[ ]        pT2      Tumor with minimal optic nerve and/or choroidal invasion.</p>
          <p>[ ]        pT2a     Tumor superficially invades optic nerve head but does not</p>
          <p>                    extend past lamina cribrosa or tumor exhibits focal</p>
          <p>                    choroidal invasion.</p>
          <p>[ ]        pT2b     Tumor superficially invades optic nerve head but does not</p>
          <p>                    extend past lamina cribrosa and exhibits focal choroidal</p>
          <p>                    invasion</p>
          <p>[ ]        pT3      Tumor with significant optic nerve and/or choroidal</p>
          <p>                    invasion</p>
          <p>[ ]        pT3a     Tumor invades optic nerve past lamina cribrosa but not to</p>
          <p>                    surgical resection line or tumor exhibits massive</p>
          <p>                    choroidal invasion</p>
          <p>[ ]        pT3b     Tumor invades optic nerve past lamina cribrosa but not to</p>
          <p>                    surgical resection line and exhibits massive choroidal</p>
          <p>                    invasion.</p>
          <p>[ ]        pT4      Tumor invades optic nerve to resection line or exhibits</p>
          <p>                    extraocular extension elsewhere</p>
          <p>[ ]        pT4a     Tumor invades optic nerve to resection line but no</p>
          <p>                    extraocular extension identified</p>
          <p>[ ]        pT4b     Tumor invades optic nerve to resection line and</p>
          <p>                    extraocular extension identified</p>
          <p></p>
          <p>Clin   Path    REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX   Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0   No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1   Regional lymph node involvement (preauricular,</p>
          <p>                    cervical, submandibular)</p>
          <p>[ ]    [ ]     N2   Distant lymph node involvement</p>
          <p></p>
          <p></p>
          <p>CLINICAL            DISTANT METASTASIS (M)</p>
          <p>[ ]         M0      No distant metastasis (no pathologic M0; use </p>
          <p>                    clinical M to complete stage group) </p>
          <p>[ ]         M1      Systemic metastasis</p>
          <p>[ ]         M1a     Single lesions to sites other than CNS</p>
          <p>[ ]         M1b     Multiple lesions to sites other than CNS</p>
          <p>[ ]         M1c     Prechiasmatic CNS lesion(s)</p>
          <p>[ ]         M1d     Postchiasmatic CNS lesions(s)</p>
          <p>[ ]         M1e     Leptomeningeal and/or CSF involvement</p>
          <p></p>
          <p>PATHOLOGIC          DISTANT METASTASIS (pM)</p>
          <p>[ ]        pM1      Metastasis to sites other than CNS</p>
          <p>[ ]        pM1a     Single lesion</p>
          <p>[ ]        pM1b     Multiple lesions</p>
          <p>[ ]        pM1c     CNS metastasis</p>
          <p>[ ]        pM1d     Discrete mass(es) without leptomeningeal and/or CSF</p>
          <p>                    involvement</p>
          <p>[ ]        pM1e     Leptomeningeal and/or CSF involvement</p>
          <p></p>
          <p>STAGE GROUPING:</p>
          <p>No stage grouping is presently recommended</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>[ ] Extension evaluated at enucleation</p>
          <p>[ ] RB gene mutation </p>
          <p>[ ] Positive family history of retinoblastoma</p>
          <p>[ ] Primary globe-sparing treatment failure</p>
          <p>[ ] Greater linear extent of choroid involved by choroidal tumor invasion</p>
          <p></p>
          <p>GRADING SYSTEM</p>
          <p>[ ] 2 grade system                        </p>
          <p>[ ] 3 grade system                        </p>
          <p>[ ] 4 grade system                        </p>
          <p>[ ] No 2,3,or 4 grade system is available </p>
          <p></p>
          <p>HISTOLOGIC GRADE</p>
          <p>[ ] Grade I or 1: Well differentiated</p>
          <p>[ ] Grade II or 2: Moderately differentiated</p>
          <p>[ ] Grade III or 3: Poorly differentiated</p>
          <p>[ ] Grade IV or 4: Undifferentiated</p>
          <p>[ ] Grade X: Grade cannot be assessed</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning:</p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
          <p></p>
          <p></p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC SALIVARY GLANDS (MAJOR) STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>MAJOR SALIVARY GLANDS</p>
          <p>(PAROTID, SUBMANDIBULAR AND SUBLINGUAL)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p>Laterality:</p>
          <p> [ ] Left</p>
          <p> [ ] Right</p>
          <p> [ ] Bilateral</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     T1      Tumor 2 cm or less in greatest dimension without</p>
          <p>                       extraparenchymal extension*</p>
          <p>[ ]    [ ]     T2      Tumor more than 2 cm but not more than 4 cm in</p>
          <p>                       greatest dimension without extraparenchymal extension*</p>
          <p>[ ]    [ ]     T3      Tumor more than 4cm and/or tumor having</p>
          <p>                       extraparenchymal extension*</p>
          <p>[ ]    [ ]     T4a     Moderately advanced disease</p>
          <p>                        Tumor invades skin, mandible, ear canal, and/or</p>
          <p>                        facial nerve.</p>
          <p>[ ]    [ ]     T4b     Very advanced disease</p>
          <p>                        Tumor invades skull base and/or pterygoid plates</p>
          <p>                        and/or encases carotid artery</p>
          <p></p>
          <p>*Note: Extraparenchymal extension is clinical or macroscopic evidence of</p>
          <p>invasion of soft tissues. Microscopic evidence alone does not constitute</p>
          <p>extraparenchymal extension for classification purposes.</p>
          <p> </p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Metastasis in a single ipsilateral lymph node, 3cm or</p>
          <p>                       less in greatest dimension.</p>
          <p>[ ]    [ ]     N2      Metastasis in a single ipsilateral lymph node, more</p>
          <p>                       than 3cm but not more than 6 cm in greatest dimension,</p>
          <p>                       or in multiple ipsilateral lymph nodes, none more than</p>
          <p>                       6 cm in greatest dimension, or in bilateral or</p>
          <p>                       contralateral lymph nodes, none more than 6 cm in</p>
          <p>                       greatest dimension</p>
          <p>[ ]    [ ]     N2a     Metastasis in a single ipsilateral lymph nodes, more</p>
          <p>                       than 3 cm but not more than 6 cm in greatest dimension</p>
          <p>[ ]    [ ]     N2b     Metastasis in multiple ipsilateral lymph nodes, none</p>
          <p>                       more than 6 cm in greatest dimension</p>
          <p>[ ]    [ ]     N2c     Metastasis in bilateral or contralateral lymph nodes,</p>
          <p>                       none more than 6 cm in greatest dimension</p>
          <p>[ ]    [ ]     N3      Metastasis in a lymph node, more than 6 cm in greatest</p>
          <p>                       dimension</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>[ ]    [ ]     I       T1      N0      M0</p>
          <p>[ ]    [ ]     II      T2      N0      M0</p>
          <p>[ ]    [ ]     III     T3      N0      M0</p>
          <p>[ ]    [ ]             T1      N1      M0</p>
          <p>                       T2      N1      M0</p>
          <p>                       T3      N1      M0</p>
          <p>[ ]    [ ]     IVA     T4a     N0      M0</p>
          <p>                       T4a     N1      M0</p>
          <p>                       T1      N2      M0</p>
          <p>                       T2      N2      M0</p>
          <p>                       T3      N2      M0</p>
          <p>                       T4a     N2      M0</p>
          <p>[ ]    [ ]     IVB     T4b     Any N   M0</p>
          <p>                       Any T   N3      M0</p>
          <p>[ ]    [ ]     IVC     Any T   Any N   M1</p>
          <p>[ ]    [ ]     UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>Size of Lymph Nodes _________________</p>
          <p>Extracapsular Extension from Lymph Nodes for Head &amp; Neck __________</p>
          <p>Head &amp; Neck Lymph Nodes Levels I-III ___________</p>
          <p>Head &amp; Neck Lymph Nodes Levels IV-V  ___________</p>
          <p>Head &amp; Neck Lymph Nodes Levels VI-VII___________</p>
          <p>Other Lymph Nodes Group ___________________________________________</p>
          <p>Clinical Location of cervical nodes _______________________________</p>
          <p>Extracapsular spread (ECS) Clinical _______________________________</p>
          <p>Extracapsular spread (ECS) Pathologic _____________________________</p>
          <p></p>
          <p>GRADING SYSTEM</p>
          <p></p>
          <p>[ ] 2 grade system                        [ ]   Grade I or 1</p>
          <p>[ ] 3 grade system                        [ ]   Grade II or 2</p>
          <p>[ ] 4 grade system                        [ ]   Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available [ ]   Grade IV or 4</p>
          <p>                                          [ ]   Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>HISTOLOGIC GRADE</p>
          <p>Histologic grading is applicable only to some types of salivary cancer: </p>
          <p>Mucoepidermoid carcinoma, adenocarcinoma not otherwise specified, or when</p>
          <p>either of these is the carcinomatous element of carcinoma in pleomorphic</p>
          <p>adenoma.</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
          <p></p>
          <p></p>
          <p></p>
          <p></p>
          <p></p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC SMALL INTESTINE STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>SMALL INTESTINE</p>
          <p>(Lymphomas, carcinoid tumors, and visceral sarcomas are not included)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis     Carcinoma in situ</p>
          <p>[ ]    [ ]     T1a     Tumor invades lamina propria</p>
          <p>[ ]    [ ]     T1b     Tumor invades submucosa</p>
          <p>[ ]    [ ]     T2      Tumor invades muscularis propria</p>
          <p>[ ]    [ ]     T3      Tumor invades through the muscularis propria into the</p>
          <p>                       subserosa or into the nonperitonealized perimuscular</p>
          <p>                       tissue (mesentery or retroperitoneum) with extention </p>
          <p>                       2 cm or less*</p>
          <p>[ ]    [ ]     T4      Tumor perforates the visceral peritoneum or directly</p>
          <p>                       invades other organs or structures (includes other</p>
          <p>                       loops of small intestine, mesentery, or </p>
          <p>                       retroperitoneum more than 2 cm, and abdominal wall by </p>
          <p>                       way of serosa; for duodenum only, invasion of pancreas</p>
          <p>                       or bile duct</p>
          <p>  *The nonperitonealized perimuscular tissue is, for jejunum and ileum, part</p>
          <p>  of the mesentery and, for duodenum in areas where serosa is lacking, part </p>
          <p>  of the interface with the pancreas.</p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Metastasis in 1 to 3 regional lymph nodes </p>
          <p>[ ]    [ ]     N2      Metastasis in 4 or more regional lymph nodes</p>
          <p></p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0;</p>
          <p>                       use clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>[ ]    [ ]     0       Tis     N0      M0</p>
          <p>[ ]    [ ]     I       T1      N0      M0</p>
          <p>                       T2      N0      M0</p>
          <p>[ ]    [ ]     IIA     T3      N0      M0</p>
          <p>[ ]    [ ]     IIB     T4      N0      M0</p>
          <p>[ ]    [ ]     IIIA    Any T   N1      M0</p>
          <p>[ ]    [ ]     IIIB    Any T   N2      M0</p>
          <p>[ ]    [ ]     IV      Any T   Any N   M1</p>
          <p>[ ] UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>Pre-surgical carcinoembryonic antigen (CEA): ________</p>
          <p></p>
          <p>Microsatellite instatbility (MSI): _________</p>
          <p></p>
          <p>Presence of Crohn's Disease: _________</p>
          <p></p>
          <p></p>
          <p>GRADING SYSTEM 					GRADE</p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe): ________</p>
          <p></p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>   [ ]NCCN </p>
          <p>   [ ]Other (describe):</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC SOFT TISSUE SARCOMA STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>SOFT TISSUE SARCOMA</p>
          <p></p>
          <p>(Kaposi's sarcoma, fibromatosis [desmoid tumor], and sarcoma </p>
          <p>arising from the dura mater, brain, parenchymatous organs or hollow viscera </p>
          <p>are not included.)</p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p>Laterality:</p>
          <p>          [ ] Left</p>
          <p>          [ ] Right</p>
          <p>          [ ] Bilateral</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     T1      Tumor 5 cm or less in greatest dimension</p>
          <p>[ ]    [ ]     T1a       Superficial tumor</p>
          <p>[ ]    [ ]     T1b       Deep tumor</p>
          <p>[ ]    [ ]     T2      Tumor more than 5 cm in greatest dimension</p>
          <p>[ ]    [ ]     T2a       Superficial tumor</p>
          <p>[ ]    [ ]     T2b       Deep tumor</p>
          <p> </p>
          <p>Note:  Superficial tumor is located exclusively above the superficial</p>
          <p>fascia without invasion of the fascia; deep tumor is located either</p>
          <p>exclusively beneath the superficial fascia, or superficial to the fascia</p>
          <p>with invasion of or through the fascia, or superficial and beneath the</p>
          <p>fascia.   </p>
          <p>               REGIONAL LYMPH NODE (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1*     Regional lymph node metastasis</p>
          <p></p>
          <p>*Note:  Presence of positive nodes (N1) or M0 tumors is considered</p>
          <p> Stage III.</p>
          <p> </p>
          <p>               DISTANT METASTASIS </p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use</p>
          <p>                       Clinical M to complete stage group)</p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p> </p>
          <p>STAGE GROUPING</p>
          <p>			  (T)     (N)   (M)   Grade</p>
          <p></p>
          <p>[ ]    [ ]     IA      T1a     N0    M0    G1,GX     </p>
          <p>                       T1b     N0    M0    G1,GX     </p>
          <p>[ ]    [ ]     IB      T2a     N0    M0    G1,GX    </p>
          <p>                       T2b     N0    M0    G1,GX     </p>
          <p>[ ]    [ ]     IIA     T1a     N0    M0    G2,G3  </p>
          <p>                       T1b     N0    M0    G2,G3   </p>
          <p>[ ]    [ ]     IIB     T2a     N0    M0    G2           </p>
          <p>                       T2b     N0    M0    G2           </p>
          <p>[ ]    [ ]     III     T2a,T2b N0    M0    G3           </p>
          <p>                       Any T   N1    M0    Any G        </p>
          <p>[ ]    [ ]     IV      Any T   Any N M1    Any G      </p>
          <p>[ ]    [ ]             Stage Unknown</p>
          <p>                       </p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING:  None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>    Neurovascular invasion as determined by pathology:_________</p>
          <p>    Bone invasion as determined by imaging:____________________</p>
          <p>    If pM1, source of pathologic metastatic specimen:__________ </p>
          <p></p>
          <p> Histologic Grade (G) (also known as overall grade)</p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>[ ] Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ] Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ] Not Applicable</p>
          <p>[ ] Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>[ ] RX  Presence of residual tumor cannot be assessed.</p>
          <p>[ ] R0  No residual tumor</p>
          <p>[ ] R1  Microscopic residual tumor</p>
          <p>[ ] R2  Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]  Clinical stage was used in the treatment planning (describe):_______</p>
          <p>[ ]  National guidelines were used in treatment planning:</p>
          <p>     [ ]  NCCN</p>
          <p>     [ ]  Other</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
          <p></p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC STOMACH STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>STOMACH</p>
          <p>(Lymphomas, sarcomas and carcinoid tumors [low-grade neuroendocrine </p>
          <p> tumors] are not included)</p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ] y - Clinical staging completed after		[ ] y - pathologic staging</p>
          <p>after neoadjuvant therapy but before		after neoadjuvant therapy AND</p>
          <p>subsequent surgery					subsequent surgery</p>
          <p></p>
          <p>Tumor Size: _____________</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Tis     Carcinoma in situ: intraepithelial tumor without</p>
          <p>                       invasion of lamina propria</p>
          <p>[ ]    [ ]     T1      Tumor invades lamina propria, muscularis </p>
          <p>                       mucosae, or submucosa</p>
          <p>[ ]    [ ]     T1a     Tumor invades lamina propria or muscularis </p>
          <p>                       mucosae</p>
          <p>[ ]    [ ]     T1b     Tumor invades submucosa</p>
          <p>[ ]    [ ]     T2      Tumor invades muscularis propria</p>
          <p>[ ]    [ ]     T3      Tumor penetrates subserosal connective tissue </p>
          <p>                       without invasion of visceral peritoneum or </p>
          <p>                       adjacent structures*,**,*** </p>
          <p>[ ]    [ ]     T4      Tumor invades serosa (visceral peritoneum) or </p>
          <p>                       adjacent structures**,***</p>
          <p>[ ]    [ ]     T4a     Tumor invades serosa (visceral peritoneum)</p>
          <p>[ ]    [ ]     T4b     Tumor invades adjacent structures</p>
          <p></p>
          <p>*A tumor may penetrate the muscularis propria with extension into the </p>
          <p>gastrocolic or gastrohepatic ligaments, or into the greater or lesser </p>
          <p>omentum, without perforation of the visceral peritoneum covering these </p>
          <p>structures. In this case, the tumor is classified T3. If there is </p>
          <p>perforation of the visceral peritoneum covering the gastric ligaments </p>
          <p>or the omentum, the tumor should be classified T4.</p>
          <p></p>
          <p>**The adjacent structures of the stomach include the spleen, transverse </p>
          <p>colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, </p>
          <p>kidney, small intestine, and retroperitoneum.</p>
          <p></p>
          <p>***Intramural extension to the duodenum or esophagus is classified by </p>
          <p>the depth of the greatest invasion in any of these sites, including the </p>
          <p>stomach.  </p>
          <p></p>
          <p>               LYMPH NODE (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes(s) cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Metastasis in 1 to 2 regional lymph nodes</p>
          <p>[ ]    [ ]     N2      Metastasis in 3 to 6 region lymph nodes</p>
          <p>[ ]    [ ]     N3      Metastasis in 7 or more region lymph nodes</p>
          <p>[ ]    [ ]     N3a     Metastasis in 7 to 15 lymph nodes</p>
          <p>[ ]    [ ]     N3b     Metastasis in 16 or more region lymph nodes</p>
          <p></p>
          <p>* A designation of pN0 should be used if all examined lymph nodes are </p>
          <p>negative, regardless of the total number removed and examined.</p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group)</p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>[ ]    [ ]     0       Tis     N0      M0</p>
          <p>[ ]    [ ]     IA      T1      N0      M0</p>
          <p>[ ]    [ ]     IB      T2      N0      M0</p>
          <p>                       T1      N1      M0</p>
          <p>[ ]    [ ]     IIA     T3      N0      M0</p>
          <p>                       T2      N1      M0</p>
          <p>                       T1      N2      M0</p>
          <p>[ ]    [ ]     IIB     T4a     N0      M0</p>
          <p>                       T3      N1      M0</p>
          <p>                       T2      N2      M0</p>
          <p>                       T1      N3      M0</p>
          <p>[ ]    [ ]     IIIA    T4a     N1      M0</p>
          <p>                       T3      N2      M0</p>
          <p>                       T2      N3      M0</p>
          <p>[ ]    [ ]     IIIB    T4b     N0      M0</p>
          <p>                       T4b     N1      M0</p>
          <p>                       T4a     N2      M0</p>
          <p>                       T3      N3      M0</p>
          <p>[ ]    [ ]     IIIC    T4b     N2      M0</p>
          <p>                       T4b     N3      M0</p>
          <p>                       T4a     N3      M0</p>
          <p>[ ]    [ ]     IV      AnyT    AnyN    M1</p>
          <p>[ ]    [ ]     UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING: None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>  Tumor location: __________</p>
          <p>  Serum carcinoembryonic antigen: __________</p>
          <p>  Serum CA19.9: __________</p>
          <p></p>
          <p></p>
          <p>GRADING SYSTEM 					GRADE</p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>   [ ]NCCN </p>
          <p>   [ ]Other (describe):</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC TESTIS STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>TESTIS</p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p></p>
          <p>Laterality:</p>
          <p>          [ ] Left</p>
          <p>          [ ] Right</p>
          <p>          [ ] Bilateral</p>
          <p></p>
          <p></p>
          <p>The extent of primary tumor is usually classified after radical orchiectomy and, </p>
          <p>for this reason, a pathologic stage is assigned.</p>
          <p></p>
          <p>CLIN   PATH</p>
          <p>               PRIMARY TUMOR (T)</p>
          <p>               </p>
          <p>[ ]     pTX     Primary tumor cannot be assessed (If no </p>
          <p>[ ]     pT0     No evidence of primary tumor (e.g. histologic scar</p>
          <p>                in testis)</p>
          <p>[ ]     pTis    Intratubular germ cell neoplasia (carcinoma in Situ)</p>
          <p>[ ]     pT1     Tumor limited to testis and epididymis w/o</p>
          <p>                vascular/lymphatic invasion; tumor may invade into</p>
          <p>                the tunica albuginea but not the tunica vaginalis</p>
          <p>[ ]     pT2     Tumor limited to testis and epididymis with</p>
          <p>                vascular/lymphatic invasion, or tumor extending</p>
          <p>                through the tunica albuginea with involvement of</p>
          <p>                the tunica vaginalis</p>
          <p>[ ]     pT3     Tumor invades spermatic cord with or without</p>
          <p>                vascular/lymphatic invasion.</p>
          <p>[ ]     pT4     Tumor invades the scrotum with or without</p>
          <p>                vascular/lymphatic invasion.</p>
          <p></p>
          <p>                * Except for pTis and pT4, extent of primary tumor is classified</p>
          <p>                  by radical orchiectomy. TX may be used for other categories in </p>
          <p>                  the absensce of radical orchiectomy.</p>
          <p> </p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>               CLINICAL</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Mets with a lymph node mass 2cm or less or</p>
          <p>                       multiple lymph nodes none more than 2cm</p>
          <p>[ ]    [ ]     pN1     Mets with a lymph node mass 2cm or less and</p>
          <p>                       less than or equal to 5 nodes positive, none </p>
          <p>                       more that 2cm in greatest dimension</p>
          <p>[ ]    [ ]     N2      Metastasis with a lymph nodes mass &gt;2cm but </p>
          <p>                       not more than 5cm or multiple lymph nodes,</p>
          <p>                       any one mass greater than 2cm but not more </p>
          <p>                       than 5cm in greatest dimension</p>
          <p>       [ ]     pN2     Metastasis with a lymph nodes mass &gt;2cm but </p>
          <p>                       not more than 5cm or more than 5 nodes </p>
          <p>                       positive, none more than 5cm; or evidence of </p>
          <p>                       extranodal extension of tumor</p>
          <p>[ ]    [ ]     N3      Metastasis with a lymph node mass over 5cm</p>
          <p>       [ ]     pN3     Metastasis with a lymph node mass over 5cm</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p>[ ]    [ ]     M1a     Nonregional nodal or pulmonary mets</p>
          <p>[ ]    [ ]     M1b     Distant mets other than to non-regional lymph</p>
          <p>                       nodes and lungs</p>
          <p>  </p>
          <p>       STAGE GROUPING</p>
          <p>[ ]    [ ]     0       pTis         N0      M0      S0</p>
          <p>[ ]    [ ]     I       pT1-4        N0      M0      SX</p>
          <p>[ ]    [ ]     IA      pT1          N0      M0      S0</p>
          <p>[ ]    [ ]     IB      pT2          N0      M0      S0</p>
          <p>[ ]    [ ]             pT3          N0      M0      S0</p>
          <p>[ ]    [ ]             pT4          N0      M0      S0</p>
          <p>[ ]    [ ]     IS      Any pT/Tx    N0      M0      S1-3</p>
          <p>[ ]    [ ]     II      Any pT/Tx    N1-3    M0      SX</p>
          <p>[ ]    [ ]     IIA     Any pT/Tx    N1      M0      S0</p>
          <p>[ ]    [ ]             Any pT/Tx    N1      M0      S1</p>
          <p>[ ]    [ ]     IIB     Any pT/Tx    N2      M0      S0</p>
          <p>[ ]    [ ]             Any pT/Tx    N2      M0      S1</p>
          <p>[ ]    [ ]     IIC     Any pT/Tx    N3      M0      S0</p>
          <p>[ ]    [ ]             Any pT/Tx    N3      M0      S1</p>
          <p>[ ]    [ ]     III     Any pT/Tx    Any N   M1      SX</p>
          <p>[ ]    [ ]     IIIA    Any pT/Tx    Any N   M1a     S0</p>
          <p>[ ]    [ ]             Any pT/Tx    Any N   M1a     S1</p>
          <p>[ ]    [ ]     IIIB    Any pT/Tx    N1-3    M0      S2</p>
          <p>[ ]    [ ]             Any pT/Tx    Any N   M1a     S2</p>
          <p>[ ]    [ ]     IIIC    Any pT/Tx    N1-3    M0      S3</p>
          <p>[ ]    [ ]             Any pT/Tx    Any N   M1a     S3</p>
          <p>[ ]    [ ]             Any pT/Tx    Any N   M1b     Any S</p>
          <p>[ ]    [ ]     UNKNOWN STAGE</p>
          <p></p>
          <p>REQUIRED FOR STAGING:  Serum Tumor Markers (S)</p>
          <p>SX     Marker studies unavailable or not performed</p>
          <p>S0     Marker study levels within normal limits</p>
          <p>S1     LDH &lt;1.5 x N* AND hCG(mlu/ml) &lt;5000 AND AFP &lt;1000</p>
          <p>S2     LDH 1.5-10x N OR hCG(mlu/ml)5000-50,000 OR AFP 1000-10,000</p>
          <p>S3     LDH&gt; 10 x N OR hCG (mlu/ml) &gt;50,000 OR AFP &gt; 10,000</p>
          <p> </p>
          <p>*N indicates the upper limit of normal for the LDH assay</p>
          <p></p>
          <p>Serum tumor marker levels should be measured prior to orchiectomy, but levels after orchiectomy are</p>
          <p>used for assignment of S category, taking into account the half life of AFP and hCG. Stage grouping of</p>
          <p>classification of Stage IS requires persistent elevation of serum tumor markers following orchiectomy.</p>
          <p></p>
          <p>The Serum Tumor Markers (S) category is comprised of the following:</p>
          <p>  Alpha Fetoprotein (AFP)  half life 57 days</p>
          <p>  Human Chorionic Gonadotropin (hCG)  half life 13 days</p>
          <p>  Lactate Dehydrogenase (LDH)</p>
          <p></p>
          <p>CLINICALLY SIGNIFICANT</p>
          <p>  Size of Largest Metastases in Lymph Nodes __________</p>
          <p>  Radical Orchiectomy performed [ ]</p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
          <p></p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC THYROID STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>THYROID GLAND</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p></p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     T1      Tumor 2 cm or less in greatest dimension limited to</p>
          <p>                       the thyroid</p>
          <p>[ ]    [ ]     T1a     Tumor 1 cm or less, limited to the thyroid</p>
          <p>[ ]    [ ]     T1b     Tumor more than 1 cm but not more than 2 cm in</p>
          <p>                       greatest dimension, limited to the thyroid.</p>
          <p>[ ]    [ ]     T2      Tumor more than 2 cm but not more than 4 cm in</p>
          <p>                       greatest dimension, limited to the thyroid.</p>
          <p>[ ]    [ ]     T3      Tumor more than 4 cm in greatest dimension limited to</p>
          <p>                       the thyroid, or any tumor with minimal extrathyroid</p>
          <p>                       extension (e.g., extension to sternothyroid muscle or</p>
          <p>                       perithyroid soft tissues)</p>
          <p>[ ]    [ ]     T4a     Moderately advanced disease.</p>
          <p>                        Tumor of any size extending beyond the thyroid</p>
          <p>                        capsule to invade subcutaneous soft tissues, larynx,</p>
          <p>                        trachea, esophagus or recurrent laryngeal nerve</p>
          <p>[ ]    [ [     T4b     Very advanced disease.</p>
          <p>                        Tumor invades prevertebral fascia or encases carotid</p>
          <p>                        artery or mediastinal vessels.</p>
          <p></p>
          <p>   All anaplastic carcinomas are considered T4 tumors</p>
          <p>[ ]    [ ]     T4a     Intrathyroidal anaplastic carcinoma</p>
          <p>[ ]    [ ]     T4b     Anaplastic carcinoma with gross extrathyroid extension</p>
          <p></p>
          <p></p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1a     Metastasis to Level VI (pretracheal, paratracheal and</p>
          <p>                       prelaryngeal/Delphian lymph nodes)</p>
          <p>[ ]    [ ]     N1b     Metastasis to unilateral, bilateral or contralateral</p>
          <p>                       cervical (Levels I, II, III, IV or V) or</p>
          <p>                       retropharyngeal or superior mediastinal lymph nodes</p>
          <p>                       (Level VII)</p>
          <p></p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>Papillary or Follicular (differentiated)</p>
          <p>UNDER 45 YEARS</p>
          <p></p>
          <p>[ ]    [ ]     I       Any T   Any N   M0</p>
          <p>[ ]    [ ]     II      Any T   Any N   M1</p>
          <p></p>
          <p>Papillary or Follicular (differentiated)</p>
          <p>45 YEARS AND OLDER</p>
          <p></p>
          <p>[ ]    [ ]     I       T1      N0      M0</p>
          <p>[ ]    [ ]     II      T2      N0      M0</p>
          <p>[ ]    [ ]     III     T3      N0      M0</p>
          <p>                       T1      N1a     M0</p>
          <p>                       T2      N1a     M0</p>
          <p>                       T3      N1a     M0</p>
          <p>[ ]    [ ]     IVA     T4a     N0      M0</p>
          <p>                       T4a     N1a     M0</p>
          <p>                       T1      N1b     M0</p>
          <p>                       T2      N1b     M0</p>
          <p>                       T3      N1b     M0</p>
          <p>                       T4a     N1b     M0</p>
          <p>[ ]    [ ]     IVB     T4b     Any N   M0</p>
          <p>[ ]    [ ]     IVC     Any T   Any N   M1</p>
          <p></p>
          <p>Medullary Carcinoma (all age groups)</p>
          <p>[ ]    [ ]     I       T1      N0      M0</p>
          <p>[ ]    [ ]     II      T2      N0      M0</p>
          <p>                       T3      N0      M0</p>
          <p>[ ]    [ ]     III     T1      N1a     M0</p>
          <p>                       T2      N1a     M0</p>
          <p>                       T3      N1a     M0</p>
          <p>[ ]    [ ]     IVA     T4a     N0      M0</p>
          <p>                       T4a     N1a     M0</p>
          <p>                       T1      N1b     M0</p>
          <p>                       T2      N1b     M0</p>
          <p>                       T3      N1b     M0</p>
          <p>                       T4a     N1b     M0</p>
          <p>[ ]    [ ]     IVB     T4b     Any N   M0</p>
          <p>[ ]    [ ]     IVB     Any T   Any N   M1</p>
          <p></p>
          <p></p>
          <p>Anaplastic Carcinoma</p>
          <p>All Anaplastic carcinomas are considered Stage IV</p>
          <p>[ ]    [ ]     IVA     T4a     Any N   M0</p>
          <p>[ ]    [ ]     IVB     T4b     Any N   M0</p>
          <p>[ ]    [ ]     IVC     Any T   Any N   M1</p>
          <p></p>
          <p>[ ]    [ ]     UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>Solitary or Multifocal tumors in the primary site ___________</p>
          <p>Extrathyroid extension ______________________________________</p>
          <p>Histology ___________________________________________________</p>
          <p>GRADING SYSTEM</p>
          <p>[ ] 2 grade system                        </p>
          <p>[ ] 3 grade system                        </p>
          <p>[ ] 4 grade system                        </p>
          <p>[ ] No 2,3,or 4 grade system is available </p>
          <p></p>
          <p>HISTOLOGIC GRADE</p>
          <p>[ ]   Grade I or 1: Well differentiated</p>
          <p>[ ]   Grade II or 2: Moderately differentiated</p>
          <p>[ ]   Grade III or 3: Poorly differentiated</p>
          <p>[ ]   Grade IV or 4: Undifferentiated</p>
          <p>[ ]   Grade X: Grade cannot be assessed</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
          <p></p>
          <p></p>
          <p></p>
          <p></p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC URETHRA STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>URETHRA</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p></p>
          <p>CLIN   PATH    PRIMARY TUMOR (T)(MALE AND FEMALE)</p>
          <p>[ ]    [ ]     TX      Primary tumor cannot be assessed</p>
          <p>[ ]    [ ]     T0      No evidence of primary tumor</p>
          <p>[ ]    [ ]     Ta      Non-invasive papillary, polypoid or verrucous</p>
          <p>                        carcinoma</p>
          <p>[ ]    [ ]     Tis     Carcinoma in situ</p>
          <p>[ ]    [ ]     T1      Tumor invades subepithelial connective tissue</p>
          <p>[ ]    [ ]     T2      Tumor invades any of the following: corpus spongiosum,</p>
          <p>                        prostate, periurethral muscle.</p>
          <p>[ ]    [ ]     T3      Tumor invades any of the following: corpus cavernosum,</p>
          <p>                        beyond prostatic capsule, anterior vagina, bladder</p>
          <p>                        neck</p>
          <p>[ ]    [ ]     T4      Tumor invades other adjacent organs</p>
          <p></p>
          <p>Urothelial (Transitional Cell) Carcinoma of the Prostate</p>
          <p>[ ]    [ ]     Tis pu  Carcinoma in situ, involvement of the prostatic</p>
          <p>                        urethra</p>
          <p>[ ]    [ ]     Tis pd  Carcinoma in situ, involvement of the prostatic ducts</p>
          <p>[ ]    [ ]     T1      Tumor invades urethral subepithelial connective tissue</p>
          <p>[ ]    [ ]     T2      Tumor invades any of the following: prostatic stroma,</p>
          <p>                        corpus spongiosum, periurethral  muscle.</p>
          <p>[ ]    [ ]     T3      Tumor invades any of the following: corpus cavernosum,</p>
          <p>                        beyond prostatic capsule, bladder neck</p>
          <p>                       (extraprostatic extension) </p>
          <p>[ ]    [ ]     T4      Tumor invades other adjacent organs (invasion of the</p>
          <p>                       bladder)</p>
          <p> </p>
          <p>               REGIONAL LYMPH NODES (N)</p>
          <p>[ ]    [ ]     NX      Regional lymph nodes cannot be assessed</p>
          <p>[ ]    [ ]     N0      No regional lymph node metastasis</p>
          <p>[ ]    [ ]     N1      Metastasis in a single lymph node 2 cm or less in</p>
          <p>                       greatest dimension</p>
          <p>[ ]    [ ]     N2      Metastasis in a single node more than 2 cm in greatest</p>
          <p>                       dimension, or in multiple nodes</p>
          <p> </p>
          <p> </p>
          <p>               DISTANT METASTASIS (M)</p>
          <p>[ ]            M0      No distant metastasis (no pathologic M0; use </p>
          <p>                       clinical M to complete stage group) </p>
          <p>[ ]    [ ]     M1      Distant metastasis</p>
          <p></p>
          <p></p>
          <p></p>
          <p>               STAGE GROUPING</p>
          <p>[ ]    [ ]     0a      Ta      N0      M0</p>
          <p>[ ]    [ ]     0is     Tis     N0      M0</p>
          <p>[ ]    [ ]             Tis pu  N0      M0</p>
          <p>[ ]    [ ]             Tis pd  N0      M0</p>
          <p>[ ]    [ ]     I       T1      N0      M0</p>
          <p>[ ]    [ ]     II      T2      N0      M0</p>
          <p>[ ]    [ ]     III     T1      N1      M0</p>
          <p>[ ]    [ ]             T2      N1      M0</p>
          <p>                       T3      N0      M0</p>
          <p>                       T3      N1      M0</p>
          <p>[ ]    [ ]     IV      T4      N0      M0</p>
          <p>[ ]    [ ]             T4      N1      M0</p>
          <p>[ ]    [ ]             Any T   N2      M0</p>
          <p>[ ]    [ ]             Any T   Any N   M1</p>
          <p>[ ] UNKNOWN STAGE</p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING : None</p>
          <p>CLINICALLY SIGNIFICANT :</p>
          <p>World Health Organization/International Society of Urologic pathology (WHO/ISUP) grade (see Histologic Grade below)</p>
          <p></p>
          <p>GRADING SYSTEM</p>
          <p>[ ] 2 grade system                        </p>
          <p>[ ] 3 grade system                        </p>
          <p>[ ] 4 grade system                        </p>
          <p>[ ] No 2,3,or 4 grade system is available </p>
          <p></p>
          <p>HISTOLOGIC GRADE</p>
          <p>World health Organization/International Society of Urologic Pathology (WHO/ISUP) recommended grading system:</p>
          <p>[ ]   LG: Low grade</p>
          <p>[ ]   HG: High grade</p>
          <p></p>
          <p>If a grading system is not specified, generally the following system is used: </p>
          <p>[ ]   Grade I or 1: Well differentiated</p>
          <p>[ ]   Grade II or 2: Moderately differentiated</p>
          <p>[ ]   Grade III or 3: Poorly differentiated</p>
          <p>[ ]   Grade IV or 4: Undifferentiated</p>
          <p>[ ]   Grade X: Grade cannot be assessed</p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been </p>
          <p>combined into Lymph-Vascular Invasion (LVI) for collection by cancer </p>
          <p>registrars. The College of American Pathologists' (CAP) Checklist </p>
          <p>should be used as the primary source. Other sources may be used in </p>
          <p>the absence of a Checklist. Priority is given to positive results.</p>
          <p></p>
          <p>[ ]Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ]Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ]Not Applicable</p>
          <p>[ ]Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment. In some </p>
          <p>cases treated with surgery and/or with neoadjuvant therapy there </p>
          <p>will be residual tumor at the primary site after treatment because </p>
          <p>of incomplete resection or local and regional disease that extends </p>
          <p>beyond the limit of ability of resection.</p>
          <p></p>
          <p>[ ]RX Presence of residual tumor cannot be assessed</p>
          <p>[ ]R0 No residual tumor</p>
          <p>[ ]R1 Microscopic residual tumor</p>
          <p>[ ]R2 Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]Clinical stage was used in treatment planning (describe):</p>
          <p>[ ]National guidelines were used in treatment planning </p>
          <p>[ ]NCCN </p>
          <p>[ ]Other (describe):</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC UTERUS STAGING (CORPUS UTERI) 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>CORPUS UTERI CARCINOMA STAGING FORM</p>
          <p>(Carcinosarcomas should be staged as carcinomas)</p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p></p>
          <p></p>
          <p>CLIN    PATH    TNM    FIGO    Primary Tumor (T)</p>
          <p>[ ]     [ ]     TX              Primary tumor cannot be assessed</p>
          <p>[ ]     [ ]     TO              No evidence of primary tumor</p>
          <p>[ ]     [ ]     Tis     *       Carcinoma in situ (preinvasive carcinoma)</p>
          <p>[ ]     [ ]     Tl      I       Tumor confined to corpus uteri</p>
          <p>[ ]     [ ]     Tla     IA      Tumor limited to endometrium or invades</p>
          <p>                                less than one-half of the myometrium</p>
          <p>[ ]     [ ]     Tlb     IB      Tumor invades one-half or more of the</p>
          <p>                                myometrium</p>
          <p>[ ]     [ ]     T2      II      Tumor invades stromal connective tissue of</p>
          <p>                                the cervix  but does not extend beyond </p>
          <p>                                the uterus **</p>
          <p>[ ]     [ ]     T3a     IIIA    Tumor involves serosa and/or adnexa(direct</p>
          <p>                                extension or metastasis)</p>
          <p>[ ]     [ ]     T3b     IIIB    Vaginal involvement (direct extension or </p>
          <p>                                metastasis) or parametrial involvement</p>
          <p>[ ]     [ ]     T4      IVA     Tumor invades bladder mucosa and/ or bowel</p>
          <p>                                mucosa (bullous edema is not sufficient to</p>
          <p>                                classify a tumor as T4)</p>
          <p>    </p>
          <p>    *FIGO staging no longer includes Stage 0 (Tis)</p>
          <p>   **Endocervical glandular involvement only should be considered as stage I</p>
          <p>     and not stage II.</p>
          <p></p>
          <p>CLIN      PATH    TNM   FIGO    Regional Lymph Nodes (N)</p>
          <p></p>
          <p>[ ]       [ ]     NX            Regional lymph nodes cannot be assessed</p>
          <p>[ ]       [ ]     NO            No regional lymph node metastasis</p>
          <p>[ ]       [ ]     Nl    IIIC1   Regional lymph node metastasis to pelvic</p>
          <p>                                lymph nodes</p>
          <p>[ ]       [ ]     N2    IIIC2   Regional lymph node metastasis to para-</p>
          <p>                                aortic lymph nodes, with or without</p>
          <p>                                positive pelvic lymph nodes.</p>
          <p></p>
          <p></p>
          <p>CLIN      PATH    TNM   FIGO   Distant Metastasis (M)</p>
          <p></p>
          <p>[ ]       [ ]     MO            No distant metastasis (no pathologic M;</p>
          <p>                                use clinical M to complete stage group)</p>
          <p>[ ]       [ ]     MI    IVB     Distant metastasis (includes metastasis</p>
          <p>                                to inguinal lymph nodes intraperitoneal</p>
          <p>                                disease, or lung, liver or bone.  It</p>
          <p>                                excludes metastasis to para-aortic lymph </p>
          <p>                                nodes, vagina, pelvic serosa, or adnexa)</p>
          <p></p>
          <p>Stage Grouping </p>
          <p></p>
          <p>CLIN      PATH    TNM</p>
          <p>[ ]       [ ]     0*      Tis     NO      MO</p>
          <p>[ ]       [ ]     I       Tl      NO      MO</p>
          <p>[ ]       [ ]     IA      Tla     NO      MO</p>
          <p>[ ]       [ ]     IB      Tlb     NO      MO</p>
          <p>[ ]       [ ]     II      T2      NO      MO</p>
          <p>[ ]       [ ]     III     T3      NO      MO</p>
          <p>[ ]       [ ]     IlIA    T3a     N       MO</p>
          <p>[ ]       [ ]     IIIB    T3b     NO      MO</p>
          <p>[ ]       [ ]     IIIC1   Tl-T3   Nl      MO</p>
          <p>                  IIIC2   T1-T3   N2      MO</p>
          <p>[ ]       [ ]     IVA     T4      AnyN    MO</p>
          <p>[ ]       [ ]     IVB     AnyT    AnyN    Ml</p>
          <p></p>
          <p>Histologic Grade (G)</p>
          <p> </p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING:  None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>   FIGO Stage:__________________________________________________________</p>
          <p>   Peritoneal cytology results:________________________________________</p>
          <p>   Pelvic nodal dissection with number of nodes positive/examined:______</p>
          <p>   Para-aortic nodal dissection with number of nodes positive/examined:</p>
          <p>   _____________________________________________________________________</p>
          <p>   Percentage of non-edometriod cell type in mixed histology tumors:____</p>
          <p>   Omentectomy performed:_______________________________________________</p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>Checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>[ ] Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ] Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ] Not Applicable</p>
          <p>[ ] Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>[ ] RX  Presence of residual tumor cannot be assessed.</p>
          <p>[ ] R0  No residual tumor</p>
          <p>[ ] R1  Microscopic residual tumor</p>
          <p>[ ] R2  Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]  Clinical stage was used in the treatment planning (describe):_______</p>
          <p>[ ]  National guidelines were used in treatment planning:</p>
          <p>     [ ]  NCCN</p>
          <p>     [ ]  Other</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC UTERUS SARCOMA STAGING (CORPUS UTERI) 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>CORPUS UTERI SARCOMA</p>
          <p>(Carcinosarcomas should be staged as carcinomas)</p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p></p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p></p>
          <p></p>
          <p>CLIN    PATH    TNM     FIGO    Primary Tumor (T)</p>
          <p>                                Leiomyosarcoma, Endometrial Stromal </p>
          <p>                                Sarcoma</p>
          <p>[ ]     [ ]     TX              Primary tumor cannot be assessed</p>
          <p>[ ]     [ ]     T0              No evidence of primary tumor</p>
          <p>[ ]     [ ]     T1      I       Tumor limited to the uterus</p>
          <p>[ ]     [ ]    T1a      IA      Tumor 5 cm or less in greatest dimension</p>
          <p>[ ]     [ ]    T1b      IB      Tumor more than 5 cm</p>
          <p>[ ]     [ ]    T2       II      Tumor extends beyond the uterus, within </p>
          <p>                                the pelvis</p>
          <p>[ ]     [ ]    T2a      IIA     Tumor invades the adnexa</p>
          <p>[ ]     [ ]    T2b      IIB     Tumor involves other pelvic tissues</p>
          <p>[ ]     [ ]    T3       III*    Tumor infiltrates abdominal tissues</p>
          <p>[ ]     [ ]    T3a      IIIA    One Site</p>
          <p>[ ]     [ ]    T3b      IIIB    More than one site</p>
          <p>[ ]     [ ]    T4       IVA     Tumor invades bladder or rectum</p>
          <p></p>
          <p></p>
          <p>                                Adenosarcoma</p>
          <p>[ ]     [ ]    TX               Primary tumor cannot be assessed</p>
          <p>[ ]     [ ]    T0               No evidence of primary tumor</p>
          <p>[ ]     [ ]    T1       I       Tumor limited to the uterus</p>
          <p>[ ]     [ ]    T1a      IA      Tumor limited to the endometrium/</p>
          <p>                                endocervix</p>
          <p>[ ]     [ ]    T1b      IB      Tumor invades to less than half of</p>
          <p>                                the myometrium</p>
          <p>[ ]     [ ]    T1c      IC      Tumor invades more than half of the </p>
          <p>                                myometrium</p>
          <p>[ ]     [ ]    T2       II      Tumor extends beyond the uterus,</p>
          <p>                                within the pelvis</p>
          <p>[ ]     [ ]    T2a      IIA     Tumor involves adnexa</p>
          <p>[ ]     [ ]    T2b      IIB     Tumor involves other pelvic tissues</p>
          <p>[ ]     [ ]    T3       III*    Tumor involves abdominal tissue</p>
          <p>[ ]     [ ]    T3a      IIIA    One site</p>
          <p>[ ]     [ ]    T3b      IIIB    More than one site</p>
          <p>[ ]     [ ]    T4       IVA     Tumor invades bladder or rectum</p>
          <p>      Note:  Simultaneous tumors of the uterine corpus and ovary/pelvis</p>
          <p>             in association with ovarian/pelvic endometriosis should be </p>
          <p>             classified as independent primary tumors.</p>
          <p>     *In this stage, lesions must infiltrate abdominal tissues and not</p>
          <p>     just protrude into the abdominal cavity.</p>
          <p></p>
          <p></p>
          <p>CLIN    PATH    TNM    FIGO    REGIONAL LYMPH NODES (N)</p>
          <p>[ ]     [ ]     NX             Regional lymph nodes cannot be assessed</p>
          <p>[ ]     [ ]     N0             No regional lymph nodes</p>
          <p>[ ]     [ ]     N1     IIIC    Regional lymph nodes metastasis</p>
          <p></p>
          <p></p>
          <p>CLIN    PATH    TNM    FIGO    DISTANT METASTASIS (M)</p>
          <p>[ ]     [ ]     M0             No distant metastasis (use pathologic M to</p>
          <p>                               complete stage group)</p>
          <p>[ ]     [ ]     M1     IVB     Distant metastasis (excluding adexa,</p>
          <p>                               pelvic, and abdominal tissue)</p>
          <p></p>
          <p>Stage Grouping</p>
          <p></p>
          <p>CLIN      PATH    TNM</p>
          <p>[ ]       [ ]     I       Tl      NO      MO</p>
          <p>[ ]       [ ]     IA*     Tla     NO      MO</p>
          <p>[ ]       [ ]     IB*     Tlb     NO      MO</p>
          <p>[ ]       [ ]     IC**    Tlc     NO      MO</p>
          <p>[ ]       [ ]     II      T2      NO      MO</p>
          <p>[ ]       [ ]     IIIA    T3a     NO      MO</p>
          <p>[ ]       [ ]     IIIB    T3b     NO      MO</p>
          <p>[ ]       [ ]     IIIC    T1-T3   N1      MO</p>
          <p>[ ]       [ ]     IIIA    T3a     N       MO</p>
          <p>[ ]       [ ]     IVA     T4      Any N   MO</p>
          <p>[ ]       [ ]     IVB     Any T   Any N   Ml</p>
          <p>[ ]               Stage Unknown</p>
          <p></p>
          <p>    *Note Stages IA and IB differ from those applied for leiomyosarcoma</p>
          <p>     and endometrial stromal sarcoma.</p>
          <p>   **Note: Stage IC does not apply for leiomyosarcoma and endometrial</p>
          <p>     stromal sarcoma.</p>
          <p></p>
          <p></p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING:  None</p>
          <p>CLINICALLY SIGNIFICANT:</p>
          <p>   FIGO Stage:__________________________________________________________</p>
          <p>   Peritoneral cytology results:________________________________________</p>
          <p>   Pelvic nodal dissection with number of nodes positive/examined:______</p>
          <p>   Para-aortic nodal dissection with number of nodes positive/examined:</p>
          <p>   _____________________________________________________________________</p>
          <p>   Percentage of non-edometriod cell type in mixed histology tumors:____</p>
          <p>   Omentectomy performed:_______________________________________________</p>
          <p></p>
          <p></p>
          <p>Histologic Grade (G)</p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Endometroid adenocarcinoma should be graded according to the degree </p>
          <p>of differentiation of the adenocarcinoma as follows:</p>
          <p></p>
          <p> [ ] G1  5% or less of non-squamous or non-morular solid growth pattern</p>
          <p> [ ] G2  6% to 50% of non-squamous or non-morular solid growth pattern</p>
          <p> [ ] G3  More than 50% of non-squamous or non-morular solid growth pattern</p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>[ ] Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ] Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ] Not Applicable</p>
          <p>[ ] Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>[ ] RX  Presence of residual tumor cannot be assessed.</p>
          <p>[ ] R0  No residual tumor</p>
          <p>[ ] R1  Microscopic residual tumor</p>
          <p>[ ] R2  Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]  Clinical stage was used in the treatment planning (describe):_______</p>
          <p>[ ]  National guidelines were used in treatment planning:</p>
          <p>     [ ]  NCCN</p>
          <p>     [ ]  Other</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC VAGINA STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>VAGINA STAGING</p>
          <p> 7th edition AJCC Cancer Staging Manual</p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p></p>
          <p>FIGO CLIN PATH TNM     PRIMARY TUMOR (T)</p>
          <p>     [ ]  [ ]  TX      Primary tumor cannot be assessed</p>
          <p>     [ ]  [ ]  T0      No evidence of primary tumor</p>
          <p> *   [ ]  [ ]  Tis     Carcinoma in situ </p>
          <p> I   [ ]  [ ]  T1      Tumor confined to vagina </p>
          <p> II  [ ]  [ ]  T2      Tumor invades paravaginal tissues but not to pelvic</p>
          <p>                       wall</p>
          <p> III [ ]  [ ]  T3      Tumor extends to pelvic wall** </p>
          <p> IVA [ ]  [ ]  T4      Tumor invades mucosa of the bladder or rectum</p>
          <p>                       and/or extends beyond the true pelvis (bullous</p>
          <p>                       edema is not sufficient evidence to classify a</p>
          <p>                       tumor as T4).</p>
          <p>              *FIGO staging no longer includes Stage 0 (Tis).</p>
          <p>             **Pelvic wall is defined as muscle, fascia, neurovascular</p>
          <p>               structures, or skeletal portions of the bone pelvis.</p>
          <p></p>
          <p></p>
          <p>FIGO CLIN PATH TNM     REGIONAL LYMPH NODES (N)</p>
          <p>     [ ]  [ ]  NX      Regional lymph nodes cannot be assessed</p>
          <p>     [ ]  [ ]  N0      No regional lymph node metastasis</p>
          <p> III [ ]  [ ]  N1      Pelvic or inguinal lymph node metastasis</p>
          <p> </p>
          <p>FIGO CLIN PATH TNM     DISTANT METASTASIS (M)</p>
          <p>     [ ]       M0      No distant metastasis (no pathologic M);  use</p>
          <p>                       clinical M to complete stage group)</p>
          <p> IVB [ ]  [ ]  M1      Distant metastasis</p>
          <p> </p>
          <p>CLIN PATH STAGE GROUPING </p>
          <p>[ ]  [ ]  0    Tis    N0     M0     </p>
          <p>[ ]  [ ]  I    T1     N0     M0     </p>
          <p>[ ]  [ ]  II   T2     N0     M0     </p>
          <p>[ ]  [ ]  III  T1-T3  N1     M0     </p>
          <p>[ ]  [ ]       T3     N0     M0</p>
          <p>[ ]  [ ]  IVA  T4     Any N  M0</p>
          <p>[ ]  [ ]  IVB  Any T  Any N  M1</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)</p>
          <p>REQUIRED FOR STAGING:  None</p>
          <p>     FIGO Stage:__________</p>
          <p>     Pelvic nodal status and method of assessment:___________</p>
          <p>     Distant (Mediastinal, scalene) nodal status and method of</p>
          <p>     assessment:________</p>
          <p></p>
          <p>Histologic Grade (G) (also known as overall grade)</p>
          <p> </p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>Checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>[ ] Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ] Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ] Not Applicable</p>
          <p>[ ] Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>[ ] RX  Presence of residual tumor cannot be assessed.</p>
          <p>[ ] R0  No residual tumor</p>
          <p>[ ] R1  Microscopic residual tumor</p>
          <p>[ ] R2  Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]  Clinical stage was used in the treatment planning (describe):_______</p>
          <p>[ ]  National guidelines were used in treatment planning</p>
          <p>     [ ] NCCN</p>
          <p>     [ ] Other</p>
          <p></p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
          <p></p>
          <p></p>
          <p></p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
      <TEMPLATE NAME="AJCC VULVA STAGING 7TH. ED.">
        <TYPE>T</TYPE>
        <STATUS>A</STATUS>
        <BOILERPLATE_TEXT>
          <p>VULVA  </p>
          <p>(Mucosal malignant melanoma is excluded) </p>
          <p></p>
          <p>7th edition AJCC Cancer Staging Manual</p>
          <p>[ ]y clinical staging completed</p>
          <p>   after neoadjuvant therapy but</p>
          <p>   before subsequent surgery</p>
          <p></p>
          <p>[ ]y pathologic - staging completed</p>
          <p>   after neoadjuvant therapy AND</p>
          <p>   subsequent surgery</p>
          <p></p>
          <p>Tumor Size:__________</p>
          <p></p>
          <p>FIGO CLIN PATH         PRIMARY TUMOR (T)</p>
          <p>     [ ]  [ ]  TX      Primary tumor cannot be assessed </p>
          <p>     [ ]  [ ]  T0      No evidence of primary tumor</p>
          <p>  *  [ ]  [ ]  Tis     Carcinoma in situ (Preinvasive carcinoma)</p>
          <p> 1A  [ ]  [ ]  T1a     Tumor confined to the vulva or vulva and perineum,</p>
          <p>                       2cm or &lt; in greatest dimension, and with stromal</p>
          <p>                       invasion no &gt; 1mm</p>
          <p> 1B  [ ]  [ ]  T1b     Tumor confined to the vulva or vulva and perineum,</p>
          <p>                       2cm or &lt; in greatest dimension, &amp; with stromal</p>
          <p>                       invasion &gt; 1mm </p>
          <p> 11  [ ]  [ ]  T2***   Tumor confined to the vulva or vulva and perineum</p>
          <p>                       &gt; 2cm</p>
          <p> IVA [ ]  [ ]  T3****  Tumor of any size with contiguous spread to the</p>
          <p>                       lower urethra &amp;/or vagina or anus</p>
          <p>       *FIGO staging no longer includes Stage 0 (Tis)</p>
          <p>      **The depth of invasion is defined as the measurement of the tumor</p>
          <p>        from the epithelial-stromal junction of the adjacent most</p>
          <p>        superficial dermal papilla to the deepest point of invasion.</p>
          <p>     ***FIGO uses the classification T2 T3.  This is defined at T2 in TNM.</p>
          <p>    ****FICO uses the classification T4.  This is defined at T3 in TNM.</p>
          <p></p>
          <p>FIGO CLIN PATH         REGIONAL LYMPH NODES (N)</p>
          <p>     [ ]  [ ]  NX      Regional lymph nodes cannot be assessed</p>
          <p>     [ ]  [ ]  N0      No regional lymph node metastasis</p>
          <p>     [ ]  [ ]  N1      One or two regional lymph node with the following</p>
          <p>                       features</p>
          <p>IIIA [ ]  [ ]  N1a     One or two lymph node metastasis each 5 mm or less</p>
          <p>IIIA [ ]  [ ]  N1b     One lymph node metastases 5 mm or greater </p>
          <p>IIIB [ ]  [ ]  N2      Regional lymph nodes metastasis with the following</p>
          <p>                       features:</p>
          <p>IIIB [ ]  [ ]  N2a     Three or more lymph node metastases each less than</p>
          <p>                       5 mm</p>
          <p>IIIB [ ]  [ ]  N2b     Two or more lymph node metastases 5 mm or greater</p>
          <p>IIIC [ ]  [ ]  N2c     Lymph node metastasis with extracapsular spread</p>
          <p>IVA  [ ]  [ ]  N3      Fixed or ulcerated regional lymph node metastasis</p>
          <p>                       An effort should be made to describe the site and</p>
          <p>                       Laterality of lymph node metastases. </p>
          <p></p>
          <p>FIGO CLIN PATH         DISTANT METASTASIS (M)</p>
          <p>     [ ]       M0      No distant metastasis (no pathologic M0;  uses</p>
          <p>                       clinical M to complete Stage group)</p>
          <p>     [ ]  [ ]  M1 IVB  Distant metastasis (including pelvic lymph node</p>
          <p>                       metastasis)</p>
          <p> </p>
          <p>CLIN   PATH  STAGE GROUPING                       </p>
          <p> </p>
          <p>[ ]    [ ]  0*    Tis      N0       M0 </p>
          <p>[ ]    [ ]  I     T1       N0       M0 </p>
          <p>[ ]    [ ]  IA    T1a      N0       M0 </p>
          <p>[ ]    [ ]  IB    T1b      N0       M0 </p>
          <p>[ ]    [ ]  II    T2       N0       M0 </p>
          <p>[ ]    [ ]  IIIA  T1,T2    N1a,N1b  M0 </p>
          <p>[ ]    [ ]  IIIB  T1,T2    N2a,N2b  M0 </p>
          <p>[ ]    [ ]  IIIC  T1,T2    N2c      M0 </p>
          <p>[ ]    [ ]  IVA   T1,T2    N3       M0 </p>
          <p>[ ]    [ ]        T3       Any N    M0 </p>
          <p>[ ]    [ ]  IVB  Any T     Any N    M1 </p>
          <p>*FIGO no longer includes Stage 0 (Tis) </p>
          <p>[ ]    Stage Unknown</p>
          <p></p>
          <p>PROGNOSTIC FACTORS (SITE-SPECIFRIC FACTORS)</p>
          <p>REQUIREMENT FOR STAGING: None</p>
          <p>CLINCIALLY SIGNIFICANT:</p>
          <p>     FICO Stage:________</p>
          <p>     Pelvic nodal status and method of assessment:_____________</p>
          <p>     Femoral-Inguinal nodal status and method of assessment:____________</p>
          <p></p>
          <p>Histologic Grade (G) (also known as overall grade)</p>
          <p></p>
          <p>GRADING SYSTEM    </p>
          <p></p>
          <p>GRADING SYSTEM </p>
          <p>                                 </p>
          <p>[ ] 2 grade system                              [ ]    Grade I or 1</p>
          <p>[ ] 3 grade system                              [ ]    Grade II or 2</p>
          <p>[ ] 4 grade system                              [ ]    Grade III or 3</p>
          <p>[ ] No 2,3,or 4 grade system is available       [ ]    Grade IV or 4</p>
          <p>                                                [ ]    Grade cannot be assessed</p>
          <p></p>
          <p>Grade I:  Well differentiated</p>
          <p>Grade II: Moderately differentiated</p>
          <p>Grade III:Poorly differentiated</p>
          <p>Grade IV: Undifferentiated</p>
          <p>Grade X:  Grade cannot be assessed</p>
          <p></p>
          <p>Code to the higher grade when more than one grade is stated. </p>
          <p></p>
          <p></p>
          <p></p>
          <p>ADDITIONAL DESCRIPTORS</p>
          <p>Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined</p>
          <p>into Lymph-Vascular Invasion (LV) for collection by cancer registrars.</p>
          <p>The College of American Pathologists' (CAP) Checklist should be used as</p>
          <p>the primary source.  Other sources may be used in the absence of a</p>
          <p>checklist.</p>
          <p>Priority is given to positive results.</p>
          <p></p>
          <p>[ ] Lymph-Vascular Invasion Not Present (absent)/Not Identified</p>
          <p>[ ] Lymph-Vascular Invasion Present/Identified</p>
          <p>[ ] Not Applicable</p>
          <p>[ ] Unknown/Indeterminate</p>
          <p></p>
          <p>Residual Tumor (R)</p>
          <p>The absence or presence of residual tumor after treatment.  In some cases </p>
          <p>treated with surgery and/or with neoadjuvant therapy there will be</p>
          <p>residual tumor at the primary site after treatment because of incomplete</p>
          <p>resection of local and regional disease that extends beyond the limit of</p>
          <p>ability of resection.</p>
          <p></p>
          <p>[ ] RX  Presence of residual tumor cannot be assessed.</p>
          <p>[ ] R0  No residual tumor</p>
          <p>[ ] R1  Microscopic residual tumor</p>
          <p>[ ] R2  Macroscopic residual tumor</p>
          <p></p>
          <p>[ ]  Clinical stage was used in the treatment planning (describe):_______</p>
          <p>[ ]  National guidelines were used in treatment planning</p>
          <p>     [ ] NCCN</p>
          <p>     [ ] Other</p>
          <p></p>
          <p>Reproduced with permission and under license from the AJCC</p>
          <p></p>
          <p></p>
          <p></p>
          <p></p>
        </BOILERPLATE_TEXT>
      </TEMPLATE>
    </ITEMS>
  </TEMPLATE>
</CPRS_TEMPLATE>
